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Abstract 
 
Understanding the immune system in patients with cancer and how it interacts 
with malignant cells is critical for the development of successful 
immunotherapeutic strategies at a time when novel cancer treatment approaches 
are required. Acute myeloid leukaemia (AML) results in widespread interaction 
between the malignant cells and T cells and as such, offers an opportunity to study 
these interactions. 
 
A flow cytometric analysis of T cells in the peripheral blood of patients presenting 
with AML illustrated that the absolute number of T cells is increased in AML 
compared with healthy controls. Furthermore, a large population of CD3+56+ 
cells was identified. These cells are not natural killer T cells but effector T cells 
that may represent a failing immunosurveillance mechanism. Two technical issues 
were explored: how to separate T cells from the peripheral blood of newly 
diagnosed AML patients and the impact of the method of immunomagnetic cell 
separation on the gene expression profile of healthy T cells. Gene expression 
profiling was subsequently performed on T cells from AML patients compared 
with healthy controls. Global differences in transcription were observed 
suggesting aberrant T cell activation patterns in AML. As differentially regulated 
genes involved in actin cytoskeletal formation were noted, a functional 
assessment of the ability of T cells from AML patients to form immunological 
synapses was performed. This illustrated that although T cells from AML patients 
can form conjugates with autologous blasts, their ability to form immune synapses 
and recruit phosphotyrosine signalling molecules to that signalling interface is 
impaired. Taken together, these findings demonstrate that numerically T cells are 
plentiful in AML however they are abnormal in terms of the genes they are 
transcribing and in their interactions with tumour cells. Targeting immunological 
synapse formation may represent an important means of improving T cell 
recognition of tumour cells across a range of cancers.  
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Chapter 1 
Introduction 
 
Cancer is characterised by an uncontrollable proliferation of cells that have the 
ability to invade and metastasize. Original descriptions were found on Egyptian 
papyri dating from 1600BC on which the author stated “there is no treatment” 
(Breasted 1922). Since that time prognosis has improved radically. However, 
despite rapid recent advances in genomics, pharmacology and biotechnology, 
further improvements in cancer survival remain small. To achieve the aim of a 
cure, alternative methods of cancer therapy need to be pursued. One such avenue 
is to harness the immune system.  
 
1.1 T Cells 
1.1.1  White Blood Cells 
T lymphocytes form one part of the white blood cell (leucocyte) population found 
in human peripheral blood. On the basis of nuclear shape, leucocytes are defined 
as either polymorphonuclear (granulocytes) or mononuclear cells. While 
granulocytes are made up of neutrophils, eosinophils and basophils, mononuclear 
cells are the monocytes and lymphocytes (Figure 1.1).  
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Figure 1.1: Haematopoiesis  
HSC: haematopoietic stem cell; HPC: haematopoietic progenitor cell; CMP (CFU-S): common 
myeloid progenitor; CLP: common lymphoid progenitor; CFU-GEMM: colony-forming unit- 
granulocytes, erythroblasts, macrophages, megakaryocytes (From Google Images). 
 
In the peripheral blood, lymphocytes make up 20-40% of all leucocytes with a 
typical absolute count in a Caucasian adult being 1.0-3.2 x 10
9
/L. In the bone 
marrow, they make up 16.1% of the cellular component (95% range 6.0-26.2%). 
These cells vary in diameter from 10 to 16 m and characteristically have scanty 
cytoplasm and a round nucleus with condensed chromatin (Bain 2002, Bain 2001) 
(Figure 1.2).  
 
1.1.2  Lymphocytes 
There are 3 major subsets of lymphocytes; T cells (thymus-derived), B cells (bone 
marrow-derived) and NK (natural killer) cells. In the peripheral blood, around 
80% of circulating lymphocytes are T cells, 10-15% are B cells and ~10% are NK 
cells whereas in the bone marrow B cells predominate within the precursor cell 
subset and T cells amongst mature lymphocytes (Hoffbrand 2002). In general it is 
not possible to distinguish the subsets of lymphocytes morphologically. However, 
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activated T cells and NK cells are within the population of „large granular 
lymphocytes‟ (LGL) characterised by more abundant cytoplasm and prominent 
azurophilic granules (Figure 1.3).  
 
Lymphocytes are crucial for protection against disease. This is most clearly shown 
by genetic disorders in humans that result in their absence. The commonest cause 
of X-linked severe combined immune deficiency (SCID) is a mutation in the 
common gamma chain ( c) resulting in widespread failure of interleukin signalling 
with the result that there are low or absent T and NK cells and non-functional B 
cells. Unless transplanted, these children die within one year due to severe 
recurrent infections (Buckley 2000).  
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Figure 1.2: A Peripheral Blood Lymphocyte  
(ASH Image Bank) 
 
 
 
 
 
Figure 1.3: A Large Granular Lymphocyte  
(ASH Image Bank) 
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The immune system is composed of two major arms; the adaptive and innate 
responses. The adaptive immune response has a number of fundamental features: 
specificity – distinct antigens will elicit distinct responses, diversity – responses 
can be made to a vast number of antigens, memory – resulting in enhanced 
responses to repeated exposure to the same antigen, specialisation – responses are 
tailored to the defence required, self-limitation – responses are triggered by 
antigen to destroy antigen and therefore wane over time and lastly, non-reactivity 
to self or tolerance. T and B cells make up the adaptive immune system with T 
cells being responsible for cell-mediated immunity and B cells for humoral 
immunity via the production of antibodies. This response is complemented by the 
innate immune response which is non-specific and has no memory but has the 
advantage of rapid, maximal response on exposure to antigen largely via pattern 
recognition receptors such as toll-like receptors and mannose receptors. NK cells 
form part of the cellular innate immune response that also includes phagocytes 
(macrophages, neutrophils, dendritic cells (DCs)), mast cells, basophils and 
eosinophils. NK cells distinguish self from non-self on the basis of surface 
expression of the major histocompatibility complex (MHC) Class I molecule via 
inhibitory killer immunoglobulin-like receptors (KIRs) (Abbas 2000). 
 
1.1.3  The T Cell Receptor and T Cell Subsets 
T cells are characterised by the expression of a heterodimeric T cell receptor 
(TCR). In more than 90% of cases, it is made up of alpha and beta glycoprotein 
chains with fewer than 10% of circulating T cells expressing a TCR made up of 
gamma and delta chains. However, /  T cells make up the majority of the 
intraepithelial lymphocyte population within the gut and other epithelial mucosa. 
This unconventional T cell subset borders between the adaptive and the innate 
immune response (Hayday 2000). Further subclassification of T cells is on the 
basis of expression of cluster of differentiation (CD) surface proteins. A protein is 
given a CD number if it identifies a particular lineage or differentiation stage of 
the cell, has a defined structure and is recognised by a group or „cluster‟ of 
monoclonal antibodies. Thus T cells are characterised by the expression of CD3, 
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CD4 or CD8 whereas B cells express CD19, CD20 and CD22 and NK cells 
express CD16 and CD56 but not CD3. /  T lymphocytes consist of two major 
subsets, helper and regulatory T cells that express CD4 and cytotoxic T cells that 
express CD8. CD4 cells predominate in the peripheral blood whereas CD8 cells 
make up the dominant T cell population in the bone marrow and the gut. 
Cytotoxic CD8 T lymphocytes (CTLs) destroy cells expressing their cognate 
antigen through release of the effector molecules perforin and granzyme B. Helper 
CD4 cells differentiate into TH1, TH2 or TH17 subsets depending on the cytokine 
signals received with each secreting a different selection of cytokines to assist a 
local adaptive immune response (Zhu and Paul 2008). Regulatory CD4 cells 
(Tregs) maintain immunological tolerance by switching off T-cell mediated 
immunity when it is no longer required. There are two main subsets – the 
naturally occurring (CD4+CD25+FOXP3+) generated within the thymus and the 
adaptive (Tr1 or TH3) that arise in the periphery during an immune response 
(Sakaguchi 2004). 
 
The function of the T cell receptor is to recognise antigen; that is, any molecule 
that can prompt the generation of antibody. T cell receptors recognise peptide 
fragments of protein. However recognition is only possible when these peptides 
are appropriately displayed or presented to them on the surface of an antigen-
presenting cell (APC) in association with an MHC molecule. There are two types 
of MHC heterodimers. Class I molecules can be found on almost all nucleated 
cells. They present endogenous peptides sampled from the cellular cytosol and are 
recognised by CD8 T cells. This function is crucial for the killing of intracellular 
microbes such as viruses which may infect any cell within the body. CD4, T 
helper cells, recognise Class II MHC molecules which are only found on 
professional APCs (DCs, B lymphocytes and macrophages) and which present 
exogenous peptides that have been sampled from the extracellular compartment 
by the process of endocytosis. MHC class I molecules are designated HLA 
(human leucocyte antigen)-A, HLA-B and HLA-C in humans. They are made up 
of a polymorphic  chain encoded on the MHC locus on chromosome 6 and a 
non-polymorphic subunit called 2-microglobulin. Peptides of between 8 and 11 
residues can be presented within the peptide binding groove. MHC Class II 
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molecules (HLA-DR, DP and DQ) are composed of an  and a  polypeptide 
chain both encoded on the MHC locus. These molecules accommodate slightly 
larger peptides of 10-30 residues (Figure 1.4).  
 
 
Figure 1.4: Structure of Class I and II MHC Molecules  
(From (Abbas 2000)) 
 
Each MHC molecule can present multiple peptides but cannot distinguish between 
those that are foreign and those that are self. Binding specificity is determined by 
polymorphic residues known as anchor residues located within the peptide-
binding domain that are complementary to residues on the bound peptide. This 
association is a low affinity interaction with a slow on-rate and very slow off rate 
which allows for peptide-MHC complexes to persist for long enough to be 
recognised by an antigen-specific T cell (Germain 1994). 
 
1.1.4  T Cell Development 
All leucocytes are derived from a common cell of origin, a pluripotent stem cell 
that is located within the bone marrow. From here, the immature T cells (CD4-
CD8-) migrate to the thymus to undergo maturation as thymocytes. As they 
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migrate from the cortex to the medulla of the thymus, the double-negative (CD4-
CD8-) T cells gradually become double-positive (CD4+CD8+) and finally single-
positive (CD4+CD8- or CD4-CD8+). Around 98% of thymocytes are deleted 
during their passage through the thymus through the processes of positive and 
negative selection. The immature T cells are exposed to thymic epithelial cells 
expressing self-antigens in association with an MHC molecule. T cells that 
recognise and avidly bind to these self antigens are deleted in a process of 
negative selection (selects against T cells reactive to self antigen resulting in 
tolerance to self) whereas those T cells that bind self MHC molecules with only 
low affinity are positively selected (selects for functional cells capable of 
interacting with MHC molecules) (Germain 2002). T cells that pass both levels of 
selection leave the thymus as naïve lymphocytes and enter the peripheral blood 
circulation. Once mature, naïve lymphocytes survive for long periods of time; 
they have been shown to divide only once every 3.5 years in humans (McLean 
and Michie 1995). From the post-capillary venules, the naïve lymphocytes 
migrate into the peripheral lymphoid organs; the lymph nodes, the spleen and the 
mucosal and cutaneous lymphoid tissue. These organs concentrate foreign 
antigens that have entered the body via the skin, gastrointestinal or respiratory 
tracts. Here T cells home to the paracortical areas of the lymph nodes and the 
periarteriolar sheaths surrounding the central arterioles within the spleen. Within 
the lymphoid organs, the naïve cells recognise antigens presented by professional 
APCs (DCs, macrophages or B cells) and subsequently differentiate into the 
effector (cytotoxic or helper) and memory cells of the adaptive immune response. 
Differentiated lymphocytes subsequently return to the peripheral blood via the 
efferent lymphatic system and the thoracic duct in the process of lymphocyte 
recirculation. From here, effector cells home to the site of antigen entry within the 
peripheral tissues and destroy those cells expressing the appropriate foreign 
antigen. Memory cells can be divided into central memory (TCM) or effector 
memory (TEM) categories and can be either CD4 or CD8 positive. Central memory 
cells express L-selectin and CCR7 in contrast to effector memory cells. In 
addition, TCM produce interleukin-2 (IL-2) rather than the cytokines interferon-
gamma (IFN  and interleukin-4 (IL-4) that are produced by TEM (Sallusto, et al 
2004). Memory cells take up residence in normal tissue in preparation for the next 
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exposure to antigen allowing a more rapid response to secondary exposure 
(recall). In contrast to naïve and recently activated lymphocytes, memory cells 
may survive in a quiescent state without exposure to antigen for many years. 
Historically, naive and memory T cells have been distinguished by the expression 
of the cell surface markers CD45RA (naive) and CD45RO (memory). It is now 
clear that this is inaccurate and other combinations of markers have been reported 
(De Rosa, et al 2001). In this study the combination of the cell surface markers 
CD45RA and CD27 has been used to phenotypically distinguish effector, naive 
and memory CD8 T cells (Hamann, et al 1997, Hamann, et al 1999). At any one 
time, 20-50% of all lymphocytes are within the peripheral circulation, the 
remainder being within the lymphoid organs (von Andrian and Mackay 2000). 
 
1.1.5  The Diversity of the Immune Response 
It is estimated that the immune system of an individual can recognise between 10
7
 
and 10
9
 different antigens. This vast lymphocyte repertoire is possible due to the 
variability in the antigen recognition sites on lymphocytes – the T and B cell 
antigen receptors (TCR/BCR). The genes for the four proteins of the TCR are 
encoded in three different loci within the genome. The TCR  chain locus is on 
chromosome 7, the  chain locus is contained within the  chain locus on 
chromosome 14 and the chain locus on chromosome 7. Each germline TCR 
locus is made up of multiple copies of at least three different types of gene 
segments; V (variable), J (joining), C (constant) and D (diversity) separated by 
non-coding DNA (Figure 1.5).  
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Figure 1.5: Germline Organisation of Human TCR Locus  
(From (Abbas 2000)) 
 
Transcription of this germline DNA will not give rise to antigen receptor proteins. 
It is only within developing lymphocytes that different V, D and J regions are 
brought together by rearrangements within the DNA and functional antigen 
receptor genes are created. This process is known as somatic recombination and is 
the means by which random individual V, J and D (when present) are brought 
together to form a single V(D)J gene that will encode the variable region of the 
receptor. The lymphocyte-specific recombinase responsible for this process is a 
complex of two proteins encoded by recombination-activating gene 1 and 
recombination-activating gene 2 (RAG-1 and RAG-2). The C region is joined 
post-transcription resulting in an mRNA transcript that on translation produces 
one of the chains of the antigen receptor. The association with a different, 
randomly generated V region on the other receptor chain introduces further 
combinatorial diversity. Another mechanism by which diversity is introduced is 
junctional diversity. At the time of VDJ joining, enzymes randomly remove or 
add nucleotides at the junctions of gene segments. These areas (complementarity-
determining or CDR3 regions) therefore show the greatest variability and are also 
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the most important for determining the specificity of antigen binding. The 
rearrangement of TCR genes is completed during the double-positive maturation 
stage just before the thymocytes enter the medulla. In this way, every T 
lymphocyte clone expresses a unique TCR capable of recognising an individual 
peptide. However, although the potential number of molecules that can be 
expressed is very large, it is estimated that each individual only expresses a 
fraction of the potential repertoire (~10
7
) (Davis and Bjorkman 1988). 
 
1.1.6  T Cell Activation 
A T cell becomes activated when it recognises the antigen. This happens when the 
TCR binds to antigen in association with an MHC molecule on the surface of an 
APC. This ensures that only a T cell with a TCR specific to the antigen is 
activated. However, this alone is insufficient to activate the cell. To license the T 
cell to respond to the antigen, a second signal must occur. If no second signal is 
given, the T cell becomes anergic, or unresponsive and will be more difficult to 
activate in the future. The second signal is provided by costimulation. The only 
costimulatory receptor constitutively expressed on T cells is CD28. This binds to 
CD80/CD86 on APCs. Once this costimulatory signal has been provided, a range 
of other costimulatory receptors are expressed on the T cell surface such as 
CD40L (CD154), ICOS and PD-1 which reinforce the activation signal (Figure 
1.6).  
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Figure 1.6: The Two-Signal Hypothesis for T Cell Activation 
 
The point of physical contact between a T cell and an APC is known as the 
immunological synapse. Once antigen recognition has occurred, actin polymerises 
within the cytoskeleton resulting in cellular polarisation and rapid mobilisation of 
the TCR complex, CD4 or CD8 coreceptors, costimulatory receptors, enzymes 
and adaptor proteins to the centre of the synapse to form supramolecular 
activation clusters (SMAC). Integrins such as LFA-1 remain on the periphery to 
maintain stability (Dustin and Cooper 2000). The TCR not only consists of the 
/  heterodimer but also the protein CD3. One of its homodimers, CD3  consists 
of 6 immunoreceptor tyrosine-based activation motifs (ITAMs). On activation, 
these ITAM motifs are phosphophorylated by Lck, a Src family tyrosine kinase 
that is associated with the cytoplasmic tails of CD4 and CD8. This results in the 
recruitment of ZAP-70 to the TCR complex. ZAP-70 is critical for sustaining the 
signalling cascade initiated by TCR recognition of antigen. The tyrosine kinases 
Lck and ZAP-70 go on to phosphorylate tyrosine residues on numerous other 
molecules including CD28, LAT and SLP-76 culminating in an aggregation of 
signalling complexes around the TCR. Phosphorylated LAT recruits SLP-76 to 
the membrane which in turn recruits PLC , Vav1, Itk and potentially PI3K. LAT 
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is also responsible for activating the Ras-MAP kinase signalling pathway. Both 
PLC  and PI3K act on phosphatidylinostitol 4,5-bisphosphate on the inner surface 
of the cell membrane to release diacylglycerol (DAG) and inositol triphosphate 
(IP3). DAG binds to and activates various protein kinase Cs (PKC) especially 
PKCØ in T cells. This is important for activating the transcription factors nuclear 
factor kappa B (NF B) and activator protein 1 (AP1). IP3 activates receptors 
within the endoplasmic reticulum resulting in intracellular calcium release. The 
calcium activates calcineurin which in turn causes the translocation of the 
transcription factor nuclear factor of activated T cells (NFAT) into the nucleus. 
Here it regulates the transcription of numerous genes, most importantly, the 
cytokine IL-2 which promotes the proliferation of the activated T cell. Once 
activated, the T cell will differentiate, proliferate and secrete cytokines (Acuto and 
Cantrell 2000) (Figure 1.7).  
 
 
Figure 1.7: Intracellular Signalling Events during T Cell Activation  
(From (Abbas 2000)) 
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1.2  Cancer Immunoediting 
The immune system has the potential to prevent cancer in three ways. Firstly, it 
can eliminate virally infected cells and so prevent virus-induced tumours. 
Secondly, an inflammatory microenvironment promotes tumorigenesis therefore 
rapid resolution of infection and termination of the immune response is critical in 
cancer prevention. Finally, the immune system can recognise transformed cells 
when they arise due to their expression of novel antigens, either tumour-specific 
antigens (molecules unique to cancer cells) or tumour-associated antigens 
(molecules expressed differently by cancer cells and normal cells). This process is 
known as immunosurveillance. Although it has long been established that the 
immune system protects the individual from infection by exogenous organisms, 
the existence of cancer immunosurveillance has been more hotly debated. 
 
1.2.1  A History of Immunosurveillance 
The theory that the immune system can recognise and eliminate primary tumour 
cells without external intervention was first postulated by Paul Ehrlich in 1900 
(Ehrlich 1900). However, it took over 50 years for the field of immunology to 
develop sufficiently far to allow this hypothesis to be experimentally tested. In the 
1950s, the first step was taken when Medawar and colleagues used non-inbred 
strains of mice to demonstrate that the immune response can recognise and 
destroy allogeneic transplanted tumours thus establishing the critical role of the 
cellular components of the immune system in mediating graft rejection 
(Billingham, et al 1953, Billingham 1956). It was then illustrated that tumour cells 
are themselves immunologically distinct from normal cells by the demonstration 
that mice could be immunised against transplanted syngeneic tumours induced by 
chemical carcinogens or viruses. This work established the existence of „tumour-
specific antigens‟ (Klein 1966, Old 1964). These discoveries were incorporated 
into the formal hypothesis of „cancer immunosurveillance‟ made by Sir Frank 
Macfarlane Burnet and Lewis Thomas (Burnet 1957, Thomas 1959). Burnet 
stated: 
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 “It is by no means inconceivable that small accumulations of tumour cells may 
develop and because of their possession of new antigenic potentialities provoke 
an effective immunological reaction with regression of the tumour and no clinical 
hint of its existence”.  
 
The natural challenge to this hypothesis was a demonstration that hosts with 
impaired immune function had an increased incidence of spontaneous or 
chemically induced tumours. A number of groups set about addressing this 
question using thymectomised or genetically athymic (nude) mouse models 
(Grant and Miller 1965, Stutman 1974, Stutman 1975). Unfortunately their results 
were discordant and inconclusive and in 1982 Thomas noted “the greatest trouble 
with the idea of immunosurveillance is that it cannot be shown to exist in 
experimental animals” (Thomas 1982). However, with the discovery of NK cells 
and the realisation that nude mice possess detectable populations of  T cell 
receptor bearing lymphocytes, it became clear that no conclusions could be 
reliably drawn from the experiments previously performed. The development of 
the RAG-1 and RAG-2 -/- mouse corrected this problem. These mice lacked the 
recombinase activating gene 1 or 2 which are required for repairing the breaks in 
double-stranded DNA and are expressed exclusively in lymphocytes. These mice 
failed to rearrange lymphocyte antigen receptors and completely lacked NK, T 
and B cells. DNA repair mechanisms in all other cell compartments were normal 
(Shinkai, et al 1992). When these mice were injected with chemical carcinogens, 
they developed sarcomas more rapidly and with greater frequency than wild-type 
animals. The same was true for spontaneous tumour growth. For the first time, the 
impact of loss of immune function on tumour development could be seen 
(Shankaran, et al 2001).  
 
In humans, evidence for immunosurveillance is now accumulating. Perhaps the 
strongest data comes from reports of spontaneously regressing melanoma lesions 
associated with a clonal expansion of T cells (Ferradini, et al 1993, Zorn and 
Hercend 1999a, Zorn and Hercend 1999b). However, these reports are rare and it 
is unclear why spontaneous regression should occur in melanoma in particular. 
More generally, reviews of transplant registries have demonstrated that 
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immunocompromised individuals post-transplant have a higher risk of developing 
a variety of malignancies with non-viral aetiologies with the most recent detailing 
a 7.1 fold increased incidence compared with the non-transplant population 
(Birkeland, et al 1995, Roithmaier, et al 2007). Another study, from Japan looked 
at the cytotoxicity of peripheral blood mononuclear cells (PBMCs) from 3625 
healthy individuals. Over an 11 year follow-up, those individuals whose 
lymphocytes had shown a high or medium level of cytotoxicity had a lower risk of 
developing cancer of any type compared with those whose lymphocytes had 
shown low cytotoxicity as the start of the study (Imai, et al 2000). The immune 
system also influences the outcome of cancer once a diagnosis has been made. 
Data from melanoma has suggested a positive correlation between the presence of 
tumour-infiltrating lymphocytes and increased survival (Clemente, et al 1996). 
Similar observations have been made in colon cancer (Galon, et al 2006), 
follicular lymphoma (Dave, et al 2004, Lee, et al 2006), cervical cancer (Piersma, 
et al 2007), breast cancer (Kohrt, et al 2005) and urothelial cancers (Sharma, et al 
2007). Multiple myeloma provides a clinical model of immunoediting. In its pre-
malignant stage, monoclonal gammopathy of uncertain significance (MGUS), T 
cells from the bone marrow show vigorous responses to the autologous pre-
malignant cells. These responses are not seen in patients with multiple myeloma 
(Dhodapkar, et al 2003b). It is therefore now becoming clear that evaluation of 
the immune response in and around the tumour should be included at the time of 
the initial diagnosis to aid prognostic evaluation and guide treatment. 
 
1.2.2  Schreiber’s ‘Three E’ Hypothesis 
The question that then arises is – why do tumours occur in immunocompetent 
individuals? Schreiber and colleagues have proposed the „Three E‟s‟ hypothesis 
of cancer immunoediting. The immune system functions to protect the host but 
also to sculpt the developing tumour. Early immunosurveillance results in the first 
E, „elimination‟ the evidence for which is detailed above. Secondly, „equilibrium‟ 
occurs when the cells have transformed but are held in check by the immune 
system. During this time, a Darwinian selection process takes place whereby the 
immune system selects for less immunogenic tumour cells in the course of the 
antitumour immune response. This is aided by the intrinsic genetic instability of 
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tumour cells. The targets that are often affected are tumour associated antigens 
(TAAs), MHC molecules and components of the IFN  signalling pathway. 
Evidence for this part of the process was more difficult to obtain but was recently 
demonstrated in a mouse model by Schreiber‟s group (Koebel, et al 2007). The 
third E is „escape‟ and represents the point when the tumour starts to proliferate 
uncontrollably and becomes clinically apparent as a result of acquired 
insensitivity to immunological detection (Dunn, et al 2002).  
 
1.2.3  Tumour Escape Mechanisms 
Malignant cells have evolved numerous mechanisms for suppressing and 
therefore escaping the immune response both within the local tumour 
microenvironment and systemically (Rabinovich, et al 2007). One of the most 
common ways that a tumour can hide from the immune system is by 
downregulating its antigen presentation machinery. Mutation of the 2-
microglobulin gene results in complete loss of MHC Class I expression whereas 
transcriptional regulation of the gene can cause decreased expression. Genetic 
instability within the tumour can result in selective loss of individual HLA alleles 
or mutations of the transporter associated with antigen processing (TAP) or 
molecules within the immunoproteosome (LMP2, LMP7). Mutations and/or 
deletions within the tumour DNA may also mean that the initial tumour antigen is 
no longer expressed (antigen-loss variants) and therefore cannot by recognised by 
cytotoxic T cells (Khong and Restifo 2002). As well as failing to appropriately 
present TAA, tumour cells can fail to deliver adequate costimulatory signals 
necessary for T cell activation by lack of expression of the costimulatory 
molecules CD80 and CD86 (Chen, et al 1992, Townsend and Allison 1993). The 
consequences of T cell recognition of tumour antigen would then be anergy rather 
than activation (Schwartz 2003). Tumours may also evolve to express T cell 
inhibitory molecules B7-H1 (Dong, et al 2002), HLA-G (Malmberg, et al 2002) 
or HLA-E (Derre, et al 2006). 
 
Tumour-induced T cell tolerance may be induced by inadequate presentation of 
TAAs by tumours themselves but also by APCs (cross-priming) (Sotomayor, et al 
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2001). The context of antigen presentation by APCs is critical. When dendritic 
cells present antigen in a non-inflammatory microenvironment, as exists around 
tumours, it results in T cell tolerance rather than T cell priming (Steinman, et al 
2003). Tumours further inhibit DC maturation and function by secreting such 
molecules as IL-10 (Gerlini, et al 2004) and vascular endothelial growth factor 
(VEGF) (Gabrilovich, et al 1996). Stat3 (Cheng, et al 2003) and SOCS1 (Evel-
Kabler, et al 2006) have been recognised as important signalling molecules in 
DCs in regulating the delicate balance between inducing T cell tolerance and T 
cell priming. Aside from the microenvironment, several other abnormalities have 
been noted in DCs in patients with cancer. Firstly, fewer numbers of these cells 
are found the peripheral blood of cancer patients (Almand, et al 2000). Secondly, 
those DCs that are recruited to tumour sites appear to be functionally immature 
with low expression of the costimulatory molecules CD80 and CD86 (iDCs) 
(Nestle, et al 1997, Troy, et al 1998). Furthermore, a number of studies have 
demonstrated that a form of regulatory DC, known as plasmacytoid DCs (pDC) 
are more likely to accumulate in tumour sites. These pDCs can effectively present 
antigen to T cells but instead of priming result in anergy (Hartmann, et al 2003, 
Vermi, et al 2003, Zou, et al 2001). Therefore, although tumour cells, despite 
being self, should be visible to the immune system they have developed 
mechanisms of inhibiting DCs so they become invisible.  
 
As well as hiding from the immune system, malignant cells can disable it in a 
number of ways. Tumours have been shown to secrete a variety of 
immunosuppressive factors such as transforming growth factor (TGF ), soluble 
Fas ligand (Houston, et al 2003), prostaglandin E2 (Akasaki, et al 2004) and 
sialomucins (Agrawal, et al 1998). Modulation of tryptophan metabolism by the 
enzyme indoleamine 2,3-dioxygenase (IDO) also contributes to 
immunosuppression. It causes a shortage of tryptophan resulting in proliferation 
arrest in T cells (Munn, et al 1999). IDO was previously recognised for its role in 
inducing maternal tolerance to fetal antigens (Munn, et al 1998). It was then 
demonstrated that IDO is also expressed by tumour cells. When immunogenic 
tumours were engineered to overexpress IDO they grew more aggressively and 
were less likely to be associated with an activated T cell infiltrate (Uyttenhove, et 
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al 2003). Another means of tumour escape is via protein-glycan interactions. The 
level of expression of galectin-1 by tumours correlates with aggressiveness (Liu 
and Rabinovich 2005) and there is accumulating evidence that this is via its 
inhibitory effect on T cell effector functions. Galectin-1 sensitises to T cells to 
FasL-induced death (Matarrese, et al 2005), induces T cell apoptosis (Perillo, et al 
1995), blocks proximal TCR signalling (Chung, et al 2000) and suppresses the 
secretion of pro-inflammatory cytokines (Rabinovich, et al 1999).  
 
The recruitment and expansion of CD4+CD25+ Tregs represents a systemic 
method of tumour escape. These cells comprise about 5-10% of all peripheral T 
cells and may be identified by the expression of the intracellular forkhead box P3 
(FOXP3) transcription factor in combination with glucocorticoid-induced TNF 
receptor (GITR), cytotoxic T lymphocyte antigen-4 (CTLA-4) (Sakaguchi 2004) 
and absent expression of CD127 (Seddiki, et al 2006). The mechanism by which 
Tregs induce immunosuppression is unclear but direct contact with CD4+CD25+ 
Tregs causes long-lasting anergy and production of IL-10 by CD4+CD25- T cells 
(Dieckmann, et al 2002). IL-10 inhibits cytokine production from T cells and 
exerts anti-inflammatory and suppressive effects on most types of haemopoietic 
cells. IL-10 also potently inhibits antigen-presenting cells (Mocellin, et al 2001). 
Curiel and colleagues were the first to demonstrate that CD4+CD25+FOXP3+ 
Tregs suppress tumour-specific T cell immunity and contribute to cancer growth in 
vivo with cell numbers inversely correlated with overall survival of patients with 
ovarian carcinoma (Curiel, et al 2004). Increased numbers of these cells in the 
peripheral blood have been observed in breast and pancreatic cancer (Liyanage, et 
al 2002), head and neck cancers (Chikamatsu, et al 2007), acute myeloid 
leukaemia (AML) (Wang, et al 2005), chronic lymphocytic leukaemia (CLL) 
(Beyer, et al 2005) and myeloma (Beyer, et al 2006).  
 
Another type of suppressor cell shown to induce tumour-specific T cell tolerance 
is the myeloid-derived suppressor cell (MDSC) or immature cell (ImC) 
(Kusmartsev, et al 2005). These are bone marrow derived precursors of 
macrophages, granulocytes and DCs that express CD33 but lack markers of 
mature myeloid or lymphoid cells including MHC Class II that are thought to 
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induce T cell anergy by direct cell contact via the TCR (Almand, et al 2001). In 
the mouse these cells are thought to inhibit the differentiation of APCs through 
the production of hydrogen peroxide (H2O2) (Kusmartsev and Gabrilovich 2003). 
ImCs have been found to be increased in the peripheral blood of patients with 
cancer and correlate with stage of disease. On surgical removal of tumours, the 
number of ImCs dropped within 3-4 weeks (Almand, et al 2000). Macrophages 
themselves may also contribute to suppression of tumour immunity. Tumour-
associated macrophages (TAMs) have been identified that have an polarised T2 
phenotype that promotes cancer progression and metastasis (Mantovani, et al 
2002) and this can be induced in vitro by cancer cells (Hagemann, et al 2006).  
 
Defects have also been demonstrated directly within the T cells themselves that 
prevent them responding appropriately. Impaired proximal T cell signalling with 
reduced expression of CD3  and the tyrosine kinases Lck and Fyn was noted in 
tumour-infiltrating lymphocytes in mouse models (Koneru, et al 2005, Mizoguchi, 
et al 1992), a finding that has now been reproduced in humans in multiple cancer 
types (Kurt, et al 1998, Nakagomi, et al 1993, Reichert, et al 1998, Wang, et al 
1995).  
 
The downstream effect of the escape mechanisms detailed above is anergic T cells 
that fail to respond to tumour cells adequately. This has been demonstrated in 
mouse models by experimental evidence from two research groups that 
independently showed that antigen-specific CD4 cells become tolerant during 
tumour growth in vivo (Bogen 1996, Staveley-O'Carroll, et al 1998). There is now 
also a body of data from patients demonstrating defective T cell function in a 
variety of solid tumours (Alexander, et al 1993, Miescher, et al 1986, Yoshino, et 
al 1992) and the haematological malignancies AML (Buggins, et al 1999), acute 
lymphoblastic leukaemia (ALL) (Nash, et al 1993), myeloma (Frassanito, et al 
2001) and CLL (Scrivener, et al 2003). 
 
This data illustrates that there is now overwhelming evidence that the immune 
system has a vital role to play in the development of cancer. If an attempt is to be 
made to treat or prevent cancer by immune manipulation a detailed understanding 
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of how T cells and tumours interact is required. For example, the most 
immunogenic TAA identified in vitro may be no use as a vaccine if the 
corresponding T cells within the patient are effectively exhausted whereas a 
weaker antigenic target might be able to draw on reserves of previously 
unstimulated T cells which in the presence of appropriate adjuvants could result in 
an effective immune response. In addition, the efficacy of T cell infusions as 
adoptive immunotherapy may be limited in the presence of tumour. 
 
1.3  Acute Myeloid Leukaemia (AML) 
1.3.1  Classification 
The name leukaemia, from the Greek „white blood‟, was first coined by the 
German histopathologist Rudolf Virchow in 1847 as a result of the microscopic 
appearance of what seemed to be pus in the bloodstream of affected individuals 
(Virchow 1847). This followed the original, largely ignored, clinical description 
of the disease by Velpeau in 1827 (Velpeau 1827). AML is a heterogeneous 
aggressive disorder in which malignant transformation results in the accumulation 
within the bone marrow of early haematopoietic progenitors, called myeloblasts 
(blasts) (Figure 1.8) arising from a leukaemic stem cell (Bonnet and Dick 1997). 
These myeloblasts have a characteristic immunophenotype: they express markers 
typical of haemopoietic precursors – CD34, HLA-DR, TdT and CD45 in addition 
to myeloid lineage markers CD13, CD33, CD15, cytoplasmic myeloperoxidase 
(MPO) and CD117. A diagnosis of AML is made when myeloblasts make up 
more than 20% of the cells within the bone marrow (Jaffe 2001). AML was 
originally classified on the basis of the morphology and cytochemistry of the 
blasts (French-American-British (FAB)) (Bennett, et al 1976, Bennett, et al 1985) 
but more recently the World Health Organisation (WHO) classification has 
incorporated immunophenotypic, cytogenetic and clinical features in addition to 
morphology in order to provide a more clinically relevant classification (Jaffe 
2001) (Table 1.1). 
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Figure 1.8: Myeloblasts  
(ASH Image Bank) 
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Table 1.1: Classification of Acute Myeloid Leukaemia 
 
FAB Classification WHO Classification 
M0: undifferentiated myeloblastic  
M1: myeloblastic without differentiation 
M2: myeloblastic with maturation 
M3: hypergranular promyelocytic 
M3-variant: hypogranular bilobed 
promyelocytes 
M4: myelomonocytic 
M5a: monoblastic 
M5b: monocytic 
M6: erythroleukaemia 
M7: megakaryoblastic 
AML with recurrent cytogenetic translocations 
 AML with t(8;21)(q22;q22), 
AML1(CBF )/ETO 
 Acute promyelocytic leukaemia (AML 
with t(15;17)(q22;q11-12) and variants, 
PML/RAR  
 AML with abnormal bone marrow 
eosinophils (inv(16)(p13q22) or 
t(16;16)(p13;q22) CBF /MYH11 
 AML with 11q23 (MLL) abnormalities 
AML with multilineage dysplasia 
 With prior myelodysplastic syndrome 
 Without prior myelodysplastic syndrome 
AML and myelodysplastic syndromes, 
therapy-related 
 Alkylating agent-related 
 Topoisomerase type II inhibitor-related 
 Other types 
AML not otherwise categorised 
 AML minimally differentiated 
 AML without maturation 
 AML with maturation 
 Acute myelomonocytic leukaemia 
 Acute monoblastic and monocytic 
leukaemia 
 Acute erythroid leukaemia 
 Acute megakaryoblastic leukaemia 
 Acute basophilic leukaemia 
 Acute panmyelosis with myelofibrosis 
 Myeloid sarcoma 
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1.3.2  Epidemiology and Aetiology  
AML occurs in all age groups but becomes increasingly common with advancing 
age with a median age of presentation of 68. Data from the Office of National 
Statistics from 2005 for England document an incidence of AML of 4.2 per 
100,000 people for men and 3.4 per 100,000 of the population for women across 
all age groups. Of the 1049 new cases of AML in men and 868 in women 
recorded in England in 2005 more than half were in the over 60 age group 
(http://www.statistics.gov.uk/ ). Obvious aetiological factors may only be 
identified in around 1% of cases. These include viruses, ionising radiation, 
cytotoxic chemotherapy and benzene (Sandler and Ross 1997). The majority of 
AML is thought to be due to sporadic errors during cell division in haematopoietic 
stem cells resulting in chromosomal translocations. Transcription factors 
important for normal haematopoiesis are frequently targeted such as core binding 
factor (CBF), retinoic acid receptor alpha (RAR ) and mixed lineage leukaemia 
(MLL) genes (Class II mutations). The consequence of these translocations is loss-
of-function and impaired haematopoietic differentiation. However, evidence from 
mouse models and twin studies now suggests that these mutations alone are 
insufficient to cause AML. Acquired activating mutations in tyrosine kinases such 
as FLT3 and C-KIT or their downstream effector molecules such as N-RAS and K-
RAS (Class I mutations) confer a proliferative and/or survival advantage without 
resulting in any block to differentiation. It is thought that only patients who 
develop both Class I and Class II mutations over time will develop the clinical 
phenotype of AML (Kelly and Gilliland 2002) although this view has recently 
been challenged (Liso, et al 2008). Individuals can also inherit such mutations that 
predispose them to the development of AML. Perhaps the best characterised is the 
autosomal dominant mutation in the transcription factor RUNX1 that results in 
familial platelet disorder with propensity to myeloid malignancy (FPD/AML). 
The median incidence of AML/MDS in individuals who inherit this mutation is 
35% (Owen, et al 2008). 
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1.3.3  Prognostic Stratification 
The dominant clinical feature of AML is bone marrow failure; anaemia, 
neutropenia and thrombocytopenia, and the disease is rapidly fatal if untreated. At 
diagnosis patients are stratified into prognostic risk groups according to the 
cytogenetic abnormalities found within the leukaemic cells (Grimwade, et al 
1998). Patients with t(8;21), t(15;17) and inv(16) whether alone or in conjunction 
with other abnormalities have a relatively favourable prognosis in that they are 
less likely to have primary resistant disease and have a higher overall survival and 
a lower relapse risk. Patients with complex cytogenetic changes (>5 unrelated 
changes within one clone), -5/del(5q), abnormalities of 3q or -7 whether alone or 
in conjunction with intermediate or other adverse risk abnormalities have an 
unfavourable/adverse outcome. They are less likely to achieve a complete 
remission (CR) with induction chemotherapy, have a lower overall survival and 
higher relapse rate. All other patients are classed as intermediate risk and include 
those with a normal karyotype (Figure 1.9).   
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Figure 1.9: Survival in AML  
Overall survival of previously untreated AML patients diagnosed < 60 with respect to cytogenetic 
risk category (1988-2005) (St. Bartholomew‟s Hospital data). 
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The so-called „normal karyotype‟ group makes up the majority of patients and 
consequently there is much interest in stratifying them further by the identification 
of new prognostic mutations. Those identified thus far include CCAAT enhancer 
binding protein alpha (CEBPA) (Leroy, et al 2005), nucleophosmin (NPM1) 
(Falini, et al 2005), FMS-like tyrosine kinase 3 (FLT3) internal tandem 
duplication (ITD) (Kottaridis, et al 2001, Thiede, et al 2002) and there is 
increasing evidence for Wilms‟ tumour 1 (WT1) (King-Underwood, et al 1996, 
Summers, et al 2007, Virappane, et al 2008). The aim of this stratification is to 
aid treatment decisions. 
 
1.3.4  Treatment 
Despite major advances in the understanding of the biology of AML over the last 
20 years, pharmacological agents used in the treatment of AML have changed 
very little. These drugs include the cytotoxic anthracycline antibiotic, 
daunorubicin which inhibits the enzyme topoisomerase II that is critical for 
effective DNA synthesis; mitoxantrone which is structurally related to 
daunorubicin; the podophyllotoxin, etoposide, another topoisomerase II inhibitor 
and the antimetabolite cytarabine (ara-C), an analogue of the naturally occurring 
nucleoside 2‟deoxycytidine that allows it to be incorporated into DNA and RNA 
but its main cytotoxic action is to inhibit DNA polymerase (Rang). Alone, each of 
these agents only has a small impact on the disease. It is in their combination that 
their strength lies. The combination DA (daunorubicin and ara-C) resulted in a CR 
rate of 60-65% when initially introduced and became the template for modern 
drug regimens in AML (Yates, et al 1973). 
 
Therapy involves initial induction chemotherapy to induce a morphological CR 
defined as <5% myeloblasts present in a normocellular bone marrow. This is 
followed by multiple courses (between two and three) of consolidation 
chemotherapy to eradicate minimal residual disease and maintain the remission. 
Each course induces a profound, though transient bone marrow hypoplasia with 
the requirement for transfusional support with packed red cells and platelets and 
the risk of neutropenic sepsis. In older patients or those with existing co-
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morbidities, this curative treatment regimen may be inappropriate. The alternative 
is to provide supportive care with blood products, antibiotics and low dose ara-C 
(Burnett, et al 2007). All AML subtypes are treated in the same way apart from 
acute promyelocytic leukaemia (APL) associated with the t(15;17). In this case, 
all patients are given all-trans retinoic acid (ATRA), a derivative of vitamin A, 
which causes differentiation of the immature promyelocytes into mature 
granulocytes. 
 
1.3.5  Outcomes 
Despite these intensive treatment regimens, the outcome for individuals who 
develop AML is not good with the greatest risk being relapse. Several multicentre 
prospective studies have now shown that around 80% of patients under the age of 
60 will enter CR of whom 40-50% will survive 5 years. Relapses generally occur 
within three years of initial treatment. Once a relapse has occurred, around 40% of 
patients will achieve a second remission but this is often short-lived with only 10-
15% surviving long-term (Treleaven 2009) (Table 1.2). Varying the combination 
of existing chemotherapeutic agents is unlikely to have a large impact on these 
overall survival figures and hope rests with alternative therapeutic strategies. 
 
Group No. of 
Patients 
CR  
(%) 
ID  
(%) 
RD  
(%) 
Relapse 
Risk at 
5yr 
(%) (SE) 
Survival 
at 5yr (%) 
(SE) 
Favourable 377 91 8 1 35 (2.8) 65 (2.5) 
Intermediate 1,072 86 6 8 51 (1.8) 41 (1.5) 
Adverse 163 63 14 23 76 (4.5) 14 (2.8) 
 
Table 1.2: Outcomes in AML 
CR rates, reasons for failure, relapse risk and survival by hierarchical cytogenetic risk group  
CR: complete remission, ID: induction death, RD: refractory disease, SE: standard error. (From 
(Grimwade, et al 1998)). 
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1.3.6  Haematopoietic Stem Cell Transplantation (SCT) 
Once a patient has relapsed, their prognosis is awful. The current role of stem cell 
transplantation in AML is therefore to prevent this complication. There is 
accumulating evidence that AML can be cured with allogeneic stem cell 
transplantation (Clift, et al 1987, Gale, et al 1996). This procedure involves 
ablating an individual‟s haemopoietic and immune system by chemo/radiotherapy 
rendering them aplastic and then replacing it with stem cells harvested from 
another individual. These allogeneic stem cells repopulate the bone marrow. 
Immunocompetent donor T cells transferred with the graft can recognise and 
destroy residual malignant cells in the graft-versus-leukaemia effect (GVL). 
However, these healthy T cells can also recognise normal host cells resulting in 
the major side effect of graft-versus-host disease (GVHD), a life-threatening 
disorder affecting the skin, gut and liver (Billingham 1966). Attempting to 
separate the GVHD from the GVL effect is a major research focus. The incidence 
of GVHD and other complications result in significant transplant-related mortality 
(TRM) of 20-25% which means that, despite the antileukaemic efficacy of 
allogeneic transplantation, it is not without risk. Autologous stem cell 
transplantation by definition allows no GVL effect and relies purely on the 
chemo/radiotherapy to eradicate residual malignancy and as a result has a lower 
TRM of around 5%. An early concern was the risk of re-infusing malignant cells 
with the stem cell graft as a result of which purging techniques were developed. 
 
Four major study groups, EORTC-Gimema, GOELAM, US Intergroup and UK 
MRC performed pivotal studies in the 1980s and 90s in an attempt to address the 
issue of which treatment modality, allogeneic transplant, autologous transplant or 
chemotherapy alone, was best in CR1 (Burnett, et al 2002, Cassileth, et al 1998, 
Harousseau, et al 1997, Zittoun, et al 1995). In the autograft comparison, in all 
cases, a reduced risk of relapse was seen but no survival benefit could be 
demonstrated due to transplant-related mortality effects and the ability to salvage 
patients who relapsed after chemotherapy. With regards to allogeneic 
transplantation, a donor versus no donor analysis showed there was no significant 
survival difference at four years in any of the four trials. These studies have been 
criticised however on the basis that 30% of patients with a donor did not go on to 
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receive an allograft. A more recent meta-analysis looked at studies that evaluated 
the outcome of patients with AML in CR1 by availability of a donor using an 
intention-to-treat approach regardless of treatment actually received to try to 
eliminate the selection bias demonstrated previously (Yanada, et al 2005). This 
analysis did demonstrate an overall survival advantage for patients with donors. It 
also showed for the first time the effect of cytogenetic risk group on outcome 
from allogeneic transplant with an advantage observed for poor-risk patients with 
donors. Allogeneic transplant conferred no benefit to favourable-risk patients but 
for the intermediate risk group the situation was unclear. 
 
Therefore, the current strategy in the UK is to use autologous transplantation in 
AML in patients with APL in second molecular remission, older patients who 
would otherwise have been considered for allogeneic transplant and younger 
patients who lack a sibling or unrelated donor (Apperley 2008). Due to their high 
risk of relapse, poor risk patients in first CR, less than 35 years with good 
performance status should be treated with allogeneic stem cell transplantation. If a 
suitable sibling donor is unavailable, efforts should be made to use an alternative 
donor; matched unrelated (MUD), cord blood or haploidentical (Apperley 2008). 
It remains an ongoing topic of debate as to the most suitable treatment for 
intermediate risk patients. Further identification of molecular markers should aid 
stratification and treatment decisions. Currently, if patients in this category are to 
be transplanted in CR1, it should only be in the context of a clinical trial 
(Treleaven 2009). The current MRC AML 15 study aims to answer this question 
(Figure 1.10). 
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Figure 1.10: MRC AML15 Flowchart for Non-APL AML Treatment 
 
In view of the treatment intensity, allogeneic transplant is only an option for 
young, fit individuals. In recent years, there has been a push towards less intensive 
conditioning regimens in order to broaden the applicability of this form of 
treatment. The reduced intensity non-myeloablative allogeneic transplant relies on 
an immunosuppressive conditioning regimen to allow donor stem cells to engraft 
and then makes use of donor lymphocyte infusions later on to encourage complete 
engraftment. Rather than using a myeloablative conditioning regimen to get rid of 
residual disease, this type of transplant relies on the GVL effect. Despite a lack of 
prospective randomised controlled trial data, reduced intensity transplants have 
been widely adopted and now account for 27% of allogeneic stem cell transplants 
in Europe, a rise from <1% 3 years previously (Gratwohl, et al 2002). However 
despite the early reduction in TRM because of the less intense conditioning, long-
term morbidity and mortality remain high, largely due to GVHD and relapse. 
Currently no AML-specific prospective trials comparing results of reduced 
intensity protocols with standard myeloablative conditioning regimens have been 
published.  
 
1.3.7  Molecular Targeted Therapies 
More targeted treatments are currently being investigated in AML (Burnett and 
Knapper 2007). These include FLT3 inhibitors such as CEP-70 and farnesyl 
transferase inhibitors such as tipifarnib. Farnesyl transferases catalyse post-
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translation modification of RAS and other proteins involved in signal transduction 
in proliferating cells. C-KIT inhibitors such as dasatinib are being evaluated in the 
30% of CBF leukaemias that have a C-KIT mutation. Potential epigenetic changes 
in AML are being targeted through the investigation of demethylating agents and 
histone deacetylase inhibitors. Interest has also focused on targeting the 
CD34+CD38- leukaemic stem cell (Bonnet and Dick 1997) using the monoclonal 
antibody IL3-R  (Yalcintepe, et al 2006) and mammalian target of rapamycin 
(mTOR) inhibitors (Recher, et al 2005). Alone, none of these agents alone show 
significant efficacy and are therefore all being evaluated in combination with 
existing drug regimens.  
 
1.4  The Immune System in AML 
There is accumulating evidence of the power of the immune system to cure AML. 
Spontaneous remissions in association with concurrent infections have been 
reported (Fozza, et al 2004, Ifrah, et al 1985, Maywald, et al 2004, Trof, et al 
2007). A study in the New England Journal of Medicine from 1971 looked at the 
„immune competence‟ (as assessed by delayed type hypersensitivity skin testing, 
antibody response to immunisation with keyhole limpet haemocyanin (KLH) and 
lymphocyte proliferative response to stimulation with the mitogen 
phytohaemagglutinin) in 25 AML patients pre and post chemotherapy and found 
that those with normal immune competence were more likely to achieve a 
complete or partial response to therapy (Hersh, et al 1971). The emergence of 
anti-tumour CTLs was associated with the maintenance of remission in children 
with AML treated with chemotherapy alone or with autologous transplants 
(Montagna, et al 2006). However, it is in the allogeneic setting that the ability of 
healthy T cells to eliminate residual leukaemic blasts in the graft-versus-
leukaemia effect is really apparent (Horowitz, et al 1990). This data suggests that 
it is possible for a healthy immune system to control AML. However, before 
successful immunotherapeutic interventions can be made in this disease it is 
crucial to understand what impact the leukaemic blasts have on the immune 
system that allows them to escape immunosurveillance mechanisms.  
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The microenvironment in AML is immunosuppressive. This was first noted in the 
1970s when autologous tumour cells were shown to inhibit the proliferation of 
remission lymphocytes stimulated with alloantigen. This suppressive effect could 
be inhibited by ultrasonic disintegration of the blasts, exposing the blasts to UV 
light or by adding them more than twenty-four hours after stimulation of the 
lymphocytes (Taylor, et al 1979). Several mechanisms may be important in the 
induction of this effect and numerous cell types have been implicated.  
 
1.4.1  Costimulatory Molecules 
Despite expressing dendritic cell-like surface antigens such as CD11c, HLA-DR, 
CD86 and CD83, myeloblasts are thought to be poor antigen presenting cells. This 
is because their expression of MHC Class I and the co-stimulatory molecules 
CD40 (which enhances the efficacy of antigen presentation) and CD80 is low 
(Brouwer, et al 2000, Vollmer, et al 2003, Whiteway, et al 2003). Expression of 
these molecules can be induced by 24 hours in culture and results in enhanced 
recognition by T cells. However, even when costimulatory molecule expression is 
induced in leukaemia cell lines and a T cell proliferative response obtained, T cell 
production of the „anti-cancer‟ T-helper 1 (TH1) type cytokine profile is still 
inhibited. Thus up-regulation of co-stimulatory molecule expression alone is not 
sufficient for anti-tumour immunity (Buggins, et al 1999). Of note, in blocking 
experiments, no single co-stimulatory or adhesion molecule plays a crucial role in 
the recognition of leukaemic blasts by cytotoxic T cells. Instead it is the 
combination that is required (Brouwer, et al 2000). 
 
The heterogeneous nature of AML is demonstrated in that not all FAB types act as 
poor APCs. Cell lines derived from AML blasts with the inv(16) cytogenetic 
abnormality are able to induce activation and proliferation of autologous and 
allogeneic T cells which are then capable of lysing inv(16) positive blasts whereas 
cell lines derived from other FAB types can only induce T cell activation (Banat, 
et al 2003). This allows speculation that improved antigen presentation to the 
immune system may be one mechanism for the improved prognosis in these 
patients.  
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1.4.2  Secretion of Inhibitory Molecules 
The possibility that AML myeloblasts secrete an inhibitory serum factor was 
postulated by Lim and colleagues in 1991 (Lim, et al 1991). Twenty-seven 
patients with AML were shown to have impaired cytotoxic function of CD3+ T 
cells despite increased expression of cytoplasmic cytotoxic markers. The presence 
of such an inhibitory molecule was later confirmed. T cells were purified from the 
peripheral blood or bone marrow of healthy donors. These were then cultured 
either alone or in the presence of primary AML cells placed in a cell culture insert 
that prevented contact with the T cells. T cell activation was induced with either 
anti-CD3/anti-CD28 or phorbol myristate acetate (PMA)/ionomycin and 
subsequent T cell activation and proliferation then assessed. It was found that the 
presence of the AML cells inhibited the production of IL-2 and IFN  by the T 
cells and this inhibition occurred in the absence of cell contact. The nature of this 
secreted inhibitory factor was investigated by pre-incubating the AML blasts with 
ganglioside synthesis inhibitors, nitric oxide inhibitor, indomethacin and 
neutralising antibodies to TGF  and IL-10, none of which were able to reverse the 
inhibitory effect. Furthermore, an enzyme-linked immunosorbant assay (ELISA) 
for VEGF levels in AML cell supernatants was undetectable. The fact that this 
inhibitor was a protein was established as trypsinisation of the supernatant prior to 
addition to AML cells destroyed the inhibitory effect. In addition, pre-incubation 
of the AML cells with the inhibitors of golgi function, brefeldin A or sodium 
monesin, also overcame the inhibitory effect. The consequences to T cell 
signalling of incubation with tumour supernatant were firstly, prevention of 
nuclear translocation of NF B and NFATc thus preventing their function as 
transcription factors for the production of cytokines and up-regulation of cell 
surface receptors and secondly, inhibiting entry of T cells into the cell cycle by 
preventing phosphorylation of pRb and p130 and preventing induction of p107 
and c-myc. The group concluded that inhibition of NF B by the protein produced 
by AML cells would be sufficient to account for all the effects noted (Buggins, et 
al 2001). A further late event in T cell immunosuppression by AML cells is the 
loss of CD3  chain which of note is also important for the transduction of 
activating signals in NK cells (Buggins, et al 1998, Moretta, et al 2001). These 
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findings were independently confirmed and extended to show that AML blasts 
also inhibit the proliferative activity of NK cells (Orleans-Lindsay, et al 2001). 
 
The microenvironment in AML is also anti-apoptotic (Milojkovic, et al 2004). 
Not only does the tumour supernatant delay apoptosis of both resting and 
stimulated T cells, it also has this effect on peripheral B cells, monocytes and 
neutrophils as well as promoting the survival of other AML myeloblasts. The 
mechanism postulated for this is a reduction in cleavage of pro-caspase-3, - 8, -9 
and the caspase substrate poly (ADP-ribose) polymerase (PARP) perhaps as a 
result of up-regulated bcl-2 (which is down-regulated in anti-CD3/anti-CD28 
activated T cells). These effects may be mediated by inhibition of c-myc or by 
prevention of phosphorylation of pRb. 
 
It is interesting to note that other myeloid diseases display similar characteristics. 
However, in chronic myeloid leukaemia (CML) and myelodysplasia the 
immunosuppressive effect upon T cells correlated with disease stage. The higher 
the blast count, the greater the T cell immunosuppressive effect seen and the 
lower the level of c-myc (Milojkovic, et al 2005).  
 
Although it has been established that the immunosuppressive molecule secreted 
by blasts is a protein, to date its identity remains unknown.  
 
1.4.3  Regulatory T Cells 
The peripheral blood of patients with AML contains an increased population of 
CD4+ CD25+ regulatory T cells (4.1% +/- 1.8% in AML patients compared with 
2.0% +/- 0.5% in healthy donors) (Wang, et al 2005). Although, these Tregs have a 
similar immunophenotype and cytokine secretion pattern to Tregs from healthy 
individuals they have enhanced apoptotic and proliferative capabilities compared 
with Tregs from healthy individuals. Furthermore, they suppress the proliferation 
and secretion of TH1 type cytokines (IL-2 and IFN ) but improve the secretion of 
IL-10. Thus this population of cells may be contributing to the evasion of the 
immune response by the tumour. 
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1.4.4  NK Cells 
AML blasts, in common with many other tumour cells, down-regulate MHC 
molecules and are thus targets for NK cell attack. The anti-tumour activity of NK 
cells has been demonstrated in mouse models where they have been shown to 
inhibit radiation-induced lymphomagenesis (Datta 1996) and to control the 
tumorigenesis induced by human T-cell leukaemia virus (Feuer, et al 1995, 
Stewart, et al 1996). In human cancer, it has been shown in CML that NK cell 
number and function progressively decrease during the spontaneous course of the 
disease (Pierson and Miller 1996) and that both recover on treatment with 
interferon-  (Pawelec, et al 1995). In AML, impaired NK cell activity and lack of 
production of the NK stimulatory cytokines IL-1 , IFN and IL-2 have been 
associated with early relapse (Lowdell, et al 2002, Tajima, et al 1996).  
 
NK cells also express natural cytotoxicity receptors (NCRs). Engagement of these 
receptors strongly enhances NK-mediated cytolytic activity. In contrast to healthy 
donors, in most patients with AML the majority of NK cells have a low NCR 
surface density which correlates with weak cytolytic activity against autologous 
leukaemic cells (Costello, et al 2002b).  
 
1.4.5  Dendritic Cells 
In AML, circulating DCs exhibit the cytogenetic abnormalities of the leukaemic 
blasts suggesting they have arisen from the leukaemic clone. Furthermore 
abnormalities have been noted in the ratio of myeloid DCs to the regulatory pDCs. 
Ex vivo pDCs were also found to have impaired function (Mohty, et al 2001). 
Thus normal cross-priming responses may be inhibited. 
 
1.4.6  Fibroblasts  
The role of the bone marrow microenvironment in supporting leukaemic cell 
growth is becoming evident. Leukaemia cell apoptosis was shown to be inhibited 
by co-culture of AML cells in direct contact with a fibroblast cell line (Garrido, et 
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al 2001). It has subsequently been shown that there is bidirectional cytokine 
cross-talk between leukaemic blasts and fibroblasts resulting in increased 
proliferation, anti-apoptotic signaling and increased local levels of the pro-
angiogenic IL-8 (Ryningen, et al 2005).  
 
1.5  Curing AML by Immune Manipulation 
Current therapies for AML rely on drugs that target proliferating cells and 
therefore they also have profound effects on normal dividing cells the result of 
which is often life-threatening side effects. Interest has focused on 
immunotherapy as it has the potential to be the most tumour-specific „magic 
bullet‟ that can be devised. It can take the form of active immunity whereby the 
host‟s own weak immune response to tumour is augmented either by vaccinations 
with tumour cells or antigens or the use of cytokines. Alternatively, tumour –
specific antibodies or tumour-specific cytotoxic T cells (adoptive cellular therapy) 
can be administered as a form of passive immunity.  
 
1.5.1  Vaccination 
A requirement for the development vaccines is the identification of TAAs. This 
has been made technically possible through the introduction of serological 
screening of cDNA expression libraries with autologous serum (SEREX) (Sahin, 
et al 1995) and microarray technologies. AML-specific TAAs identified by these 
techniques include receptor for hyaluronic acid mediated motility 
RHAMM/CD168 (Greiner, et al 2002), the cancer-testis antigens MPP11 
(Greiner, et al 2003) and PASD1 (Guinn, et al 2005), Proteinase 3 and 
preferentially expressed antigen of melanoma (PRAME) (Greiner, et al 2000). 
Other antigens identified as possible targets for immunotherapy due to their 
overexpression in AML include CD33 (Bae, et al 2004), BCL-2 (Andersen, et al 
2005), oncofetal antigen-immature laminin receptor (OFA-iLRP) and WT1 
(Bergmann, et al 1997). 
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Naturally occurring cytotoxic T cells directed towards TAAs in AML patients 
have been identified in the cases of proteinase 3 and WT1 (Scheibenbogen, et al 
2002), RHAMM/CD168 (Greiner, et al 2005)and PRAME (Rezvani, et al 2008). 
 
Identification of these TAAs has allowed one of the earliest vaccine approaches to 
be utilised; immunisation with purified tumour antigen in the form of peptide 
along with an adjuvant to improve immunogenicity. Phase I clinical trials have 
already been reported for WTI and RHAMM/CD168 that demonstrated clinical 
responses in association with an increase in frequency of antigen-specific CTLs 
(Oka, et al 2004) (Schmitt, et al 2008). Others are underway for the PR1 peptide 
(derived from proteinase 3) (Heslop, et al 2003) and the Hammersmith Hospital 
has initiated a study combining vaccines for WT1 and PR1 (K. Rezvani; 
Leukaemia Research Fund (LRF) Immunotherapy Day, Institute of Child Health 
12.11.08). 
 
Vaccination strategies have also been investigated using the antigenic DNA rather 
than peptide. Naked DNA in association with some form of adjuvant is injected 
into muscle or skin employing a method to improve transfection rates such as a 
gene gun or electroporation (Heslop, et al 2003). DNA is subsequently taken up 
by muscle or skin cells, processed and the resultant protein shed as antigen to be 
taken up by local APCs and presented on both Class I and Class II molecules. The 
advantage of this approach is that all arms of the immune response are activated. 
Such a strategy has been investigated for the treatment of APL. This form of 
AML is characterised by the expression of the fusion oncoprotein PML-RAR  
which represents a tumour specific antigen. Mice with APL that were vaccinated 
with naked DNA from PML-RAR  in association with the tetanus toxin fragment 
C survived longer than unvaccinated mice. Increased antibody and IFN  
production as well as relatively higher numbers of CD4 and CD8 T cells were 
seen in responding animals (Padua, et al 2003). 
 
An alternative form of vaccination that avoids the requirement for identification 
of TAAs is to use autologous tumour cells that have been „re-activated‟ to 
improve their antigen-presenting capacity. Gamma-irradiation of myeloblasts 
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induces the expression of co-stimulatory molecules. The blasts are then effective 
stimulators of T cell proliferation in vitro (Vereecque, et al 2004a). This technique 
was used in an early clinical trial at St. Bartholomew‟s Hospital (Powles, et al 
1977). More recently, autologous blasts have been genetically modified ex vivo to 
express costimulatory molecules such as CD80 alone (Hirst, et al 1997) or in 
combination with stimulatory cytokines such granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Stripecke, et al 2000) or IL-2 (Chan, et al 2005). 
Genes may be transferred by electroporation or lipofection but both these methods 
result in low gene transfer frequencies and high cell death. A much more effective 
strategy is the use of viral vectors. Both retroviral and adenoviral vectors have 
been tried but the gene transduction rate was found to be poor as AML blasts fail 
to cycle in culture and AML cells only rarely express the coxsackie and 
adenovirus receptor (CAR) required by adenoviruses for infection. As lentiviral 
vectors can infect non-dividing cells they have proved much more successful 
(Chan, et al 2006). This method results in tumour cells becoming potent 
stimulators of autologous and allogeneic T cells and NK cells. A clinical trial is 
now underway at King‟s College Hospital in which AML patients in first 
remission post allogeneic stem cell transplant will receive irradiated autologous 
tumour cells modified to express CD80 and IL-2 (Chan, et al 2006).  
 
An alternative method of reactivation is to culture blasts with the cytokines IL-4, 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumour 
necrosis factor –alpha (TNF  This converts them into effective APCs with 
costimulatory molecule expression – so-called „leukaemia-derived dendritic cells 
(LDDC) (Cignetti, et al 1999). These have been generated from patients at 
diagnosis and reinjected as vaccine therapy once the patients had achieved 
complete remission in a phase I/II trial involving 22 patients (Roddie, et al 2006). 
Anti-leukaemic T cell responses were seen but the technique is not broadly 
applicable as only around a quarter of patients have AML cells that can 
successfully differentiate into LDDC.  
 
Rather than using leukaemia-derived DCs, DCs of non-leukaemic origin can be 
used. These can be loaded ex vivo with tumour antigen and then injected as 
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cellular vaccines. There are numerous ways that antigen can be loaded onto DCs; 
if the antigen is known DCs can be pulsed with the peptide of interest itself, if it is 
unknown, DCs can be pulsed with tumour cell lysate, apoptotic tumour cell bodies 
or tumour–derived RNA or DNA. Alternatively, DCs can be fused directly to 
tumour cells. These techniques have resulted in tumour regressions in animal 
models and numerous clinical trials in solid tumours are underway in the USA 
(Galea-Lauri 2002). In AML, several groups have used these methods to 
demonstrate the generation of anti-leukaemic CTLs in vitro using DCs pulsed 
with autologous peptides eluted from AML blasts (Delluc, et al 2005), irradiated 
autologous blasts (Fujii, et al 1999, Spisek, et al 2002), a MUC1-derived peptide 
(Brossart, et al 2001) and fusion hybrids (Klammer, et al 2005). A window 
between 20 and 60 days post chemotherapy has been demonstrated for generating 
autologous monocyte-derived DCs from AML patients (Royer, et al 2008) and the 
potential for using monocyte-derived DCs from an HLA-matched allogeneic 
donor established (Lee, et al 2008). One case report illustrated the use of a WT1 
and KLH pulsed donor-derived DC vaccine administered in a patient who 
relapsed post allogeneic stem SCT. Immune responses were observed towards the 
KLH but not the WT1 and the leukaemia clinically progressed (Kitawaki, et al 
2008). 
 
Despite the widespread interest in vaccine therapy in cancer, it has yet to 
demonstrate a real therapeutic benefit. In a review of 1,306 vaccine treatments 
only a 3.3% overall response rate was observed (Rosenberg, et al 2004). Possibly 
one of the biggest disappointments in the field of haematology are the recently 
discussed results of a phase III trial of anti-idiotype vaccines in follicular 
lymphoma that showed no improvement in progression-free survival (Levy 2008). 
What could be the reasons for these poor results? Some vaccines only manage to 
recruit CD8 T cells and it is becoming increasingly apparent that CD4 help is 
crucial for effective vaccination strategies therefore antigens chosen must also be 
able to be presented by class II MHC molecules. Another potential reason for this 
could be that anti-tumour CTL responses induced by immunization are being 
suppressed by Tregs. Such TAA-specific Tregs have been identified for WT1 in 
AML patients (Lehe, et al 2008). Investigators have attempted to eliminate Tregs 
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using IL-2 conjugated to diphtheria toxin (ONTAK) with some improvement in 
tumour-specific T cell responses (Dannull, et al 2005). As CD25 is also present 
on effector T cells, more selective depletion strategies may be appropriate. Anti-
CTLA-4 has been used as part of vaccination strategies in solid tumours with 
objective clinical responses but with the side effect of auto-immunity (Phan, et al 
2003). Finally, as discussed by Professor Ron Levy in the context of his follicular 
lymphoma trial (LRF Immunotherapy Meeting, Institute of Child Health 
12.11.08) and mirroring the data from 1971 by Hersh and colleagues (Hersh, et al 
1971) it would seem that some individuals are better able to mount immune 
responses than others and these patients do show better survival. The challenge 
lies in identifying those patients who are more likely to respond to vaccination 
protocols or alternatively finding methods to improve the immune responses of 
those who currently do not mount effective responses to tumour vaccines. 
 
1.5.2  Cytokines 
As well as engineering vaccines to carry cytokines in addition to antigen, 
cytokines may be administered systemically. The cytokine IL-2 has a critical role 
in the activation and proliferation of B and T cells as well as the ability to 
generate lymphokine-activated killer cells (LAK) that can lyse leukaemia cells in 
vitro (Oshimi, et al 1986). The first reports of the use of IL-2 to prevent relapse in 
patients with AML in CR showed inconsistent efficacy and often severe toxicity 
(vascular leak syndrome) associated with high doses (Cortes, et al 1999, 
Macdonald, et al 1990). When the first phase II study reported two treatment-
related deaths and failed to show superiority of IL-2 treatment over no treatment, 
interest waned (Blaise, et al 1997). Low dose regimens have more recently been 
trialled in both children and adults over the age of 60 in CR, neither of which have 
demonstrated efficacy (Baer, et al 2008, Lange, et al 2008). However a phase III 
trial involving 320 patients has demonstrated improved leukaemia-free survival in 
patients who received IL-2 maintenance therapy (Brune, et al 2006). This 
discrepant result could be due to the addition of histamine dihydrochloride, an 
agent added for its potential to protect leukaemia-reactive T and NK cells from 
phagocytes. 
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The combination of IL-2 with IL-12 has also been evaluated in vitro. Together 
these cytokines have been shown to induce lysis of blasts resistant to classic LAK 
effects at doses of IL-2 much lower than previously required (Vitale, et al 1998). 
However no clinical trials using this combination have been reported. 
 
There is also a case report indicating the efficacy of IFN  in AML. Treatment 
was commenced in second chemotherapy–induced CR and the patient remained in 
remission for up to two years (Lowdell, et al 1999). 
 
1.5.3  Antibodies 
CD33 is widely expressed by myeloblasts but also leukaemic stem cells making it 
an attractive target for immunotherapy (Taussig, et al 2005). It has been targeted 
by the immuno-conjugate gemtuzumab ozogamicin (GO; Mylotarg). This is an 
IgG4 humanised monoclonal antibody conjugated to the cytotoxic agent 
calicheamicin. As a single agent it was found to be safe and to result in a CR rate 
of 26% in patients in first relapse (Larson, et al 2005, Sievers, et al 2001). It has 
subsequently been investigated in an upfront setting in combination with 
conventional chemotherapy in the elderly (Amadori, et al 2004) and in young 
AML patients (Kell, et al 2003) with encouraging results. The current MRC AML 
15 trial is randomising patients to induction therapy with or without GO and also 
randomising to examine whether GO is beneficial in consolidation. A non-
conjugated humanised CD33 monoclonal antibody (lintuzumab) has also been 
reported to cause objective responses including CRs as monotherapy in elderly 
patients at diagnosis with minimal side effects and the potential for outpatient 
therapy (Raza 2007). However, a potential problem with CD33 as a target is that it 
is also expressed on normal haematopoietic stem cells (Taussig, et al 2005) – a 
possible explanation for the prolonged cytopenias already noted with the use of 
Mylotarg (Kell, et al 2003, Sievers, et al 2001).  
 
Other antibodies that are of interest include CD44, an adhesion molecule 
expressed on AML blasts that appears capable of inducing differentiation in AML 
cell lines and in some cases inhibits proliferation and stimulates apoptosis via a 
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direct effect on leukaemic stem cells (Charrad, et al 2002, Charrad, et al 1999, 
Jin, et al 2006). A fully humanised anti-FLT3 antibody has also been developed 
that inhibits both wild-type and ITD-mutant FLT3 and prolongs survival of 
leukaemia-bearing mice (Li, et al 2004).  
 
1.5.4  Adoptive T cell Immunotherapy 
This technique involves the ex vivo expansion of cytotoxic T cells and their 
subsequent infusion. Various cell types and ex vivo manipulations have been used 
in clinical trials of adoptive immunotherapy. Most frequently utilized are 
unmanipulated donor T cells (donor lymphocyte infusions – DLI) post allogeneic 
SCT to augment GVL effects and eliminate residual disease. However, a side 
effect of infusing alloreactive cells is to induce GVHD. In attempt to limit this 
problem, donor T cells have been engineered with a suicide gene such as herpes 
simplex virus 1- thymidine kinase (HS-tk) gene. When a severe GVHD reaction is 
seen, these alloreactive T cells can be specifically eliminated by the 
administration of ganciclovir (Bonini, et al 1997). Unfortunately however the tk 
gene product is immunogenic resulting in immune destruction of the engineered 
lymphocytes therefore alternative suicide genes are being investigated. 
Autologous T cells can also be manipulated to improve their recognition of 
tumour cells. T cells can be nonspecifically activated ex vivo by incubating 
peripheral blood mononuclear cells with anti-CD3 and anti-CD28 monoclonal 
antibodies conjugated to beads. This results in T cell activation and has 
dramatically improved T cell defects in vitro in CLL (Bonyhadi, et al 2005). 
Infusion of T cells treated in this way has been the subject of early clinical trials 
(Porter, et al 2006). Two other activated T cell types can be generated ex vivo; 
cytokine-activated killer (CIK) cells and lymphokine-activated killer (LAK) cells 
(Table 1.3).  
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Cell 
Type 
Origin CD3 CD56 Culture 
Conditions 
MHC-
restriction 
In vitro activity and 
clinical efficacy 
LAK  NK 
cell 
- + Culture PBMCs 
in IL-2 at 1000 
U/ml for 3-5 
days 
No Cytolytic against NK 
resistant targets, 20-30% 
response rate when given 
with IL-2 in renal cell 
carcinoma and melanoma 
patients 
CIK T cell + + Culture PBMCs 
in IFNγ, OKT3, 
IL-2 for 3-4 
weeks 
No Activity against autologous 
and allogeneic tumour cells. 
Limited information on 
clinical trials 
 
Table 1.3: Characteristics of LAK and CIK Cells  
(Adapted from (Linn and Hui 2003)). 
 
Most work on LAK cells has been in solid tumours where these cells have been 
generated ex vivo then infused with IL-2 with modest effect (Rosenberg, et al 
1985) although their use post autologous transplant in AML has also been 
reported (Benyunes, et al 1993). 3+56+ CIK cells are thought to be an in vitro 
phenomenon derived from 3+56- T cells in the peripheral blood. At the end of 
culture CIK cells have potent cytolytic activity against tumour targets and are 
better at protecting against tumour development in SCID mice transplanted with 
human lymphoma cells compared with LAK cells with the advantage of not 
requiring the additional use of IL-2 (Lu and Negrin 1994). The feasibility of 
infusing autologous CIK cells post autologous SCT in AML has recently been 
reported in 13 patients (Arai 2007). 
  
Autologous T cells with cytotoxicity against autologous AML cells have been 
cloned from patients in cytological remission (Csako, et al 1980). Therefore the 
prospect of generating anti-leukaemic CTLs to treat residual disease would seem a 
possibility. Unfortunately the generation and expansion of such cell lines remains 
technically difficult particularly due to the poor immunogenicity of leukaemic 
blasts although they have been achieved in mouse models (Boyer, et al 1997). 
Antigen-specific CTLs may also be generated. One of the most convincing 
examples of this has been achieved by infusing polyclonal Epstein-Barr Virus 
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(EBV)-specific T cell lines or CD8 T cell clones to treat patients with post-
transplant EBV-associated lymphoproliferative disease (Khanna, et al 1999, 
Savoldo, et al 2000). Finally, T cells can be transduced with genetically 
engineered TCRs. The potential of this technique has recently been demonstrated 
in metastatic melanoma. Autologous lymphocytes were genetically engineered to 
express the genes encoding the alpha and beta chains of the TCR specific for 
MART-1, a melanoma TAA. These were then re-infused into 15 patients after 
maximum lymphodepletion. Durable engraftment was seen at levels greater than 
10% of peripheral blood lymphocytes for at least two months post infusion. In two 
patients, high sustained levels of engineered cells could be detected at one year 
post infusion and this was associated with objective clinical regression of 
metastatic lesions (Morgan, et al 2006). A similar method has also been attempted 
in AML with T cells engineered specific to the WT1 antigen (Tsuji, et al 2005) 
which were able to eliminate leukaemia in a non-obese diabetic-severe combined 
immune deficiency (NOD-SCID) mouse model (Xue, et al 2005). A phase I 
clinical trial is soon to open in patients with AML and CML run by the Royal Free 
Hospital (E. Morris; LRF Immunotherapy Day, Institute of Child Health 
12.11.08). A NK cell line, YT, has also been modified by gene transfer to express 
a humanised chimaeric TCR specific for CD33. These cells were then able to 
specifically lyse a human AML cell line. As NK cells do not have the MHC 
specificity requirements that CTLs have, this cell line potentially could represent 
an unlimited resource for immunotherapy in AML (Schirrmann and Pecher 2005). 
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1.6  Aims of this Thesis 
New therapeutic strategies are being developed with the aim of reducing the 
occurrence of relapse in AML patients. Despite the initial promise of 
immunotherapy, clinically thus far results have been disappointing. However, for 
any immunological treatment to have a chance of success, be it vaccination or 
adoptive T cell transfer, a primary requirement is to understand the host immune 
system, how it reacts to malignancy and by extension how it will respond to 
intervention. Mouse models have suggested a situation of chronic T cell 
exhaustion or anergy at the time of tumour escape but these results require 
validation in human cancers. Up to this point, work in AML has concentrated on 
examining the effects of tumour cells ex vivo on healthy or remission T cells.  
 
This project aims to look back inside the patient and characterise T cell defects 
that may be present in patients at the time of diagnosis with AML by flow 
cytometry, gene expression profiling and functional studies. If defects can be 
identified there is potential to seek methods of reversing them with the end result 
of providing an effective autologous T cell response to cancer. 
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Chapter 2 
Materials and Methods 
 
Addresses of all the companies listed below can be found in Appendix A. 
 
2.1  Ethical Considerations  
Ethical approval for the study entitled „The impact of the tissue microenvironment 
and immune system on haematological malignancies‟ was sought and obtained 
from the East London and The City HA Local Research Ethics Committee 3. REC 
reference number 05/Q0605/140. This covered the use of both stored samples and 
the acquisition of new samples of human biological material from patients with 
haematological malignancy and healthy volunteers.  
 
2.2  Samples 
Frozen PBMCs from patients with AML at the time of diagnosis were obtained 
from the Tissue Bank collected and maintained by the Medical Oncology 
Department of St. Bartholomew‟s Hospital. All patients signed consent forms to 
allow storage of specimens for research purposes. The Tissue Bank is maintained 
according to the Human Tissue Act 2004 (deemed license no. 12199). Samples 
were chosen on the basis of diagnosis, time of sampling, number of cryovials 
stored and whether other ancillary information (such as single nucleotide 
polymorphism (SNP) genotyping) was available. Much of the preliminary work 
was possible through the use of a large apheresis peripheral blood collection from 
a single patient at diagnosis. This allowed storage of around 30 cryovials of 5 x 
10
7
 PBMCs each for use in the early stages of this project. 
 
Friends, family and staff from the Medical Oncology unit at St. Bartholomew‟s 
Hospital provided blood samples when healthy volunteers were required. All were 
appropriately counselled and consented. For cell conjugation experiments, where 
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larger numbers of T cells were required, healthy T cells were retrieved from buffy 
coats supplied by the National Blood Service.  
 
2.3  Cell Freezing and Thawing 
Human cells were frozen by adding freeze mix (fetal calf serum (FCS) (PAA 
Laboratories Ltd.) + 10% dimethylsulphoxide (DMSO) (Fisher Scientific)) 
dropwise to a cell pellet. A maximum of 5 x 10
7
 cells were frozen in 1.8mls freeze 
mix per 2ml cryovial. Cryovials were left in Nalgene freezing containers 
(containing isopropanol) at -80
0
C overnight to allow gradual cooling before 
transfer to liquid nitrogen for long-term storage. On removal, cells were thawed 
rapidly at 37
0
C. The contents of the cryovial were then transferred to a 15ml 
falcon tube. 450 l 10% DNAase I (Sigma Aldrich) was then added dropwise to 
remove cellular debris followed by an equal volume of pure FCS. Samples were 
then centrifuged at 1300rpm for 5minutes at 4
0
C prior to further procedures. 
 
2.4  Separation of PBMCs from Whole Blood (Density Gradient 
Centrifugation) 
This protocol was used for processing peripheral blood samples from healthy 
volunteers and buffy coats.  
 
Venous blood was taken using standard technique and placed into an equal 
volume of Roswell Park Memorial Institute medium (RPMI) (CRUK Media 
Production Lab) +10% acid citrate dextrose-A (ACD-A) anticoagulant. Samples 
were then layered on top of 5mls of Lymphoprep (Axis-Shield) in 15ml falcon 
tubes. The tubes were spun at 1500rpm for 25 minutes at room temperature (RT) 
with the brake off. The interface layer representing live mononuclear cells was 
carefully removed with a pastette and washed twice with phosphate-buffered 
saline (PBS)+2%FCS prior to cell counting. 
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2.5  Cell Counting 
Cell counts and viability assessment were performed using a haemocytometer and 
Trypan Blue (Sigma Aldrich) exclusion. Ten l of cells diluted in trypan blue 
were added to the chamber of the haemocytometer. Cells were examined under a 
x10 objective using a Willovert inverted phase contrast microscope (Hund). Live 
and dead cells (blue) were counted separately to give an estimate of viability. The 
live cell count was subsequently used in calculations (Figure 2.1). 
 
21
3 4
 
Figure 2.1: Method used for Cell Counts 
Areas 1, 2, 3, 4 were counted then the result divided by 4 (X).  
X x 10
4 
x dilution = no. of cells / ml. 
 
Later on in the project, the department obtained an automated cell counter (Vi-cell 
XR – Beckman Coulter) on which live cell counts were obtained. 
 
2.6  Cell Separation Protocols 
2.6.1  Separation of CD4 and CD8 T Cells from Healthy PBMCs by 
Negative Immunomagnetic Selection 
MACS® columns, magnet, reagents and cell isolation cocktails (Miltenyi Biotec 
Ltd.) were used in this protocol. The buffer used was PBS pH 7.2, 0.5% bovine 
serum albumin (BSA) and 2mM ethylenediamine tetra-acetate (EDTA) prepared 
by diluting MACS BSA stock solution 1:20 with autoMACS™ Rinsing Solution. 
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PBMCs were isolated from whole blood by density gradient centrifugation as 
detailed above. Cells were counted and aliquots of 1 x 10
6
 cells removed for flow 
cytometry. The samples were then centrifuged at 1300rpm for 10 minutes and the 
subsequent pellets resuspended in 40 l buffer per 10
7
 total cells. Ten l of biotin-
labelled antibody cocktail (CD4+ or CD8+ T Cell Isolation Kit II) per 10
7
 total 
cells were then added. The samples were mixed by pipetting then incubated for 10 
minutes at 4-8
0
C. Thirty l of buffer per 10
7
 total cells were then added followed 
by 20 l of anti-biotin microbeads per 10
7
 total cells. The samples were then 
incubated for a further 15 minutes at 4-8
o
C and subsequently washed in 10-20 
times the labelling volume of buffer. The cells were then resuspended in 500 l 
buffer. The columns available for cell separation are listed below (Table 2.1) 
 
Column Max. No. of Labelled 
Cells 
Max. No. of Total 
Cells 
MS (recommended for 
positive selection) 
 
10
7
 
 
2x10
8
 
LS (recommended for 
positive selection) 
 
10
8
 
 
2x10
9
 
LD (recommended for 
depletion) 
 
10
8
 
 
5x10
8
 
Table 2.1: Cell Capacities of MACS® Columns 
 
Cells were separated on an LS column placed in the magnetic field of a MACs 
separator and prepared by rinsing with 3ml buffer. This effluent was discarded. 
The cell suspension was applied to the column and washed through with a total of 
9mls of buffer. The effluent was collected as the CD4 or CD8 positive fraction. 
The column was then removed from the magnetic field and placed on top of a 
fresh centrifuge tube. Five mls of buffer were added to the column and a plunger 
used to push the buffer through the column. This fraction represented the CD4 or 
CD8 negative fraction. 
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Every attempt was made to keep cells at 4
0
C during the separation procedure; 
columns were stored at 4
0
C prior to separation procedures and cells and buffer 
were kept on ice at all times. 
 
Post separation, cell counts were performed on both negative and positive 
fractions and aliquots of 1 x 10
6
 cells removed for flow cytometric analysis of cell 
purity. Cells were subsequently spun down at 1300rpm for 5 minutes at 4
0
C and 
then either frozen for future use in functional assays or resuspended in 1ml of 
Trizol (Invitrogen Ltd.) (for up to 10 x 10
6
 cells) then stored at –800C for future 
RNA extraction. 
 
2.6.2  Separation of CD4 and CD8 T Cells by Positive Immunomagnetic 
Selection 
MACS® columns, magnet, reagents and cell isolation cocktails (Miltenyi Biotec 
Ltd.) were used in this protocol. The buffer used was PBS pH 7.2, 0.5% BSA and 
2mM EDTA prepared by diluting MACS BSA stock solution 1:20 with 
autoMACS™ Rinsing Solution. 
 
Healthy PBMCs 
PBMCs were isolated from whole blood by density gradient centrifugation as 
detailed above. Cells were counted and aliquots of 1 x 10
6
 cells removed for flow 
cytometry. The PBMCs were then washed twice with 10mls of buffer before 
resuspension in 80 l of buffer per 10
7
 cells. Twenty l of CD4 or CD8 
Microbeads (Miltenyi Biotec Ltd.) per 10
7
 cells were added, mixed well then 
incubated for 15 minutes at 4–80C. Cells were then washed with 1-2ml buffer per 
10
7
 cells and spun at 1300rpm for 10 minutes at 4
0
C. Labelled cells were 
resuspended in 500 l of buffer. Magnetic separation of labelled cells was 
performed as described previously, in this instance using an MS column as the 
number of labelled cells was lower than when performing negative selection. 
Columns were prepared by rinsing with 500 l of buffer and, after the cells had 
been applied, washed with 3 x 500 l of buffer. Magnetically labelled CD4 or CD8 
Rifca Le Dieu                                                                                                   Materials and Methods 
75 
 
cells were eluted from the column after removing it from the magnet and placing 
it in a fresh 15ml falcon tube. One ml of buffer was applied to the column and the 
cells were flushed out by applying the supplied plunger to the column. The CD4/8 
negative fraction was spun down and resuspended in freeze mix for long-term 
storage. A cell count was performed on the CD4/8 positive fraction, aliquots were 
removed for flow cytometry and the remaining cells pelleted for subsequent RNA 
extraction. 
 
AML PBMCs 
Certain modifications were made to the protocol above to improve the purity and 
yield of T cells separated from AML PBMCs.  
 1) After thawing, cells were put through a density gradient centrifugation 
step to remove dead cells. 
 2) Once the live mononuclear cells had been recovered and washed, they 
were passed through a 70 m cell strainer (BD) to remove cell clumps. 
 3) After counting, cells were resuspended in 2% human anti-globulin 
(HAG) (Sigma Aldrich) at a concentration of 80 l per 10
7
 cells (rather than 
buffer) and incubated on ice for 20 minutes to allow blockade of non-specific Fc 
receptors. 
 4) Cell separation was performed on LS columns because of their higher 
cell capacity. To improve T cell purity, the column was washed with double the 
recommended volume of buffer (i.e. with 18mls of buffer). 
 5) To improve cell yield, the negative T cell fraction was subsequently 
spun down, resuspended in the same volume as prior to the first cell separation 
and then passed over a second LS column which was also washed with double the 
recommended volume of buffer. Positive T cell fractions from the 2 columns were 
then combined, spun down, resuspended in 1ml of buffer, counted, aliquots 
removed for flow and finally resuspended in 1ml Trizol (Invitrogen Ltd.) and 
stored at -80
0
C for future RNA extraction. 
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2.6.3  Separation of CD4 and CD8 T Cells from Presentation AML 
Specimens by Negative Selection  
StemSep™ cocktails, columns and pump (StemCell Technologies) were used for 
this protocol. Both fresh and frozen samples were used. 
 
After thawing and washing, cells were passed over a 70 m cell strainer into a 
50ml falcon tube to remove cell clumps. Cells were then counted and aliquots of 1 
x 10
6
 cells were removed for flow cytometry. Samples were centrifuged at 
1300rpm for 5 minutes at 4
0
C then resuspended in 2% HAG at a concentration of 
5 x 10
7
 cells/ml. After a 30 minute incubation on ice to allow blockade of Fc 
receptors, StemSep™ antibody cocktails were added at the recommended volume 
per ml of cells. Cells were left on ice at 4
0
C for 30 minutes. Magnetic colloid was 
then added at a volume of 100 l per ml of cells (rather than 60 l as 
recommended) and samples were again left for 30 minutes at 4
0
C with occasional 
agitation. Magnetic separation of labelled cells was then performed on 0.3” or 
0.6” columns depending on total cell number (Table 2.2). With AML samples, 
due to the large size of cells, the optimum number of cells per column was not 
exceeded. 
 
Column Size Optimum Number of Cells Extended Range of Cells 
0.6” 5 x 108 108 – 1.5 x 109 
0.3” 5 x 107 2 - 8 x 107 
Table 2.2: Cell Capacities of StemSep™ Columns 
 
Columns were used in conjunction with StemCell Technologies Blue Magnet and 
peristaltic pump. Columns were primed with PBS without FCS until the level of 
the PBS was above the stainless steel matrix of the column and then washed with 
PBS+2%FCS using the directions below remembering to reverse the pump 
direction in between (Table 2.3).  
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Column Size Priming Washing and loading sample 
 Pump setting Pump  
setting 
Volume 
0.6” 3.0 10.0 25mls 
0.3” 1.0 3.0 8mls 
Table 2.3: Pump Set-Up for Use with StemSep™ Columns 
Pump settings and volumes of PBS+2%FCS required for priming and washing StemSep™ 
columns. 
 
Samples were loaded onto the columns and washed through with PBS+2%FCS at 
the pump setting and volume listed. At no point were the columns allowed to run 
dry. Every attempt was made to keep cells at 4
0
C during the separation procedure; 
the magnet and columns were left at 4
0
C prior to cell separation and solutions and 
eluted cell fractions were kept on ice. Post separation, cells retained on the 
column (blasts) could be recovered by removing the column from the magnet, 
inverting it over a 50ml falcon tube and using a 1ml pipette to pass PBS+2%FCS 
through the column. All cell fractions were then spun down and resuspended in 
smaller volumes of PBS+2%FCS suitable for cell counting. Aliquots of 1 x 10
6
 
cells were removed to allow purity to be assessed by flow cytometry before the 
cells were used for further experiments. Separated cells were then frozen down for 
future use in functional assays. 
 
2.7  Flow cytometry 
This was used to assess purity of T cell fractions after separation procedures and 
for phenotyping cells. Details of all antibodies used can be found in Appendix B. 
 
2.7.1  Surface Staining 
In general, 0.5 x 10
6 
cells were used for controls and 1 x 10
6
 cells for samples 
however; often considerably fewer cells would be used to avoid wasting T cells. 
Nonetheless, the protocol was not adjusted for fewer numbers of cells. Aliquots of 
cells were placed in 5ml polystyrene round-bottom tubes (BD) and left on ice 
until all samples were ready for staining. On all occasions, unlabelled and isotype 
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controls for the antibodies being used were included. Firstly, cells were washed 
with 1ml of PBS+2%FCS and spun at 1300rpm for 5 minutes at 4
0
C. Cells were 
then resuspended in 50 l of PBS+2%FCS or 2% HAG (if not previously exposed 
to this in the course of the experiment). Cells in 2% HAG were left for 20 minutes 
on ice. In general, 5 l of each required antibody was then added to the relevant 
tubes. For certain antibodies a lower volume was added after experience 
demonstrated that 5 l resulted to staining intensity that was too great. After 
mixing, samples were incubated at 4
0
C for 30 minutes. Cells were then washed in 
1ml PBS+2%FCS and subsequently resuspended in 400 l PBS+2%FCS. 4‟6-
diamidino-2-phenylindole (DAPI) was added to this final cell suspension at a 
concentration of 1 l per 5mls (stock=500 g/ml) to allow dead cell exclusion. 
Samples were left covered in foil at 4-8
0
C until analysis was performed. 
 
2.7.2  Whole Blood Lysis Method 
This method was used for phenotyping cells when fresh blood samples were 
obtained from healthy volunteers or clinic patients. 
 
Peripheral blood was taken directly into BD vacutainer tubes container EDTA as 
an anticoagulant. 5ml polystyrene round-bottomed tubes were labelled and filled 
with 4mls of cold ammonium chloride (StemCell Technologies). After gently 
inverting to mix, 50 l of anticoagulated peripheral blood was added to control 
tubes and 200 l to sample tubes. Solutions were pipetted up and down to mix. 
Red cell lysis was allowed to occur while the samples were incubated for 10 
minutes on ice. 300 l FCS was then added to each tube and samples were spun at 
1300rpm for 5 minutes at 4
0
C to pellet the cells. Cells were resuspended in 50 l 
2%HAG and left for 20 minutes on ice. Antibodies were then added to the 
relevant tubes and incubated at 4
0
C for 30 minutes. After washing with 1ml 
PBS+2%FCS, cells were resuspended in 300 l PBS+2%FCS+DAPI. For the 
purpose of cell counting, 50 l Countbright™ absolute counting beads (Invitogen) 
were added to each sample. These were vortexed for 30 seconds prior to use.  
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2.7.2  Intracytoplasmic Staining 
After staining with surface antibodies, cells were washed with 1ml of 
PBS+2%FCS. For intracellular staining the Cytofix/Cytoperm plus 
Fixation/Permeabilisation Kit with BD GolgiPlug (BD) was used. Cells were 
resuspended in 250 l of Fix/Perm buffer and left for 20 minutes at 4
0
C. Samples 
were then washed twice with 1ml of 1X Perm/Wash buffer before being 
resuspended in 50 l Perm/Wash buffer. Intracellular antibodies and isotypes were 
then added. 0.1 l of anti-perforin antibody and 1 l of anti-granzyme B antibody 
were used per sample. Following incubation for 45 minutes at 4
0
C, cells were 
washed three times with 1ml of 1X Perm/Wash buffer. Cells were finally 
resuspended in 500 l of PBS+2%FCS for flow cytometric analysis. Fixing and 
permeabilising cells changes their scatter characteristics. Control tubes were 
therefore always prepared in the same way as the sample tubes. 
 
2.7.3  Intracytoplasmic Staining for Cytokines 
Frozen cells were thawed, washed, passed over 70 m cell strainers and counted. 
Samples were divided into those which were to be stimulated and those which 
were not. Cells were then resuspended in RPMI+10%FCS in 6-well tissue culture 
plates at a concentration of 2 x 10
6 
cells/ml. Fifty ng/ml phorbol myristate acetate 
(PMA) (Sigma Aldrich), 1 g/ml ionomycin (Sigma Aldrich) and 1 l/ml brefeldin 
A (BD GolgiPlug) were added to cells undergoing stimulation. To unstimulated 
samples only 1 l/ml brefeldin A was added. Cells were then incubated for 5 hours 
at 37
0
C+5%CO2. Cells were then harvested by repeated pipetting and washing 
wells with 5mls PBS+2%FCS. After centrifuging at 1300rpm for 5 minutes at 
4
0
C, cells were resuspended in PBS+2%FCS and counted. Aliquots of 1 x 10
6
 
cells were transferred to labelled 5ml polystyrene round-bottomed tubes. These 
samples were spun down then resuspended in 50 l 2%HAG and left on ice for 20 
minutes. Surface staining antibodies and their appropriate isotype controls were 
then added and samples incubated at 4
0
C for 30 minutes. Excess antibody was 
removed by washing with 1ml PBS+2%FCS and then cells were fixed by 
resuspending them in 100 l of 4% paraformaldehye (PFA) for 15 minutes at 4
0
C. 
Cells were subsequently washed with 1ml of PBS+2%FCS twice. Fixed surface 
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stained cells were then left overnight in the dark at 4
0
C in 1ml of PBS+2%FCS. 
The following day, cells were spun down at 1300rpm for 5 minutes at 4
0
C and 
then resuspended in 1ml 1X Perm/Wash buffer (BD). After a 15 minute 
incubation at 4
0
C, cells were spun down and pellets were resuspended in 50 l of 
the same 1X Perm/Wash buffer. Intracytoplasmic staining antibodies and their 
appropriate isotype controls were then added (IL-4 phycoerythrin (PE) = 1.25 l, 
IFN  fluoroscein isothiocyanate (FITC) = 0.5 l, TNF  FITC = 1 l, IL-2 PE = 
2.5 l). Samples were left for 30 minutes in the dark at 4
0
C. After incubation, cells 
were washed twice with 1ml of 1X Perm/Wash buffer before being resuspended 
in 500ml PBS+2%FCS in preparation for flow cytometric analysis. 
 
2.7.4  Flow Cytometric Acquisition and Analysis 
Initially a FacsCalibur (BD) and later a LSR cytometer (BD) were used for flow 
cytometry. CellQuest software (BD) was used for acquisition and also analysis 
early on in the project. Subsequently, FlowJo (Tree Star Inc) software was used 
for analysis. An unlabelled sample was used to set appropriate voltages. This tube 
was also used to set a gate (R1) over the lymphocyte region as determined by 
forward (FSC) and side scatter (SSC). A second gate (R2) was set on live cells 
only as determined by SSC and DAPI. A combination of these two gates was used 
for all subsequent acquisition. Occasionally a third acquisition gate would be set 
using R1+R2 gated cells on CD3+ cells. This gating strategy is illustrated in 
Figure 2.2. Single fluorochrome-labelled samples were used to set appropriate 
compensation. A minimum of ten thousand events were acquired from R1+R2. 
During subsequent analysis, gates were set using the isotype controls. 
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Figure 2.2: Flow Cytometry Gating Strategy 
Scatter plot (A) illustrates the normal positions of cell populations on forward and side scatter 
plots. R1 indicates the mononuclear cell gate. (B) demonstrates how dead cells are excluded using 
DAPI. R2 indicates the live cell gate. (C) shows how CD3+ lymphocytes are gated (R3) on cell 
populations that have already been gated as R1+R2. 
 
For obtaining absolute cell counts, two methods were used. For fresh samples, 
Countbright™ Absolute Counting Beads (Invitrogen Ltd.) were added to samples 
as detailed above. These beads are a calibrated suspension of microspheres that 
fluoresce brightly over a wide range of emission and excitation wavelengths. A 
known volume of beads is added to a known volume of sample thus the volume of 
sample analysed can be calculated from the number of bead events recorded and 
can be used with cell events to determine concentration. A least 1000 bead events 
were acquired for statistical accuracy. The counting beads appeared in the upper 
right region of all fluorescence dot plots and were gated on the FL2/FL4 dot plot 
(Figure 2.3). 
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Figure 2.3: Location of CountBright™ Counting Beads on Fluorescence Dot 
Plots 
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The absolute cell number was then calculated using the formula below (Figure 
2.4). 
x = Concentration of sample as cells/ l
A = number of cell events
B = number of bead events
C = assigned bead count of the lot (beads/50 l)
D = volume of sample ( l)
A
B
C
D
 
Figure 2.4: Absolute Cell Counts using CountBright™ Beads  
Formula for calculating absolute cell number using CountBright™ beads. 
 
To perform absolute cell counts on frozen samples, the bead method was not 
possible as the cells had been concentrated during the preparation process. 
Therefore absolute cell count was determined from the full blood count (FBC) 
performed on the same day using the following calculation: total white cell count 
x 10
9
/L x % mononuclear gate x % DAPI gate x % CD3+ gate x % +ve cells. 
 
2.8  Cytospins 
A Shandon Cytospin 3 (Thermo Fisher Scientific Inc.) was used to perform 
cytospins of aliquots of 1 to 10000 cells from the CD4 and CD8 positive fractions. 
Samples were spun at 500rpm for 5 minutes. The area of the glass slide occupied 
by cells was subsequently demarcated using a diamond marker. Slides were then 
stained with May-Grunwald-Giemsa (MGG) prior to examination. 
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2.9  RNA Extraction 
Using the standard Trizol (Invitrogen Ltd.) protocol, the quality and quantity of 
RNA obtained from separated T cell fractions was poor. This appeared to be a 
property of T cells as when the protocol was used to extract RNA from B cell 
lines good quality material was obtained. Modifications in the protocol were 
recommended by Dr. Gullu Gorgun from Dana Farber Cancer Institute (DFCI) 
and resulted in substantial improvement in the RNA obtained from T cells. These 
modifications included improving initial phase separation with a gel to reduce 
phenol contamination and the use of a column to bind the extracted RNA and 
allow washing, the removal of DNA and subsequent elution. This protocol is 
detailed below. 
 
One ml Trizol was added to a maximum of 10
7
 cells and the sample homogenized 
by pipetting. The sample was allowed to rest at RT for 5 minutes. A MaxTract 
high density gel tube (Qiagen) was spun for 30 seconds at 12000rpm to bring the 
gel to the bottom of the tube. The Trizol extract was then added followed by 
200 l of chloroform (per 1ml Trizol) and mixed for 15 seconds. The sample was 
left at RT for 3 minutes followed by a 15 minute spin at 12000rpm at 4
o
C for 15 
minutes. The top (clear) aqueous phase should be above the gel plug and the pink 
phase should be underneath it. The top phase (approx 600 l) was transferred to a 
new tube and 1 volume of 95% ethanol (cold) was added and mixed. This mixture 
was transferred to a Promega spin column (SV Total RNA Isolation Kit) and spun 
at 12000rpm for 1 minute. The flow through was discarded and the column 
washed with 500 l SV RNA wash buffer, spun again for 1 minute and the flow 
through discarded again. 
 
Fifty l of DNAseI mix was added and the column incubated for 15 minutes at 
RT. Two hundred l of DNAse STOP buffer was then applied and the column 
spun for 1 minute at 12000rpm. The flow through was discarded and the column 
washed with 500 l SV RNA wash buffer, spun for 1 minute at 12000rpm and the 
flow through discarded once again. The washing step was repeated using 250 l 
buffer and a 2 minute spin. The collection tube was changed and 30 l of cold 
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0.1% diethyl pyrocarbonate (DEPC) water was applied to the column. This was 
allowed to rest for 2 minutes on ice and then spun at 12000rpm for 1 minute. A 
further 20 l of cold DEPC water was then added, left on ice for 2 minutes then 
spun at 12000rpm for 1 minute. A 1 l aliquot was used to assess RNA quantity 
and quality on a Nanodrop spectrophotometer. The absorbance (A) was measured 
at several different wavelengths; 230, 260 and 280nm. RNA at 1mg/ml has an 
A260 of 25. Thus quantity can be calculated. The A260/A280 ratio indicates purity 
and should be between 1.8 and 2.0. Proteins have a peak absorbance around 
280nm and will therefore reduce this ratio if present. Absorbance at 230nm 
indicates phenol contamination. The A260/A230 should be >1.8. Expected yields of 
RNA per 1 x 10
6
 cultured cells vary with tissue type but range from 1 to 25 g 
(Figure 2.5).  
 
 
Figure 2.5: Typical Absorbance Plot for RNA on the Nanodrop 
Spectrophotometer 
Illustrates good quality RNA. 
 
If the samples had low A260/A230 ratios suggestive of contamination, a second 
precipitation was performed. A 1/10 volume of 3M sodium acetate and 2.5 
volumes of 100% ethanol were added to the sample. After mixing, the sample was 
left at -20
o
C for at least 1 hour and often overnight. The samples were then spun 
at 12000rcf for 20 minutes at 4
o
C. The supernatant was carefully removed and the 
pellet was washed twice with 80% ethanol in DEPC water. The pellet was air-
dried for 10 minutes and then resuspended in DEPC water. Quality and quantity 
was reassessed on the Nanodrop spectrophotometer and the RNA was left at –
80
o
C until required. 
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2.9.1  Assessment of RNA Quality and Quantity for the Purpose of 
Microarrays 
All RNA samples to be used for gene expression microarrays were first checked 
on the Agilent 2100 Bioanalyzer. This uses a fluorescent assay involving 
electrophorectic separation to provide qualitative and quantitative assessment of 
RNA. The Agilent RNA chip contains an interconnected set of microchannels that 
is used for the separation of nucleic acid fragments based on their size as they are 
driven through a gel by electrophoresis. The Bioanalyzer measures the amount of 
fluorescence as the RNA sample is pulsed through the microchannel over time. 
Gel-dye mix is loaded into the chip using a chip priming station. Up to 12 1 l 
RNA samples (50-500ng) can be loaded onto the chip together with 1 l of RNA 
ladder. The software creates an electropherogram which documents fluorescence 
over time. Smaller molecules are pulsed through the separation channel quicker 
than larger ones and therefore appear on the left of the electropherogram. High 
quality RNA should show clear 28S and 18S peaks, low noise between those 
peaks and minimal low molecular weight contamination as demonstrated in 
Figure 2.6. The RNA Integrity Value (RIN) has a range of 1 to 10 with 1 
representing most degraded RNA and 10 most intact. >6 represents quality 
sufficient for microarrays. 
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Figure 2.6: Electropherogram of Good Quality RNA 
 
2.10  Gene Expression Microarrays (Affymetrix UK Ltd.) 
The Affymetrix Expression GeneChip® Protocol one-cycle procedure were used 
to synthesize fragmented biotin-labelled cRNA as recommended by the 
manufacturer (Figure 2.7). Two to five g of total RNA was used as starting 
material.  
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Figure 2.7: GeneChip® Eukaryotic Labelling Assay for Expression Analysis  
(From Affymetrix Expression Analysis Technical Manual) 
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2.10.1  First Strand cDNA Synthesis 
Preparation of RNA/T7-oligo(dT) primer mix 
 Total RNA (2-5 g)     variable volume 
 T7-oligo(dT) Primer, 50 M    2 l 
 DEPC-water      variable volume 
 Total Volume      12 l 
After mixing, the samples were incubated at 70
o
C for 10 minutes and then left on 
ice for at least 2 minutes.  
 
First Strand cDNA Synthesis Master Mix (prepared on ice) 
 (5x) First Strand Buffer    4 l 
 DTT (0.1M)      2 l 
 dNTPs (10 mM each)     1 l 
 Total Volume      7 l 
Seven l of master mix was added to each tube and the samples were then 
incubated at 42
o
C for 2 minutes. At this point 1 l of Superscript II was added to 
each sample giving a final volume of 20 l. Samples were then left at 42
o
C for 1 
hour. At the end of this period, the samples were allowed to cool down on ice for 
at least 2 minutes. 
 
2.10.2  Second Strand cDNA Synthesis 
Second Strand DNA Master Mix (prepared on ice) 
 DEPC-treated water     91 l 
 (5x) Second Strand Buffer    30 l 
 dNTPs (10mM each)     3 l 
 E.coli DNA Ligase (10U/ l)    1 l 
 E.coli DNA Polymerase I (10U/ l)   4 l 
 E.coli RNase H (2U/ l)    1 l 
 Total Volume      130 l 
One hundred and thirty l of master mix was added to each first strand cDNA 
reaction. After mixing, the samples were incubated at 16
o
C for 1 hour and 55 
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minutes. At this time, 2 l of T4 DNA polymerase was added to each and the 
samples left at 16
o
C for a further 5 minutes. 10 l of 0.5M EDTA pH8.0 was then 
added to stop the reaction giving a final volume of 162 l of double-stranded 
cDNA. 
 
2.10.3  Clean-up of Double Stranded cDNA 
This was performed using the Sample Cleanup Module from Affymetrix that uses 
a column on which the cDNA binds, is then washed and then eluted. 600 l of 
cDNA Binding Buffer was added to the 162 l double-stranded cDNA sample and 
mixed by vortexing for 3 seconds. Five hundred l of this mix was then applied to 
the cDNA Cleanup Spin Column placed in a 2 ml Collection Tube. This was then 
centrifuged for 1 minute at 8000rcf and the flow-through discarded. The spin 
column was then reloaded with the remaining mixture (262 l) and centrifuged as 
before. At this point the collection tube was discarded and the column placed in a 
new 2ml collection tube. To wash the bound cDNA, 750 l of cDNA Wash Buffer 
was pipetted onto the column which was then spun at 8000rcf for 1 minute. The 
cap of the spin column was then opened and the samples centrifuged for 5 minutes 
at maximum speed. The collection tubes were again discarded. The cDNA was 
eluted by adding 14 l of cDNA Elution Buffer directly onto the spin column 
membrane and incubating for 1 minute at RT. The columns were centrifuged for 1 
minute at maximum speed. The volume of the eluate was assessed and the 
contents made up to 20 l with DEPC-treated water. 
  
2.10.4  Synthesis of Biotin-labelled cRNA by In Vitro Transcription (IVT) 
An IVT master mix was prepared at RT. 
 cDNA sample      20 l 
 10x IVT labeling buffer    4 l 
 IVT labeling NTP mix    12 l 
 IVT labeling enzyme mix    4 l 
 Total Volume      40 l 
The samples were incubated for 16 hours overnight at 37
o
C. 
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2.10.5  Clean-up of Biotin-labelled cRNA 
Sixty l of DEPC-treated water was added to the in vitro transcription reaction. 
350 l of IVT cRNA Binding Buffer was subsequently added and mixed by 
vortexing for 3 seconds. Two hundred and fifty l of 100% ethanol was then 
added and mixed by pipetting. This made a total sample volume of 700 l. This 
was applied to an IVT cRNA Clean-up Spin Column in a 2ml collection tube and 
spun for 15 seconds at 8000rcf. The flow-through and collection tube were then 
discarded. Once placed in a fresh collection tube, 500 l IVT cRNA wash buffer 
was added to the spin column that was spun at 8000rcf for 15 seconds. This step 
removes unincorporated dNTPs. Five hundred l of 80% ethanol was then applied 
to the spin column and centrifuged for 15 seconds at 8000rcf. The cap of the 
column was then opened and the column re-centrifuged this time at maximum 
speed for 5 minutes. Once the column had been transferred to a fresh 1.5 ml 
collection tube, 11 l of DEPC-treated water was added directly onto the 
membrane of the column. This was then spun for 1 minute at maximum speed. A 
further 10 l DEPC-water was applied to the membrane and the spin repeated. 
This made a total volume of 21 l of eluted biotin-labelled cRNA. 
 
At this point, 0.5 l of each sample was removed and made up to 10 l with DEPC-
treated water (1 in 20 dilution). A 1 l aliquot of this mix was used to check the 
quality and quantity of cRNA using the Nanodrop spectrophotometer. 
 
Once the quantity of cRNA had been determined, an adjustment to the 
concentration was made to reflect the possibility of carryover of unlabelled total 
RNA from the start of the experiment. An assumption of 100% carryover was 
made. 
 
Adjusted cRNA yield = cRNA amount after IVT – total starting RNA 
 
The minimum concentration of cRNA required for fragmentation is 0.6 g/ l. 
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2.10.6  Fragmentation of cRNA 
Once the cRNA concentrations in each sample had been adjusted, 20 g of cRNA 
was removed from each. To this, 8 l of 5X fragmentation buffer was added and 
the volume made up to 40 l with DEPC-treated water. The sample was incubated 
for 35 minutes at 94
o
C and then placed on ice. Two l of the fragmented cRNA 
was then removed to run on a 1.2% agarose gel for 30 minutes at 100V. The 
fragmentation should produce a distribution of RNA fragment sizes from 
approximately 35 to 200 base pairs. 
 
2.10.7  Preparation of the Hybridisation Cocktail 
Once fragmented, 15 g of biotin-labelled cRNA (30 l) were added to a 
hybridisation cocktail prepared as shown.  
 Control oligoB2     5 l 
 20X eukaryotic hybridisation controls  15 l 
 herring sperm DNA     3 l 
 acetylated BSA     3 l 
 2X hybridisation buffer    150 l 
 DEPC-treated water     94 l 
 Total Volume      300 l 
 
At this point, samples were passed to the Affymetrix operator Mrs. T. Chaplin 
who performed hybridisation of the samples onto the chips, washing, staining and 
scanning.  
 
2.10.8  Hybridisation, Washing, Staining and Scanning 
Although previous studies in CLL were performed using the Affymetrix U133A 
GeneChip®, here the Affymetrix U133Plus2 GeneChips® were used as they offer 
the most comprehensive coverage of the whole human genome. Expression levels 
of over 47,000 transcripts covering 38,500 well-characterised human genes are 
analysed on the array. Eleven pairs of oligonucleotide probes are used to measure 
the level of transcription of each sequence represented. 
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The Affymetrix GeneChips® were stored at 4
o
C shielded from light. Prior to 
hybridisation, they were equilibrated to RT for at least 30 minutes. Meanwhile, 
the samples in hybridisation cocktail were heated to 95
o
C for 5 minutes, then 
cooled to 48
o
C and finally centrifuged at maximum speed for 5 minutes to 
precipitate any insoluble material. At this point, the samples were loaded onto the 
chips and hybridisation allowed to occur by incubating at 45
o
C for 16 hours in a 
rotating hybridisation oven set at 60rpm. The following morning, the samples 
were removed from the chips and replaced with low-stringency wash buffer. The 
chips were then placed in a GeneChip® 450 Fluidics wash station where they 
were washed to remove non-hybridised probes and then stained with Streptavidin 
Phycoerthyrin (SAPE) that labels the biotinylated cRNA fragments that have 
hybridised to the array. Finally, the chips were scanned using the GeneChip® 
3000 scanner. This converts the fluorescent signal generated from each bound 
cRNA fragment into an expression value (raw value) and a flag (present, marginal 
or absent calls). A report is produced listing these values for each probe set. In 
addition, certain quality control values are reported which reflect the hybridisation 
quality. In particular, the noise signal should be less than 4, the scale factor 
around 1, the background noise less than 100 and around 50% of the probes had to 
be present, the remaining 50% being absent or marginal. In addition, 
housekeeping genes were reported as controls. For these, the 3‟/5‟ signal ratio 
should be less than 1 with values higher than this reflecting degradation in the 
RNA. 
 
2.10.9  Microarray Analysis 
Various software packages were used for analysis; Genespring GX v7.3 (Agilent 
Technologies) and Partek Genomics Suite (Partek Inc.) in the Medical Oncology 
Department and Bioconductor (www.bioconductor.org) was used by Richard 
Mitter, bioinformatician at Cancer Research UK, Lincoln‟s Inn Fields. Subsequent 
pathway analysis was done using Ingenuity software (Ingenuity Systems Inc.). 
Details of specific analyses performed can be found in the relevant chapters. 
 
Rifca Le Dieu                                                                                                   Materials and Methods 
94 
 
2.11  Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
Gene expression changes observed in microarray experiments were validated 
using this technique.  
 
2.11.1  cDNA Synthesis from RNA 
For qRT-PCR reactions, single-stranded RNA was reverse transcribed into 
complementary cDNA. One hundred ng of RNA was used as starting material. A 
no template (water-only) control was always included. The RNA was added to 
0.5ml eppendorfs and made up to 11.5 l with molecular biology grade water 
(Sigma Aldrich). To this, 1.5 l of random hexamers (50 M) (Sigma Aldrich) 
were added. Samples were heated to 70
0
C for 5 minutes to denature RNA 
secondary structures then left on ice for 2-5 minutes to allow the primers to anneal 
to the RNA. Seventeen l of the following master mix was then added: 
 M-MLV 5X buffer (Promega UK Ltd.)  6 l 
 dNTP mix (Amersham)    10 l 
 M-MLV RT enzyme (Promega UK Ltd.)  1 l (200U) 
Total Volume      30 l 
 
Samples were incubated in a PTC-225 thermocycler (MJ Research) at 42
0
C for 1 
hour to allow reverse transcription, followed by 95
0
C for 5 minutes to inactivate 
the enzyme.  
 
cDNA synthesis was confirmed by performing a standard PCR for the 
ubiquitously expressed beta-actin gene. Sequences of the primers used were 5‟-
GCGGGAAATCGTGCGTGCGTGACATT-3‟ (forward), 5‟-
GATGGAGTTGAAGGTAGTTTCGTG-3‟ (reverse) (Sigma Aldrich). The no 
template control from the cDNA synthesis reaction and a no template control for 
the beta-actin PCR were included to exclude contamination. Cell line cDNA was 
also included to ensure consistency of the reverse transcription. Reactions were 
set up in 0.2ml PCR tubes on ice.  
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The following master mix was made up per sample: 
 cDNA       2 l 
 10X buffer (Invitrogen Ltd.)    2.5 l 
 dNTPS (10mM) (Amersham)    0.5 l 
 MgCl2 (Invitrogen Ltd.)    0.75 l 
 Forward primer (see above)    1 l 
 Reverse primer (see above)    1 l 
 Taq DNA Pol (5u/ml) (Invitrogen Ltd.)  0.2 l 
 Water (Sigma Aldrich)    17.05 l 
 Total Volume      25 l 
The reaction was performed on a PTC-225 thermocycler (MJ Research) using the 
following programme: 95
0
C for 1 minute, 35 cycles of 95
0
C of 30s (template 
denaturation), 62
0
C of 30s (primer annealing), 72
0
C for 45s (extension), 4
0
C 
forever.  
 
Four l of PCR product with 2 l of loading buffer (bromphenol blue or orangeG 
– Sigma Aldrich) were checked on a 1.2% agarose (Invitrogen Ltd.) gel 
(containing ethidium bromide) with 4 l of a 1Kb DNA ladder (Invitrogen Ltd.). 
Gels were run at 100V for 20-40 minutes. Expected product size was 250-300bp. 
The band sizes for the DNA ladder used are shown in Figure 2.8. Gels were 
visualised under UV light using a GeneFlash Bio-Imager (Syngene). 
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Figure 2.8: Expected Bands for 1Kb DNA Ladder 
 
2.11.2  qRT-PCR Set-up 
Reactions were set up in a dedicated hood that was cleaned and UV 
decontaminated between uses. MicroAmp fast optical 96 well plates (Applied 
Biosystems) were used. In all cases, Applied Biosystems TaqMan® Gene 
Expression Assays were used for qRT-PCR probes and primers. Assays were 
preferentially chosen on the basis of whether they were inventoried and also 
contained a probe that spanned an exon-exon junction of the associated genes and 
therefore would not detect genomic DNA (_m suffix) (Online Selection Guide for 
TaqMan Gene Expression Assays, Applied Biosystems). Table 2.4 lists the assays 
used in this project. 
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Gene Name Description TaqMan® Gene 
Expression Assay 
NR4A2 nuclear receptor subfamily 4, group A, member 2 Hs01118813_ml 
CXCR4 chemokine (C-X-C motif) receptor 4 Hs00976734_ml 
MS4A3 membrane-spanning 4-domains, subfamily A, 
member 3 (hematopoietic cell-specific) 
Hs00960994_ml 
EEA1 early endosome antigen 1 Hs00185960_ml 
ACTN1 actinin, alpha 1 Hs00998100_ml 
ATM ataxia telangiectasia mutated Hs00175892_ml 
FOSB FBJ murine osteosarcoma viral oncogene 
homolog B 
Hs01547109_ml 
JUN Jun oncogene Hs99999141_sl 
CD48 CD48 molecule Hs00381156_ml 
 
Table 2.4: List of TaqMan® Gene Expression Assays  
 
GAPDH was chosen as the endogenous control (housekeeping gene) for all qRT-
PCR reactions. This was after reviewing the expression of standard endogenous 
controls (18S, GAPDH, B2M and Actin) across all gene expression datasets 
generated. GAPDH was found to show the least variability across all datasets with 
the exception of the 5‟ probeset. This was felt to be irrelevant as the qRT-PCR 
probe binds to the 3‟ end of the transcript. The assay used was Human GAPDH 
Endogenous Control (VIC/TAMRA Probe, Primer Limited), part number 
4310884E from Applied Biosystems. 
 
Reactions were set up on ice. Reaction master mix was made up per sample as 
follows: 
 TaqMan Universal PCR Master Mix (Applied Biosystems) 10 l 
 TaqMan Gene Expression Assay (Applied Biosystems) 1 l 
 Water (Sigma Aldrich)     8 l 
 Total Volume       19 l 
Reaction mix was added to the plate first then 1 l of cDNA was added to each 
well. Contents were stirred to mix. Plates were sealed with MicroAmp Optical 
Adhesive Film (Applied Biosystems) and briefly centrifuged up to 1000rpm. 
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Reactions were performed on an Applied Biosystems 7900HT Fast Real-Time 
PCR System using the standard thermal cycler protocol (50
0
C for 2 minutes, 95
0
C 
for 10 minutes, then 40 cycles of 95
0
C for 15s and 60
0
C for 1 minute). All 
reactions were performed in triplicate. No template controls (water-only) and 
known positive controls were included on each plate.  
 
2.11.3  qRT-PCR Analysis  
Through the use of fluorescent reporter probes that interchelate with double-
stranded DNA, the amplified PCR product is quantified as it accumulates in real 
time after each amplification cycle. During the exponential phase of the reaction 
the relative amount of DNA present can be calculated by plotting fluorescence 
against cycle number on a logarithmic scale. A threshold is set where fluorescence 
rises above background levels. Each sample in the reaction is then assigned a CT 
(cycle threshold) value. This is the fractional cycle number at which fluorescence 
from that sample passed the threshold. In this analysis, CT values for each sample 
were calculated using SDS 2.3 software. All subsequent analysis was done using 
Excel. The mean and standard deviation (SD) of CT values for each triplicate were 
calculated. To ensure data accuracy, identical replicate samples should have a CT 
standard deviation <0.3. The change in expression of each target gene was then 
calculated relative to the reference gene GAPDH using the 2
- C
T
 
method. This 
approach was validated by demonstrating that the efficiencies of the target and 
reference gene amplification were approximately equal. A CT value was derived 
by subtracting the mean CT
 
value of the reference gene from the mean CT
 
value of 
the target gene. This is a normalisation step to adjust for possible variability in the 
amount of RNA added to the reverse transcription reactions. To allow comparison 
of data from separate plates, the CT value for the calibrator (positive control) was 
subtracted from the CT value for each sample ( CT). Fold change compared 
with the positive control was calculated using the formula 2
- C
T. To obtain error 
bars, the standard deviation of the CT (s) value was calculated from the 
standard deviation of target gene CT value (s1) and standard deviation of the 
reference gene CT value (s2) using the formula, s = √(s1
2 
+s2
2
) (ABI User Bulletin 
#2, Applied Biosystems). 
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CT sample Mean CT target gene – Mean CT reference gene 
CT CT sample – CT calibrator (positive control) 
Expression fold change 2
- C
T 
SD of CT (s) √s1
2 
+s2
2
 
 
Table 2.5: qRT-PCR Formulae 
CT: cycle threshold, SD: standard deviation, s1: SD of target gene CT value and s2: SD of 
reference gene CT value
 
 
 
To correlate gene expression changes seen by qRT-PCR and microarray, log base 
2 of the 2- CT value was plotted against log base 2 of the ratio of normalised 
microarray values for target gene to GAPDH. Correlation coefficients were 
calculated using Excel. The significance of the correlation coefficients was 
determined using the t-statistic [r/(sqrt(1-r
2
)/(N-2) where r is the correlation 
coefficient and N, the degrees of freedom]. 
 
2.12  T Cell Receptor Gene Clonality Assay 
2.12.1  Fluorescence Activated Cell Sorting of 3+4+, 3+8+ and 3+56+ 
Populations 
AML PBMC samples were initially depleted of blasts using the StemSep™ cell 
separation protocol (StemCell Technologies) prior to cell sorting in order to 
reduce the time required on the cell sorter.  
 
After thawing, cells were resuspended in 10mls of PBS+2% FCS. Cells were 
counted and then the samples were spun down at 1300rpm for 5 minutes at 4
0
C 
before being resuspended in 2% HAG at a concentration of 5 x 10
7
 cells/ml. 
Samples were then left for 20 minutes on ice. StemSep™ custom blast cocktail, 
CD11c and CD36 (Stem Cell Technologies) were added at concentrations of 
100 l per ml of cells. Samples were left for 30 minutes at 4
0
C prior to the addition 
of colloid at a concentration of 100 l per ml of cells. After a further incubation at 
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4
0
C for 30 minutes with occasional agitation, blast separation was performed 
using 0.6” pump feed columns and a peristaltic pump. Column preparation and 
pump speeds were as defined in the manual. After cell separation, blasts were 
eluted from the column using 15mls of PBS + 2%FCS. All cell fractions were 
spun down at 1300 for 5 minutes at 4
0
C then resuspended in 5mls PBS+2%FCS. 
Cell counts were then performed. 1 x 10
6
 cells from the blast fraction were 
removed for flow cytometric analysis of purity. Blast fractions were then pelleted 
and left at -20
0
C for future DNA extraction. 
 
Cells for sorting were spun down at 1300rpm for 5 minutes at 4
0
C then 
resuspended at a concentration of 1.5 x 10
6
 cells in 50 l PBS+2%FCS. Five l of 
antibody per 50 l of cells were added and samples were left for 30 minutes at 4
0
C 
in the dark. Stained cells were then washed with 15X sample volume 
PBS+2%FCS. Cells were subsequently resuspended at a concentration of 10-20 x 
10
6
/ml PBS+2%FCS + DAPI (1 l per 5mls). Debris was removed by passing the 
cells over 40 m cell strainers (BD Biosciences) into 5ml round bottomed 
polypropylene tubes (BD Biosciences). Labelled collection tubes containing 1ml 
PBS +2%FCS were also prepared. 
 
Samples were sorted into three fractions: 3+4+56-, 3+8+56- and 3+56+ using a 
FACSAria cell sorter (BD Biosciences) in the flow cytometry laboratory at 
Cancer Research UK, 44 Lincoln‟s Inn Fields. The purity of each sorted cell 
fraction was checked post-sort and the total number of sorted cells was noted. 
 
Post sorting, cells were washed twice with PBS+2%FCS, pelleted and left at -
20
0
C for future DNA extraction. 
 
2.12.2  DNA Extraction (Qiagen DNAeasy) 
Cell pellets were thawed at RT. Two hundred l PBS and 200 l AL lysis buffer 
were added to each sample. After vortexing for 15s, 40 l proteinase K (0.1mg/ l) 
were added and samples were transferred into labelled 1.5ml eppendorfs. Samples 
were briefly vortexed and then incubated at 70
0
C for 10 minutes in a heated block. 
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Two hundred and ten l of 100% ethanol was then added to each. Samples were 
again vortexed and then applied to spin columns. These were then centrifuged at 
8000rpm for 1 minute at RT following which the columns were transferred into 
fresh collection tubes. Five hundred l of AW1 buffer was applied to each column 
and columns were again spun at 8000rpm for 1 minute at RT. After again 
transferring the columns to fresh collection tubes, 500 l of AW2 buffer was 
added to each. This time columns were spun for 3 minutes at 14000rpm and then 
transferred to labelled 1.5ml eppendorfs. Twenty l warm AE buffer was added to 
each column and columns were then incubated at RT for 5 minutes. After 
centrifuging for 1 minute at RT at 8000rpm, a further 20 l AE buffer was added 
to each column. The last incubation and elution steps were repeated.  
 
The quality and quantity of DNA obtained was assessed using a Nanodrop 
spectrophotometer.  
 
DNA was stored at -20
0
C until subsequent use.  
 
2.12.3  Multiplex PCR 
TCR gene rearrangements for beta, gamma and delta chains were assessed using 
multiplex PCR kits supplied by InVivoScribe Technologies (Gene Clonality 
Assays for ABI Fluorescence Detection) and used as per manufacturer‟s 
instructions. These assays were designed, standardised and validated in a 
collaborative study known as the BIOMED-2 Concerted Action (Bruggemann, et 
al 2007, van Dongen, et al 2003). The primers are listed in Figure 2.9. 
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TCRB
 
TCRG
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TCRD
 
 
Figure 2.9: BIOMED-2 Primers  
Used in 6 tubes for identifying TCR gene rearrangements. 
 
Kits were allowed to thaw and then gently vortexed to mix. Master mix tubes 
were labelled and placed on ice. Master mix was aliquoted in to the labelled tubes 
at a volume calculated as 45 l per sample plus 135 l for positive, negative and no 
template controls plus 20 l for pipetting errors. Amplitaq Gold polymerase 
(5U/ l) (Applied Biosystems) was then added to each master mix tube – for 
TCRB Tubes A and B: 0.45 l per 50 l total PCR reaction volume, for all other 
tubes: 0.25 l per 50 l total PCR reaction volume. Tubes were mixed by gently 
vortexing. Forty-five l of master mix was aliquoted into the appropriate wells of 
a thermo-fast 96 well skirted PCR plate (Abgene UK). Five l of DNA or water 
(Sigma Aldrich) was then added to relevant wells and mixed by pipetting up and 
down several times. DNA for positive and negative controls was provided with 
each kit. Plates were then sealed with MicroAmp optical adhesive film (Applied 
Biosytems) and briefly centrifuged up to 1000rpm. PCR reactions were performed 
in a PTC-225 thermocycler (MJ Research) using the following programme: 
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 Step 1: 95
0
C for 7 minutes (pre-activation) 
 Step 2: 95
0
C for 45s (denaturation) 
 Step 3: 60
0
C for 45s (annealing) 
 Step 4: 72
0
C for 90s (extension) 
 Step 5: Go to step 2, 34 more times 
 Step 6: 72
0
C for 10 minutes (final extension) 
 Step 7: Hold 15
0
C  
 
Due to large quantity of primer-dimer formation in the initial practice run, it was 
felt appropriate to clean up all the PCR products. This substantially improved the 
quality of the reaction products. 
 
The Qiagen PCR Purification Kit was used according to manufacturer‟s 
instructions. Samples were transferred from the plate to 1.5ml microfuge tubes. 
Five volumes (250 l) of DNA binding buffer PBI were added and the samples 
were transferred to spin columns. These were centrifuged at 13000rpm for 60s at 
RT. Flow-through from the columns was discarded and the columns replaced into 
the same collection tube. Seven hundred and fifty l of wash buffer PE was then 
added and the columns re-spun at 13000rpm for 60s at RT. Once the flow-through 
was discarded, the columns were spun again at 13000rpm for 60s at RT. The 
columns were then transferred to clean 1.5ml microfuge tubes and the DNA 
eluted using 50 l EB buffer and spinning for 60s at 13000rpm at RT. The cleaned 
up DNA was then transferred to another 96 well plate. 
 
2.12.4  GeneScanning 
The PCR products were analysed by differential fluorescence detection using 
capillary electrophoresis (GeneScanning) on an ABI Prism 3100 Genetic 
Analyzer in the Equipment Park at Cancer Research UK, 44 Lincoln‟s Inn Fields. 
One l of reaction product was used for analysis. No dilution was performed. To 
this was added 10 l of HI-deionised formamide containing LIZ 600 size 
standards. The reaction product mix was heated to 95
0
C for 2 minutes and then 
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snap chilled on ice for 5 minutes. A 50cm capillary was used for electrophoresis. 
Subsequent analysis was performed on Genotyper 3.7 software. 
 
2.13  Cell Conjugation Assay 
2.13.1  Cell Conjugation 
Cell conjugation assays were performed as previously published (Ramsay, et al 
2008a). In detail, coverslips were prepared on the day prior to the experiment by 
placing them in a 24 well tissue culture plate and adding 550 l of poly-L-lysine 
(Sigma Aldrich). These were left overnight at room temperature. The following 
day, T cells and APCs were thawed, washed in RPMI+10%FCS and aliquoted 
into eppendorfs - 1 x 10
6
 T cells in RPMI+10%FCS or 2 x 10
6
 APCs in RPMI 
alone. T cells were left at 37
0
C +5%CO2 to revive until conjugation. APCs were 
stained with CellTracker Blue CMAC (7-amino-4-chloromethylcoumarin) 
(Invitrogen Ltd.) by adding 1 l of a 10mM stock solution in DMSO to each 
eppendorf and then incubating at 37
0
C, 5%CO2 for 30 minutes. Residual CMAC 
was then removed by centrifuging cells at 4000rpm for 1 minute then 
resuspending in RPMI+10%FCS. APCs were then either pulsed or not pulsed with 
2 g/ml of a „cocktail‟ of staphylococcal superantigens (staphylococcal 
enterotoxins A and B) (Sigma Aldrich) by adding 1 l of cocktail or media alone 
to the resuspended cells and incubating them at 37
0
C, 5% CO2 for 30 minutes. 
Both APCs and T cells were then spun down at 4000rpm for 1 minute, washed 
with 1ml RPMI and then resuspended in 200 l RPMI. T cells were then added to 
APCs at a ratio of 1 to 2, spun at 1500rpm for 5 minutes and then incubated at 
37
0
C, 5% CO2 for 15 minutes. Next, the cell pellets were plated onto the poly-L-
lysine coated coverslips by gently pipetting cells directly onto the coverslips 
within the 24 well plate then centrifuging the plate at 1000rpm for 5 minutes. 
Cells were subsequently fixed for 15 minutes at RT in 500 l 3% methanol-free 
formaldehyde (TAAB Laboratories Equipment Ltd) in PBS. To allow 
visualisation of intracellular proteins, cells were then permeabilised with 500 l 
0.3% vol/vol triton x100 (Sigma Aldrich) in PBS for 5 minutes at RT. Non-
specific staining was prevented by blocking with 500 l 0.1% BSA (Miltenyi 
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Biotec) in PBS for 10 minutes at RT. F-actin was visualised by staining with 
400 l Rhodamine Phalloidin (Invitrogen Ltd.) 1:40 in blocking solution for 20 
minutes at RT. Phosphotyrosine recruitment to the immunological synapse was 
visualised by firstly staining with 200 l phosphotyrosine (Millipore) 1:100 in 5% 
goat serum in PBS for 45 minutes at 4
0
C and secondly adding 200 l of goat anti-
mouse Alexa 488 (Invitogen) 1:500 in 5% goat serum in PBS and incubating at 
4
0
C for a further 30 minutes. Between each step, coverslips were washed 3 times 
with PBS. Finally, coverslips were carefully mounted onto slides using 
fluorescent mounting medium (Dako) and left for 2 hours to dry prior to sealing 
the edges of the coverslips with nail hardener. Slides were left in the dark at 4 C 
until analysed. 
 
2.13.2  Immunofluorescence Confocal Microscopy 
Slides were examined using a Carl Zeiss 510 Meta confocal laser-scanning 
microscope using a x63 objective lens. Coverslips were examined consistently 
from top left top to bottom right. Images were acquired whenever a cell conjugate 
was observed with the aim of acquiring images of a minimum of 50 conjugates. 
Images to be compared from a single experiment were acquired during the same 
session using the same acquisition settings. 
 
2.13.3  Image Analysis 
Images were subsequently analysed for APC:T cell ratio, conjugate formation (% 
of total T cells forming conjugates with APCs), immunological synapse formation 
(% of cell conjugates that were immunological synapses) and phosphotyrosine 
recruitment to the T cell-APC interface (% of conjugates that demonstrated 
phosphotyrosine signalling molecule recruitment). An immunological synapse 
was defined as a conjugate that demonstrated polarisation of F-actin at the cell 
contact point. Conjugates that showed a distinct F-actin band were scored 1, 
conjugates without F-actin polarisation to the contact site were scored 0 and 
conjugates where there was weak F-actin polarisation were scored 0.5. 
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Recruitment of phosphotyrosine signalling molecules to the T cell-APC interface 
was scored in the same way. 
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Chapter 3  
Characterisation of T Cells from AML Patients 
3.1  Introduction 
The description of the morphological appearance of the bone marrow in AML is 
the effacement of normal haematopoiesis with sheets of myeloblasts. This has 
resulted in a general perception that the numbers of T cells in the bone marrow 
and peripheral blood of patients presenting with AML is low. Certainly, relative to 
the number of circulating blasts, this is often the case but few studies have 
addressed the issue of absolute numbers of T cells in the peripheral blood of 
patients with AML or attempted to characterise them further. The existence of T 
cell precursors in the bone marrow of untreated AML patients has been 
demonstrated by the generation of T cell clones with cytotoxic efficacy against 
both autologous and allogeneic blasts (Jahn, et al 1995). Most of the available 
information on T cells in the peripheral blood of AML patients relates to immune 
reconstitution following chemotherapy or stem cell transplantation where the 
observation has been made that early absolute lymphocyte count recovery is 
predictive of superior survival (Behl, et al 2006, Porrata, et al 2002). Other 
reports have characterised treatment-induced T cell defects (Bruserud 1998b, 
Bruserud, et al 1998a, Wendelbo, et al 2004). A study of 45 AML patients at 
diagnosis compared to 9 healthy controls looked at lymphocyte subsets but only in 
terms of ratios of one cell subset to another; CD4/CD8 ratio, CD4+ CD45RA/RO 
ratio and CD8+CD45RA/RO ratio (Ersvaer, et al 2007). The distribution of these 
subsets in AML did not differ significantly from the controls with the exception of 
the CD8+ CD45RA/RO ratio which was significantly lower in the AML patients 
suggesting an increased pool of memory CD8 cells. There are two previously 
published manuscripts that have addressed the issue of absolute T cell numbers. 
Vidriales and colleagues undertook a dual labelling flow cytometric analysis of 
NK and T cell subsets in 66 patients with de novo AML compared with 30 healthy 
volunteers (Vidriales, et al 1993). This demonstrated that the total CD4 and CD8 
cell counts are within the normal range in terms of both relative and absolute 
numbers. This finding was confirmed in a smaller study by Panoskaltsis et al. who 
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examined peripheral blood from 13 patients with AML and 8 healthy volunteers 
using a combination of CD45, CD3 and CD8 (Panoskaltsis, et al 2003). As a 
starting point for this project it was felt to be relevant to review this issue by 
enumerating and characterising T cells present in the peripheral blood of newly 
diagnosed patients with AML.  
 
An observation made early during this study was that certain AML patients had 
large populations of CD3 cells that co-expressed CD56 (Figure 3.1). A significant 
increase in these cells in AML patients compared to healthy individuals had also 
been noted in the Vidriales paper, although less than 3% of the 45 patients in the 
Ersvaer study had T cells that were found to express CD56. The question arose as 
to the nature of these cells. Were they true natural killer T (NKT) cells or were 
they CD56 expressing T cells?  
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Figure 3.1: A Large Population of CD3+CD56+ cells in AML Patients 
 
CD56 is the neural cell adhesion molecule (NCAM) (Thiery, et al 1977) also 
known as D2-CAM (Lyles, et al 1984), Leu19 and NKH-1 (Lanier, et al 1989). It 
was the first characterised of the immunoglobulin superfamily of cell adhesion 
molecules (Edelman and Crossin 1991) and it mediates calcium-independent 
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homophilic binding to CD56 on adjacent cells (Hoffman and Edelman 1983). It 
was initially identified in the nervous system where it was found to mediate cell-
cell interactions of glial cells during embryogenesis (Lyles, et al 1984, Thiery, et 
al 1977). Within the haematopoietic lineage, CD56 is expressed on NK and T 
cells. NK cells are divided into CD56
bright
 and CD56
dim
 (Lanier, et al 1986): the 
CD56
bright
 subset shows increased potential for cytokine production (Cooper, et al 
2001) whereas the CD56
dim
 subset, representing 90% of NK cells, has enhanced 
cytotoxicity associated with a mature differentiation state (Jacobs, et al 2001). 
Amongst T cells, CD56 has been reported to be expressed on a subset of effector 
T cells that makes up less than 5% of total peripheral blood lymphocytes (Lanier, 
et al 1986) as well as on classical NKT cells (Norris, et al 1999). True NKT cells 
and CD3+56+ cells continue to be confused within the literature (Peralta, et al 
2008, Reis, et al 2008, Srivastava, et al 2008, Zhu, et al 2008). The major 
differences between them are listed in Table 3.1. 
 
Although originally described by three groups in 1987 (Budd, et al 1987, Ceredig, 
et al 1987, Fowlkes, et al 1987), the term „NK T cell‟ was first published in 1995 
and was used to describe a distinct population of T lymphocytes in mice that 
shared some characteristics with NK cells including the expression of the C-lectin 
type NK receptor NK 1.1 (NKR-P1 or CD161c) (Makino, et al 1995). NKT cells 
are also found in humans (Dellabona, et al 1994, Porcelli, et al 1993) although no 
discriminatory cell surface marker has been identified. Characteristically, rather 
than the broad TCR chain usage found in healthy T cells, NKT cells only express 
V 24-J Q (now known as V 24-J 18) in humans (V 14-J 281 – now known as 
J 18 - in mice) and most only use V 11 (V 8.2 in mice) (Lantz and Bendelac 
1994). These cells are also unusual in that they recognise glycolipid presented by 
the monomorphic MHC class I-like molecule CD1d (Beckman, et al 1994, 
Bendelac, et al 1995). Their most potent ligand is the glycosphingolipid alpha-
galactosylceramide ( GalCer, also known as KRN7000) (Kawano, et al 1997) 
initially isolated from the marine sponge Agelas mauritanius in a screen for 
compounds that could prevent tumour metastases to the liver in mice (Kobayashi, 
et al 1995). The reactivity of NKT cells for GalCer presented by CD1d is highly 
conserved between mice and humans suggesting a fundamental importance for 
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this T cell recognition system (Brossay, et al 1998). Natural glycolipid ligands 
have now been identified. These include the mammalian isoglobotrihexosyl 
ceramide (iGb3) (Zhou, et al 2004) and glycosphingolipids from the gram-
negative bacteria Sphingomonas (Kinjo, et al 2005) and Borrelia burgdorferi 
(Kinjo, et al 2006). NKT cells have been recognised to be a potent source of 
immunoregulatory cytokines including IL-4, IFN  and TNF that are rapidly 
produced on activation (Zlotnik, et al 1992). Two subsets of NKT cells have been 
identified; the CD4 positive subset produces the anti-inflammatory TH2 cytokines 
IL-4 and IL-13 whereas the CD4 negative (also known as double-negative or DN) 
subset produces pro-inflammatory TH1 cytokines such as IFN (Gumperz, et al 
2002, Lee, et al 2002). NKT cells in humans can also express an unusual form of 
CD8, CD8αdim/β- in contrast to healthy αβ T cells that are exclusively 
CD8αbright/βbright (Prussin and Foster 1997). After activation, NKT cells are 
directly cytotoxic to cells expressing the cognate antigen using both perforin-
dependent and FasL-dependent mechanisms (Metelitsa, et al 2001). This allows 
them to kill tumour cells in vitro (Metelitsa, et al 2003, Takahashi, et al 2003, van 
der Vliet, et al 2003). However, NKT cells can also activate NK cells, CD4 and 
CD8 T cells and DCs via cell-cell contact and the production of cytokines (Fujii, 
et al 2003b, Hermans, et al 2003, Metelitsa, et al 2001). NKT cells have been 
shown to have an extremely diverse range of actions from the prevention of 
autoimmunity to controlling responses to infection suggesting that an important 
natural function of these cells is the protection of self tissues from damaging 
inflammatory immune responses (Godfrey, et al 2000). The non-specific 
mechanism by which NKT cells recognise antigen has led to interest in these cells 
for cancer immunotherapy. Rather than having to design specific peptides for T 
cell recognition, NKT cells in all individuals recognise the same glycolipids and 
they do so using the same TCR. An anti-tumour effect has been demonstrated in 
tumour-bearing mice (Smyth, et al 2000) and injection of GalCer protects mice 
from experimentally-induced tumours (Kawano, et al 1998, Nakagawa, et al 
1998). However, CD4+ NKT cells have also been shown to suppress effector CD8 
T cell function by the secretion of IL-13 and TGF , a mechanism hypothesized to 
down-regulate tumour immunosurveillance (Terabe, et al 2000). How the decision 
is made by NKT cells to promote or prevent cancer growth remains to be 
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elucidated but may involve the nature of the CD1d/glycolipid/TCR interaction, 
interaction with APCs and the prevailing cytokine milieu (Smyth, et al 2002). 
There have been several reports of reduced numbers of NKT cells or numbers of 
IFN -secreting NKT cells in the peripheral blood of patients with cancer including 
haematopoietic malignancies (Dhodapkar, et al 2003a, Fujii, et al 2003a, Molling, 
et al 2005, Tahir, et al 2001, Yoneda, et al 2005).  
 
Compared with NKT cells, CD3+CD56+ cells have a distinct morphology and 
function, have an unrestricted polymorphic TCR chain usage and are not CD1d-
restricted (Table 3.1). These cells have been variously called NK-type T cells 
(Ohkawa, et al 2001), natural T (NT) cells (Doherty, et al 1999), NK-like T cells 
(Zoll, et al 2000) and NKT-like lymphocytes (Peralbo, et al 2007). CD56 
expressing T cells were first described by two groups in 1986 (Lanier, et al 1986, 
Schmidt, et al 1986) and later further characterised by Ortaldo et al. (Ortaldo, et 
al 1991). In common with NK cells, CD3+56+ were morphologically described as 
„large granular lymphocytes‟ and, unlike normal CTLs, found to be capable of 
killing the MHC Class I negative cell line K562. An anti-CD3 antibody inhibited 
this cytotoxicity suggesting that the TCR was involved in the interaction. The 
majority of CD3+56+ cells were found to express CD8. They are potent cytotoxic 
agents with enhanced cytotoxic granule expression, cytokine production and anti-
tumour cytotoxicity compared with CD3+56- cells (Ohkawa, et al 2001, Pittet, et 
al 2000). These cells have been identified as an effector cell subset with a role in 
mucosal immunity in the intestine (Cohavy and Targan 2007), they make up a 
third of all hepatic CD3 cells (Doherty, et al 1999), have anti-viral effects 
(Kawarabayashi, et al 2000, Montoya, et al 2006) and may have a role in fertility 
(van den Heuvel, et al 2007). Numbers of these cells increase with aging (Peralbo, 
et al 2007). In addition, a case report has been described of a patient with AML 
who developed a polyclonal proliferation of CD3+CD8+CD56+ cells that killed 
autologous leukaemic blasts via engagement of the 2B4 activating receptor by the 
cell surface ligand CD48 (Costello, et al 2002a). CD3+CD56+ cells are generally 
seen as an in vitro phenomenon; „cytokine-induced killer (CIK)‟ cells can be 
generated by culturing PBMCs with various combinations of cytokines but 
including IL-2 for 3-4 weeks (Schmidt-Wolf, et al 1993, Schmidt-Wolf, et al 
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1991). CIK cells display potent lytic activity and unlike, LAK cells, are not 
dependent on IL-2. They are therefore under investigation as consolidative 
immunotherapy in the minimal residual disease state and as an alternative to 
donor lymphocyte infusions in allogeneic stem cell transplantation (Linn and Hui 
2003). Numbers of CD3+56+ cells have previously been shown to be increased in 
the peripheral blood of patients presenting with leukaemia (Vidriales, et al 1993) 
and are also increased in ascites from patients with ovarian carcinoma compared 
to blood and control ascites (Bamias, et al 2007). Another report has demonstrated 
that a large proportion of tumour-infiltrating lymphocytes in human primary and 
metastatic liver tumours are CD3+56+ cells (Shimizu, et al 1990). 
 
 NKT Cells 3+56+ Cells 
Frequency 0.01-1% of peripheral blood T 
cells 
2-5% of PBMCs 
TCR chain use V 24 V 11 Unrestricted 
Recognise Glycolipid Peptide 
Molecular context of 
recognition 
CD1d MHC 
Table 3.1: Differences between NKT cells and CD3+56+ Cells 
 
As both true NKT cells and CD3+56+ cells have a potential role in the immune 
response against tumours, the further characterisation of these CD56-expressing T 
cells in AML patients was relevant in the investigation into how the immune 
system sees AML. 
 
3.2  Aims 
The primary aim of this initial work was to quantify and classify T cells in 
patients presenting with AML in comparison to T cells in healthy volunteers. The 
secondary aim was to confirm the impression of an increased number of 
CD3+56+ cells in patients presenting with AML and to characterise the nature of 
this cell population. 
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3.3  Materials and Methods 
3.3.1  Samples 
Frozen PBMCs from newly diagnosed patients with AML were used in this 
experiment. Historical patients were chosen on the basis of quantity of available 
material. In addition, PBMCs were frozen and subsequently used on every patient 
who underwent leucopheresis while this project was ongoing. The characteristics 
of these patients are listed in Table 3.2. The method for surface staining is 
described in section 2.7.1. 
 
Number 36 
Median Age in years (Range) 55 (17-81) 
Sex  
           Female 14 
           Male 22 
FAB Type  
          M0 1 
          M1 11 
          M2 7 
          M3 0 
          M4 13 
          M5 2 
          Others 2 
Prognostic Group   
          Favourable 10 
          Intermediate 23 
          Adverse 3 
Response to first line therapy  
          Complete Remission 22 
          Fail 4 
          Death 6 
          Not applicable 4 
Relapse  
          Yes 9 
          No 27 
Median Overall Survival in years (Range) 0.8 (0.02-15) 
Table 3.2: Characteristics of AML Patients 
Rifca Le Dieu                                                                                                           Chapter 3 Results 
115 
 
 
Blood was taken from healthy volunteers for the comparative analysis. Attempts 
were made to age-match the AML and healthy samples. Fresh blood was used in a 
whole blood lysis method described in section 2.7.2. A different method was used 
in order to obtain absolute cell counts on the healthy samples for which FBCs 
were not available. A comparison was made of the relative expression of CD56 on 
T cells in fresh samples undergoing the whole blood lysis method, fresh samples 
in which PBMCs were extracted using density gradient centrifugation and frozen 
samples. Minor tube-to-tube variation in CD56 expression was observed but no 
significant differences were seen (data not shown).  
 
The characteristics of the healthy controls are listed in Table 3.3. 
 
Number 17 
Median Age in years (range) 35 (24-80)* 
Sex  
          Female 10 
          Male 7 
Table 3.3: Characteristics of Healthy Volunteers 
*p=0.11 in t-test with age of AML patients. 
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3.3.2  Flow Cytometry 
The initial staining protocol is shown in Table 3.4. 
 
  FITC PE APC PerCP PECy7 DAPI 
Tube 1 CD16 CD1d-T CD56 CD4 CD3 √ 
Tube 2 CD16 CD1d-T CD56 CD8 CD3 √ 
Tube 3   CD1d-C     CD3 √ 
Tube 4 V 11 V 24 CD56  CD3 √ 
Tube 5 IgG1 IgG1 IgG1 IgG1 IgG1 √ 
Tube 6 IgG2a IgG2b    √ 
Table 3.4: Initial Staining Protocol 
Fluorochromes are listed on the top line. APC: allophycocyanin, PerCP: peridinin-chlorophyll 
protein, CD1d-T: CD1d tetramer loaded with GalCer analogue, CD1d-C: control unloaded CD1d 
tetramer (both provided by the NIH Tetramer Facility). 
 
The gating strategy used for acquiring and analysing data and the method of 
calculating relative and absolute cell numbers is described in section 2.7.4. The 
maximum number of CD3 events possible was acquired. This was a mean of 
74848 CD3 events for the healthy samples and a mean of 27505 CD3 events for 
the AML samples. 
 
3.3.3  Statistics 
All statistical analysis was performed using Excel software. T-tests were unpaired, 
2-tailed with sample groups considered to have unequal variance. A p-value less 
than 0.05 was considered as the cut-off for statistical significance. 
 
3.3.4  Assessment of TCR Gene Rearrangements 
The clonality of T cell populations was assessed by multiplex PCR for TCR gene 
rearrangements using TCRB, TCRD and TCRG gene clonality assays provided by 
InVivoScribe Technologies. The methods used are described in section 2.12. 
CD3+4+, CD3+8+ and CD3+56+ populations were flow sorted from five patients 
with AML and two healthy individuals. The gating strategy is shown in Figure 
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3.2. Blasts were initially positively selected from AML PBMC samples prior to 
flow sorting and were included in the analysis.  
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Figure 3.2: Gates Used for Flow Sorting Cell Populations 
P1: DAPI negative live cells, P2: mononuclear cells, P3: exclusion of doublets (aggregated cells) – 
area of the fluorescent light pulse is plotted against width. Doublets have a greater pulse width 
than a single cell as they take longer to pass through the laser beam and therefore can be excluded 
from the analysis, P4: CD56 negative, P5: CD4 positive, CD56 negative, P6: CD8 positive, CD56 
negative, P7: CD56 positive. 
 
Post flow sorting, cell counts and purities were recorded. DNA was extracted 
using the method detailed in section 2.12.2 and quality and quantity was checked 
on a Nanodrop spectrophotometer. All samples were made up to 40 l as 7 
reactions were to be performed per sample with 5 l of DNA required in each. The 
clonality assay used is described as a robust assay system and that a wide range of 
DNA concentrations will yield a valid result. Details of all the samples tested are 
listed in Tables 3.5-3.8. 
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CD3+4+56- Populations 
 Cell 
Count 
post sort Recovery Purity 
DNA 
Quantity A260/A280 A260/A230 
Amount 
used in 
PCR 
AML1 6.9 x 10
6
 31.5% 99.4% 3586.3ng 1.89 2.28 448ng 
AML2 1.8 x 10
6
 2.8% 99.0% 841.0ng 2.06 3.08 105ng 
AML3 0.5 x 10
6
 44.5% 99.8% 338.4ng 1.69 0.37 42.3ng 
AML4 5.5 x 10
6
 47.0% 99.2% 550.1ng 1.92 6.34 69ng 
AML5 2.9 x 10
6
 34.5% 98.1% 4403.2ng 1.97 2.51 550.4ng 
Healthy1 1.8 x 10
6
 51.4% 99.3% 5406.6ng 1.88 2.69 675.9ng 
Healthy2 1.9 x 10
6
 51.7% 99.8% 4230.7ng 1.90 2.86 528.8ng 
Table 3.5: Data for 3+4+56- Populations 
 
 
 
 
 
CD3+8+56- Populations 
 Cell 
Count 
post sort Recovery Purity 
DNA 
Quantity A260/A280 A260/A230 
Amount 
used in 
PCR 
AML1 5.3 x 10
6
 52.0% 98.1% 3829.4ng 1.94 2.14 478.7ng 
AML2 0.8 x 10
6
 30.0% 96.7% 174.4ng 1.49 -3.18 22ng 
AML3 1.7 x 10
6
 39.5% 98.9% 1821.1ng 1.99 1.80 227.6ng 
AML4 5.6 x 10
6
 43.7% 99.5% 9644.9ng 1.91 2.37 1205.6ng 
AML5 2.4 x 10
6
 33.3% 96.6% 3477.3ng 1.90 2.43 434.7ng 
Healthy1 0.7 x 10
6
 46.7% 96.9% 1186.6ng 1.91 7.03 148.3ng 
Healthy2 0.7 x 10
6
 46.7% 96.4% 1390.0ng 1.79 2.91 173.8ng 
Table 3.6: Data for 3+8+56- Populations 
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CD3+56+ Populations 
 
 
Cell 
Count 
post sort Recovery Purity 
DNA 
Quantity A260/A280 A260/A230 
Amount 
used in 
PCR 
AML1 0.6 x 10
6
 67.8% 73.3% 116.28ng 5.33 -1.15 14.5ng 
AML2 0.7 x 10
6
 38.0% 84.2% 81.9ng 2.01 -0.98 10.2ng 
AML3 0.9 x 10
6
 44.6% 93.1% 2092.3ng 1.90 2.81 261.5ng 
AML4 3.1 x 10
6
 52.6% 90.5% 4111.1ng 1.90 2.52 513.9ng 
AML5 0.3 x 10
6
 45.0% 76.3% 303.2ng 1.31 2.63 37.9ng 
Healthy1 0.1 x 10
6
 44.8% 91.1% 346ng 1.73 11.15 43.25ng 
Healthy2 0.2 x 10
6
 43.2% 96.4% 423.7ng 1.50 2.73 53ng 
Table 3.7: Data for 3+56+ Populations 
 
Blast Populations 
 Cell 
Count 
post sort Purity 
DNA 
Quantity A260/A280 A260/A230 
Amount 
used in 
PCR 
AML1 51 x 10
6
 91.4% 22.1ug 1.95 2.02 2762.5ng 
AML2 78 x 10
6
 92.3% 207.4ug 1.86 2.04 5761ng 
AML3 230 x 10
6
 93.3% 162.7ug 1.86 2.03 4519ng 
AML4 375 x 10
6
 93.2% 237.2ug 1.88 2.2 6589ng 
AML5 149 x 10
6
 96.2% 186.1ug 1.88 1.83 5169ng 
Table 3.8: Data for Blast Populations 
 
Multiplex PCR reactions were carried out as described in section 2.12.3 and 
analysed by GeneScanning (section 2.12.4). Data was subsequently reviewed 
using Genotyper 3.7 software. 
 
3.3.5  Correlation with Clinical Data 
Clinical data was obtained on all 36 AML patients and correlations with the 
absolute numbers of total T cells and CD3+56+ cells found in the peripheral blood 
were made using GraphPad Prism. Non-parametric tests of significance were 
performed as the datasets were demonstrated to be non-normally distributed by 
analysis of means using GraphPad Instat software. 
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3.4  Results 
3.4.1  Total T Cells in AML 
Initial phenotyping results are shown in Table 3.9. These indicate a significant 
increase in the absolute number of total T cells in the peripheral blood of patients 
presenting with AML compared with healthy controls. The absolute number of 
CD4 and CD8 cells was also greater in AML. The significantly increased number 
of CD3+CD56+ cells confirmed the previous observation that this population was 
increased in patients with AML. The fact that the population of CD3 cells that 
express CD16 is not significantly increased in terms of absolute numbers suggests 
that there is not a generalised proliferative response of T cells in AML. 
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 Total CD3 CD3+4+ CD3+8+ CD3+16+ CD3+56+ 
Healthy      
     Relative 61.00%  
(+/- 10%) 
64.44%  
(+/- 11.6%) 
30.77%  
(+/-10.35%) 
3.14% 
(+/- 1.83%) 
2.96%  
(+/- 2.27%) 
    Absolute 0.8 x 10
9
/L 
(+/- 0.32) 
536.2 x 10
6
/L 
(+/- 224.8) 
263.4 x 10
6
/L 
(+/- 170.0) 
24.7 x 10
6
/L  
(+/- 20.2) 
27.6 x 10
6
/L 
(+/- 32.8) 
AML      
     Relative 13.15%  
(+/- 19.24%) 
* 
51.64%  
(+/- 13.31%) 
* 
36.87%  
(+/- 12.77%) 
1.52%  
(+/- 1.98%) 
* 
9.33%  
(+/- 6.95%) 
* 
    Absolute 1.9 x 10
9
/L 
(+/-1.54) 
 
* 
1038.7 x 
10
6
/L  
(+/- 1031.2) 
* 
722.2 x 10
6
/L 
(+/- 650.7) 
 
* 
23.3 x 10
6
/L  
(+/- 27.1) 
178.7 x 10
6
/L 
(+/- 254.2) 
 
* 
 
Table 3.9: Total T Cells in AML 
Relative and absolute numbers of total CD3+, CD3+4+, CD3+8+, CD3+16+ and CD3+56+ cells 
in the peripheral blood of patients presenting with AML and healthy volunteers. * indicates p<0.05 
in a 2-tailed unpaired t-test. For total CD3, the relative number relates to CD3+ cells as a 
percentage of live mononuclear cells. For other subsets, the relative number relates to the cells as a 
percentage of total CD3+ cells. Figures listed are means with standard deviations in the following 
brackets. 
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As expected, the percentage of T cells relative to live mononuclear cells was 
significantly lower in AML compared with healthy individuals. However, the 
absolute number of total T cells was significantly higher (Figure 3.3). 
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Figure 3.3: Bar Charts Illustrating Total T Cells in AML 
The relative and absolute numbers of T cells in peripheral blood (PB) of patients presenting with 
AML compared with healthy controls.  
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The increase in total T cell numbers is accounted for by rises in both the CD4 and 
CD8 populations but, as illustrated by the CD4 to CD8 ratio, the CD8 population 
is increased more than the CD4 (Figure 3.4). 
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Figure 3.4: CD4 and CD8 Cells in AML 
Bar charts illustrating the absolute numbers of CD4 and CD8 cells and the CD4:CD8 ratio in PB 
of patients presenting with AML compared with healthy controls. 
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3.4.2  CD56-expressing T Cells in AML  
The absolute number of CD56-expressing T cells is significantly increased in the 
PB of patients presenting with AML compared with healthy volunteers (Figure 
3.5) 
 
 
 
 
Figure 3.5: CD3+56+ Cells in AML 
Graph illustrating the significant increase in the absolute number of CD3+56+ cells in the PB of 
patients with AML compared with healthy controls. The p-value was obtained using a Mann 
Whitney unpaired, 2-tailed t test. 
 
To identify if these cells were in fact true NKT cells, cells were stained with a 
CD1d tetramer loaded with a lipid analogue of GalCer (PBS57) and labelled 
with the fluorochrome phycoerythrin kindly provided by the NIH Tetramer 
Facility. Tetramers are a means of identifying T cells specific to an antigen of 
interest by flow cytometry. Their structure is illustrated in Figure 3.6. 
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Figure 3.6: The Components of a Tetramer 
A CD1d molecule loaded with glycolipid is tagged with biotin and therefore binds to the protein 
avidin. NKT cells will recognise and bind to this complex (A). Avidin is a tetrameric protein and 
is therefore capable of binding four biotinylated CD1d molecules. It is labelled with a 
fluorochrome which allows the tetrameric complex to be detected by flow cytometry (B). 
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Non-specific background staining was excluded using an unloaded control 
tetramer. Results were confirmed by using antibodies directed towards V 24 and 
V 11 (Figure 3.7). 
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Figure 3.7: Scatter Plots of True NKT Cells 
Plot (A) demonstrates the appearance of true NKT cells labelled with CD3 and the glycolipid 
loaded tetramer (CD1dT). The minimal level of background staining seen with the control 
unloaded tetramer (CD1dC) is shown in (B). The size of the population is confirmed by staining 
for V 24 and V 11 in a separate tube (C). 
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CD56-expressing CD3 cells were shown to be largely CD8 positive, CD16 
negative and not true NKT cells on the basis of staining with a glycolipid loaded 
CD1d tetramer (Figure 3.8). 
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Figure 3.8: Basic Phenotype of CD56-expressing CD3 Cells 
T cells expressing CD56 form a distinct population although expression of CD56 is at a low 
intensity (A). Only a small percentage of this population express CD4 (B1) with the majority being 
CD8 positive (B2). Minimal expression of CD16 was seen (B3) and this population failed to bind 
to the glycolipid-laden CD1d tetramer (CD1dT) (B4). 
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As true NKT cells are a rare cell population, due to the number of events acquired, 
the phenotype of these cells as identified by binding to the CD1d tetramer was 
only assessable in 12 healthy individuals and 22 AML patients (Figure 3.9). 
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Figure 3.9: Surface Phenotype of True NKT Cells  
Plot (A) shows the expression of CD4; plot (B), the expression of CD8; plot (C), the expression of 
CD16 and plot (D), the expression of CD56. 
 
A mean of 51% of NKT cells are CD4 positive in healthy individuals (SD 15%). 
A mean of 25% express CD8 (SD 17%) (the antibody used in this analysis is 
specific for alpha subunit). CD16 is only expressed on a mean of 5% of cells (SD 
5%) and CD56 expression is also low at 14% (SD 14%). 
 
Using CD3 and the CD1d tetramer, the mean absolute number of NKT cells was 
0.95 x 10
6
/L with a standard deviation of 2.3 x 10
6
/L in healthy individuals. Using 
antibodies to V 24 and V 11, the mean absolute number was 1 x 10
6
/L with a 
standard deviation of 1.55 x 10
6
/L. There was no significant difference in the 
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absolute or relative number of NKT cells in patients with AML compared with 
healthy controls. 
 
A significant difference was seen however in the relative numbers of NKT cells in 
the CD4 positive and CD4 negative subsets. In AML, NKT cells were more likely 
to be CD4 negative than in healthy individuals (p=0.01).  
 
3.4.3  CD3+56+ Cells are not  T Cells 
Later experiments showed that CD3+56+ cells are not /  T cells (Figure 3.10). 
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Figure 3.10: TCR Phenotype of CD3+56+ Cells 
Scatter plots of healthy T cells stained with CD3, CD56 and either TCR /  or TCR / Cells 
were gated on live mononuclear cells that were either CD3 positive (plots (A) and (B)) or double 
positive for CD3 and CD56 (plots (C) and (D)). (A) demonstrates that 4.5% of healthy T cells 
express the /  TCR whereas 92% express  TCRs (B).  T cells appear to be concentrated in 
the CD3+56+ population as shown by a percentage of 15% in (C) but the majority of this 
population still expresses the  TCR (D) (N=2). The 2 populations of  T cells observed are 
expected with the antibody used (BD Biosciences, cat. no. 559878 datasheet).
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3.4.4  Extended Phenotype of CD3+56+ Cells 
Extended phenotyping was performed on CD3+CD56+ cells on frozen PBMCs 
from five healthy volunteers and five AML patients to further characterise these 
cells. CD45RA and CD27 were used to distinguish effector, naïve and memory T 
cell subsets (Hamann, et al 1997, Hamann, et al 1999). The co-stimulatory T cell 
receptor CD28 and CD57, found on NK cells and a subset of T cells were also 
examined. Other cell surface markers examined were the IL-2 receptor  chain 
CD122, the NK receptors CD94, a KIR, and NKG2D, a C-type lectin type 
receptor. In view of the previous case report on a lymphoproliferation in an AML 
patient of CD3+56+ cells that expressed 2B4 (CD244) (Costello, et al 2002a), the 
expression of this high affinity receptor for CD48 was also investigated. The 
results are summarised in Table 3.10. 
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  CD3+56+ (Healthy) 
(n=5) 
CD3+56+ (AML) 
(n=5) 
Effector: 
CD45RA
high
/CD27- 
 
 
12.7% 
 
43.78% * 
Naïve:  
CD45RA
high
/CD27+ 
 
 
23.61% 
 
7.51% * 
Memory: 
CD45RA
low
/CD27+ 
 
 
23.9% 
 
11.29% 
CD57+/CD28- 11.34% 35.36% 
CD57+ 33.92% 61.68% * 
CD28+ 84.6% 45.37% * 
CD122+ 67.85% 77.3% 
NKG2D+ 48.14% 65.05% 
CD94+ 15.3% 19.07% 
CD244 (2B4)+ 4.93% 14.27% 
Table 3.10: Extended Phenotype of CD3+56+ Cells 
Phenotypic characteristics of CD3+56+ cells in healthy individuals compared with patients with 
AML. * indicates a statistically significant difference in expression in AML compared to healthy 
(p<0.05). 
 
These results show that whereas in healthy individuals CD3+56+ cells have 
largely a naïve or memory phenotype, in AML this population is skewed towards 
an effector phenotype. This CD45RA
high
CD27- population has been associated 
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with a CD57+CD28- phenotype (Hamann, et al 1997) and these results 
demonstrate a significant difference in the expression of these surface markers in 
AML leading to a conclusion that CD3+56+ cells in AML patients have all the 
hallmarks of effector CTLs. CD3+56+ cells express the IL-2 receptor  at high 
level but there is no difference in its expression between the AML and healthy cell 
populations. Expression of NKG2D and CD94 is also seen but again no difference 
was observed between AML and healthy individuals. 2B4 was expressed at higher 
levels on CD3+56+ cells in AML patients but once again this did not meet 
statistical significance. 
 
3.4.5  Expression of Activation Markers by CD3+56+ Cells 
The percentage of CD3+56+ and CD3+56- cells that express the activation cell 
surface markers CD25 and CD69 was investigated by flow cytometry in frozen 
PBMCs from 11 healthy individuals and 21 AML patients. The results are shown 
in Figure 3.11. 
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Figure 3.11: Activation Marker Expression on CD3+56+ Cells Compared 
with CD3+56- Cells 
The bar graph shows the mean percentage of CD3+56+ and CD3+56- cells expressing CD25 and 
CD69 in patients with AML and healthy volunteers. The scatter plots below are gated on live 
mononuclear cells. Plot (A) shows the expression of CD25 and CD69 on CD3+CD56+ cells in a 
healthy volunteer. Plot (B) shows the same markers on CD3+CD56- cells in a healthy volunteer. 
Plot (C) shows expression of CD25 and CD69 on CD3+CD56+ cells in a patient with AML and 
plot (D) shows the same thing on CD3+CD56- cells in the same patient. 
 
Significantly more CD3+56+ cells express the activation markers CD25 and 
CD69 than CD3+56- cells. Furthermore, CD3+56+ cells in AML show more 
expression of these markers than in healthy controls suggesting that these cells are 
in a higher state of activation in AML patients than in healthy individuals. If the 
subpopulation of large granular lymphocytes within the CD3+56+ subset is 
considered in the AML patients, the percentage of cells expressing both activation 
markers is even higher (p=0.004 compared with total CD3+56+ cells). 
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3.4.6  CD3+56+ Cell Expression of Intracellular Cytotoxic Granules 
The expression of perforin and granzyme B in CD3+56+ cells was investigated by 
intracellular staining and flow cytometry. Frozen PBMCs were used from five 
healthy individuals and 9 patients from the time of presentation with AML.  
 
Forward and side scatter characteristics of CD3+56+ cells demonstrated these 
cells were made up of two separate populations with different scatter 
characteristics; one subset with the characteristics of normal small lymphocytes 
and one with the characteristics of large granular lymphocytes (Figure 3.12). 
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Figure 3.12: Size and Granularity Characteristics of CD3+56+ Cells 
Scatter plot (A) shows CD3+56+ cells in blue backgated onto the FSC/SSC plot. Two populations 
of cells with different scatter characteristics are apparent. Plot (B) shows CD3 plotted against SSC 
with the CD3+56+ cells shown again blue. 
 
Consistent with their granular morphology, a greater percentage of CD3+56+ cells 
express cytotoxic granules compared to CD3+56- cells in healthy individuals 
(Table 3.11) although this difference only reaches statistical significance when 
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considering perforin alone or the combined expression of perforin and granzyme 
B. 
 
Healthy (n=5) Mean % (SD) of cells expressing cytotoxic granules 
 Perforin+ GrB+ Perforin/GrB+ 
CD3+56+ 64.6% 
(+/- 10.3%) 
66.5% 
(+/- 25.9%) 
51.9% 
(+/- 19.8%) 
CD3+56- 28.5% 
(+/- 18.9%) 
32.6% 
(+/- 27.9%) 
21.4% 
(+/- 18.6%) 
p-value 0.01 0.08 0.04 
Table 3.11: Expression of Cytotoxic Granules 
The expression of the cytotoxic granules perforin and granzyme B (GrB) was compared in 
CD3+56+ cells and CD3+56- cells in five healthy individuals. Figures shown are mean values 
with the standard deviation following in brackets.  
 
There was no difference in the percentage of CD3+56+ cells expressing perforin 
and granzyme B in AML patients compared with healthy individuals. However, if 
the population of CD3+56+ cells with the highest side scatter (SSC
High
) was 
considered, that is, the large granular lymphocytes, differences did become 
apparent (Table 3.12). 
 
Mean % (SD) of cells expressing perforin and granzyme B 
CD3+SSC
High 
population Total CD3+56+ population 
AML  Healthy  AML  Healthy 
43.5% * 
(+/- 20.0%) 
85.0% 
(+/- 8.8%) 
53.3% 
(+/- 21.0%) 
51.9% 
(+/- 19.8%) 
Table 3.12: Expression of Cytotoxic Granules in the CD3+SSC
High
 Population 
The expression of perforin and granzyme B in the CD3+SSC
High
 and total CD3+56+ populations in 
AML patients was compared with healthy individuals. Figures shown are mean values with the 
standard deviation following in brackets. * p-value 0.001 in a t-test comparing AML with healthy 
samples. 
 
Therefore, although CD3+56+ cells in general express high levels of cytotoxic 
granules, the expression of these granules in the LGL population is lower in 
patients with AML than in healthy individuals. 
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3.4.7  Cytokine Production by CD3+56+ Cells 
The production of IL-2, IFN , IL-4 and TNF were examined by intracellular 
staining and flow cytometry with and without stimulation with PMA and 
ionomycin (for protocol see section 2.7.3) in frozen PBMCs from two healthy 
individuals and three AML patients.  
 
Firstly it was observed that the expression of CD56 appeared to be altered by the 
protocol (Figure 3.13). 
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Figure 3.13: Alteration in CD56 Expression During Cytokine Release 
Experiment 
The expression of CD56 on CD3+ T cells prior to five hours culture and without fixation (A), on 
fixed cells post culture but without stimulation with PMA and ionomycin (B), on fixed cells post 
culture with stimulation with PMA and ionomycin (C). PECy7: CD3, APC: CD56. 
 
CD56 expression appeared to be lost on T cells during this experiment either due 
to the process of five hours culture at 37
0
C in 4% CO2 or due to cellular fixation 
that was required for intracellular staining. 
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However, when the expression of CD56 was examined on CD3 cells without 
gating the mononuclear cell population first it was clear that the relative number 
of these CD3+56+ cells was not changing but instead a change was occurring in 
their scatter characteristics (Figure 3.14).  
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Figure 3.14: Change in FSC/SSC Characteristics of CD3+56+ Cells During 
Cytokine Release Experiment 
The CD3+56+ population (blue) has been backgated onto a FSC/SSC plot. Prior to the five hour 
culture, this population shows the two subsets previously demonstrated (A). After five hours 
culture but without stimulation, the percentage of CD3+56+ cells remains similar but the cells 
show much broader scatter characteristics (B). With stimulation, this effect is even more marked 
such that the two original subsets can no longer be identified and all cells have greater forward and 
side scatter (C). 
 
Therefore, culturing cells for five hours at 37
0
C in 4% CO2 results in CD3+56+ 
cells becoming larger and more granular. This effect is magnified by stimulating 
cells with PMA and ionomycin. The unfortunate side effect of this is that these 
cells become autofluorescent which impacts on the assessment of their production 
of cytokines (Figure 3.15). 
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Figure 3.15: Autofluorescence of CD3+56+ Cells After Culture. 
The CD3+56+ cells are clearly visible in (A) when no gating has been previously applied (PECy7: 
CD3, APC: CD56). Backgating this population onto the FSC/SSC plot of all cells confirms the 
broad scatter characteristics illustrated in figure 3.12 (B). These cells appear to strongly express 
IFN  (C1), IL-2 (C2), CD4 (C3) but also CD8 (C4). However, similar fluorescence is also seen in 
the FL4 channel (C5) in which no fluorochrome should be present. 
 
Thus the change in scatter characteristics of CD3+56+ cells with culture and 
stimulation and consequent autofluorescence meant that accurate assessment of 
their production of cytokines by this method was not possible. 
 
One noteworthy observation made was that on stimulation of PBMCs from AML 
patients with PMA and ionomycin, a marked increase in the number of CD3+56+ 
cells occurred suggesting that T cells from patients with AML start to express 
CD56 on activation (Figure 3.16). A similar observation was made on stimulation 
of healthy T cells but the effect was not as great as that seen in T cells from AML 
patients.  
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Figure 3.16: Effect of Stimulation on CD56 Expression by T Cells 
Increased numbers of CD3 cells with high expression of CD56 were seen on stimulation of 
PBMCs from AML patients. 
 
3.4.8  Assessment of Clonality of CD3+56+ Cells 
The clonality of CD3+56+ cells was assessed in five of the previously studied 
AML patients chosen on the basis of available material (FAB types: 1 M1, 1 M2, 
2 M4 and 1 M5a) and compared to that of two healthy individuals by examining 
TCR gene rearrangements of TCRB, TCRG and TCRD. The clonality of 
CD3+4+56- and CD3+8+56- populations was also investigated. Blasts were 
included in the analysis to ensure that any clonality observed was not due to 
contaminating blast cells which can also rearrange their TCR genes (Schmetzer, et 
al 2000, Yen, et al 1999). 
 
All samples were tested with a Specimen Control Size ladder to ensure that no 
inhibitors of amplification were present and that there was DNA of sufficient 
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quality and quantity to generate a valid result. All samples passed this check. 
Polyclonal and clonal controls were included with each reaction. 
 
Figure 3.17 illustrates a typical trace seen for the CD3+56+ population. 
Polyclonal 
Control
Healthy
AML 
TCRB Tube C: 3+56+
 
Figure 3.17: Typical GeneScanning Traces for CD3+56+ Cells 
Each sample has two traces as both 6FAM (blue) and HEX (green) were used to label the 
amplified product. The y-axis represents intensity and the x-axis represents size of product in base 
pairs (bp). The top trace demonstrates the typical picture seen for the polyclonal control for TCRB 
Tube C. A normal distribution type curve is seen around 170-210bp (6FAM product) and 285-
325bp (HEX product). The middle trace represents healthy samples and a similar pattern to the 
polyclonal control is seen. However, the trace from the AML sample shows that the bell-shaped 
curve pattern has been lost and individual spikes are seen suggestive of an oligoclonal expansion. 
 
Each trace was examined and subjectively graded as polyclonal or oligoclonal on 
the basis of adherence to the typical bell-shaped curve pattern. The results are 
illustrated in Table 3.13. 
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TCRB 
Tube A 
TCRB 
Tube B 
TCRB 
Tube C 
TCRG 
Tube A 
TCRG 
Tube B TCRD 
 V +J 1/2 V +J 2 D +J 1/2 
V  1-8, 
V 10 + 
J 1.3/2.3 
V 9, V 11 
+ 
J 1.3/2.3 V +D +J  
CD3+4+ 
AML1 oligoclonal polyclonal oligoclonal polyclonal polyclonal polyclonal 
AML2 polyclonal polyclonal oligoclonal polyclonal polyclonal polyclonal 
AML3 oligoclonal polyclonal polyclonal oligoclonal polyclonal polyclonal 
AML4 polyclonal polyclonal polyclonal oligoclonal oligoclonal oligoclonal 
AML5 N/A N/A polyclonal oligoclonal oligoclonal oligoclonal 
Healthy1 polyclonal N/A polyclonal polyclonal polyclonal polyclonal 
Healthy2 polyclonal N/A oligoclonal N/A oligoclonal polyclonal 
CD3+8+ 
AML1 polyclonal oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML2 oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML3 oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML4 polyclonal oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML5 N/A N/A oligoclonal oligoclonal oligoclonal oligoclonal 
Healthy1 N/A N/A polyclonal polyclonal oligoclonal polyclonal 
Healthy2 polyclonal N/A polyclonal oligoclonal oligoclonal polyclonal 
CD3+56+ 
AML1 oligoclonal polyclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML2 oligoclonal polyclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML3 oligoclonal polyclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML4 oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML5 N/A N/A oligoclonal oligoclonal oligoclonal oligoclonal 
Healthy1 polyclonal N/A polyclonal oligoclonal oligoclonal polyclonal 
Healthy2 polyclonal oligoclonal oligoclonal oligoclonal oligoclonal polyclonal 
Blasts 
AML1 polyclonal polyclonal oligoclonal N/A N/A oligoclonal 
AML2 monoclonal polyclonal oligoclonal oligoclonal oligoclonal oligoclonal 
AML3 monoclonal polyclonal oligoclonal  polyclonal oligoclonal  oligoclonal 
AML4 monoclonal polyclonal oligoclonal polyclonal oligoclonal oligoclonal 
AML5 N/A N/A oligoclonal oligoclonal oligoclonal polyclonal 
Table 3.13: TCR Gene Clonality Results 
N/A indicates that no amplification occurred. Definition of polyclonal versus oligoclonal was 
subjective. 
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These results illustrate that oligoclonality is a common phenomenon amongst T 
cell populations in patients with AML. It is most frequently seen in the CD3+8+ 
56- and CD3+56+ populations where there is a significant difference in the 
occurrence of oligoclonality in comparison with the CD3+4+56- population 
(Table 3.14).  
 
AML Samples p-value 
3+4+ v 3+8+ 3.9 x 10
-5
 
3+4+ v 3+56+ 3.9 x 10
-5
 
3+8+ v 3+56+ 1 
Table 3.14: Comparison of Clonality in Different T cell Populations in AML 
Samples  
Fishers‟ Exact Test (2-tailed). Figures in red represent a statistically significant difference in 
oligoclonality between different cell populations in AML. 
 
Oligoclonality was also seen in the healthy T cell populations which meant that 
only rarely were significant differences seen in the occurrence of oligoclonality in 
AML compared with healthy samples (Table 3.15).  
 
 TCRB 
Tube A 
TCRB 
Tube B 
TCRB 
Tube C 
TCRG 
Tube A 
TCRG 
Tube B TCRD 
CD3+4+56- 0.46 N/A 1 1 1 1 
CD3+8+56- 1 N/A 0.047 0.285 1 0.047 
CD3+56+ 0.066 0.4 0.285 1 1 0.047 
Table 3.15: Comparison of Clonality of T Cell Populations Between AML 
and Healthy Samples 
P-values obtained using Fishers‟ Exact Test (2-tailed) AML v Healthy. N/A indicates a result is 
not available. Figures in red represent a statistically significant difference in oligoclonality 
between AML and healthy cell populations. 
 
Although generally considered to be polyclonal, the phenomenon of oligoclonality 
in healthy T cell populations has previously been described in CD8 cells where 
CDR3 length variation was noted in 72% of 56 individuals studied (Monteiro, et 
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al 1995). The same group found no evidence of clonal dominance in CD4 cells in 
12 individuals examined consistent with their previous observations (Hingorani, et 
al 1993). However, other groups have reported skewing in the Vβ repertoires in 
both CD4 and CD8 populations in healthy individuals when examined by flow 
cytometry (Davey, et al 1991, Grunewald, et al 1991). This probably represents 
the continuous nature of the adaptive immune response but means that T cell 
oligoclonality in the setting of disease must be interpreted with care. CD3+56+ 
cells in healthy individuals have previously been described as having oligoclonal 
expansions within the Vβ repertoire by flow cytometry (Ohkawa, et al 2001). It 
was of interest to find that the blast populations often showed oligoclonal 
products. If blasts did rearrange their TCR genes it might be expected that the 
population would then show a clonal pattern. However, this was only seen in three 
samples. A more likely explanation for the oligoclonality seen in these samples is 
amplification of genes from contaminating T cells. 
 
3.4.9  Comparison of Absolute Numbers of CD3+56+ Cells at 
Presentation and Remission of AML 
It was possible to obtain remission PB from 7 of the original AML patients used 
in this analysis. Using the whole blood lysis method for flow cytometry, absolute 
numbers of CD3+56+ cells were quantified (Figure 3.18).  
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Figure 3.18: Absolute Numbers of CD3+56+ Cells in Remission 
Absolute numbers of CD3+56+ cells were measured in the PB of 7 patients with AML at the time 
of presentation and at remission. 
 
This shows that once patients with AML go into remission, the CD3+56+ 
population returns to the same level as in healthy individuals (mean of 50.7 x 
10
6
/L compared with a mean of 27.6 x 10
6
/L in healthy controls). 
 
3.4.10  Change in Absolute Numbers of CD3+56+ Cells in a Single Patient 
If CD3+56+ cells represented a failing mechanism of immunosurveillance, it 
might be expected that absolute numbers of these cells would increase prior to 
clinical evidence of disease. A peripheral blood sample was obtained from an 
AML patient whose presentation PBMCs had been examined when they were in a 
clinical remission with a normal FBC. One week later the patient returned to 
clinic in relapse. Another PB sample was obtained at this time. Absolute numbers 
of CD3+56+ cells were therefore available from presentation, one week prior to 
clinical relapse and at the time of clinical relapse (Figure 3.19). 
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Figure 3.19: Absolute Number of CD3+56+ Cells at Presentation, Remission 
and Relapse 
Line graph of the absolute number of CD3+56+ cells in a single patient at the time of presentation, 
one week prior to relapse (when in remission) and at relapse. 
 
Therefore, in this single example, CD3+56+ cells were within the normal range 
one week prior to relapse at a time when it was likely that tumour cells were 
escaping immune surveillance mechanisms and rapidly proliferating. The rise in 
the number of CD3+56+ cells is mirroring the rise in the blast count rather than 
preceding it as might have been predicted if these cells had a crucial role in 
control of tumour growth. These results might suggest that the changes in T cells 
occur secondarily to emergence of AML and the absence of such cells prior to 
relapse may explain why immunosurveillance failed. 
 
3.4.11  Correlation of Absolute Total CD3 and CD3+56+ Cell Numbers 
with Patient Characteristics 
Clinical notes were examined for 7 patients who had absolute CD3+56+ counts 
ranging from 7.6 x 10
6
/L to 1469.9 x 10
6
/L. No correlation could be found 
between the absolute CD3+56+ cell count and (i) whether the patient was 
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clinically ill on presentation, (ii) if the patient was on antibiotics, (iii) if the patient 
had a documented infection, (iv) albumin level and (v) significant past medical 
history. 
 
Correlations were sought between absolute T cell number and FAB type, 
prognostic group, outcome of first therapy and relapse. There was a trend towards 
a higher T cell count in patients with FAB types M2 and M4 (p = 0.05), an area 
which may be worth investigating further with larger numbers of patient samples 
(Figure 3.20). 
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Figure 3.20: Correlation between FAB Type and Absolute T Cell Number.  
Lines represent median values. 
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There was no correlation between the absolute CD3+56+ count at presentation 
and the recorded total white cell count (Figure 3.21). The same was true for the 
absolute total T cell count compared with total white cell count (data not shown).  
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Figure 3.21: Correlation between Absolute CD3+56+ Cell Count in AML 
Patients with Presentation Total White Cell Count 
Lines represent a linear regression model and 95% confidence intervals. 
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Although in the healthy controls the expected correlation between age and 
absolute number of CD3+56+ cells was seen (p = 0.03) (Peralbo, et al 2007), this 
correlation was not seen in the AML patients (Figure 3.22). 
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Figure 3.22: Correlation between Age and Total Number of CD3+56+ Cells 
Graph (A) demonstrates the significant correlation between age and CD3+56+ absolute cell 
number in healthy individuals. Graph (B) shows no significant correlation between age and 
absolute CD3+56+ cell count in patients presenting with AML. The lines on the graphs represent 
linear regression models with 95% confidence intervals.  
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There was no correlation between sex and absolute CD3+56+ count in either 
healthy or AML patients (Figure 3.23). 
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Figure 3.23: Correlation between Sex and Total Number of CD3+56+ Cells 
P-values were obtained using a 2-tailed Mann-Whitney test. M: male, F: female. Lines represent 
the median values. 
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No correlation was found between the absolute number of CD3+56+ cells and 
FAB type, prognostic group or outcome of first-line therapy. However, there was 
a trend towards a higher absolute number of CD3+56+ cells in the PB at the time 
of presentation with AML and a lower risk of relapse (p = 0.06) (Figure 3.24).  
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Figure 3.24: Correlation between Risk of Relapse and Absolute Number of 
CD3+56+ Cells 
Line represents median values. 
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3.5  Discussion 
Contrary to expectation, these results show that although the number of T cells 
relative to total live mononuclear cells is reduced in patients presenting with 
AML, the absolute number of T cells is higher than in healthy individuals. Both 
CD4 and CD8 subsets are increased but the greater rise occurs in the CD8 subset 
resulting in a significant reduction in the CD4:CD8 ratio in comparison to healthy 
volunteers. This does not appear to be the result of a general proliferative reaction 
of the bone marrow. These results differ from those published by Vidriales and 
Panoskaltsis (Panoskaltsis, et al 2003, Vidriales, et al 1993). Certainly, this study 
made use of different methods for the AML and healthy samples to enable 
calculation of absolute cell numbers. However, this approach was validated by a 
pilot experiment which showed no significant differences in relative cell number 
using the different approaches. Furthermore, the AML and healthy samples were 
not fully age-matched. Nonetheless, analysis showed no correlation between 
absolute cell numbers and age in the AML samples. Another issue is that 
leucopheresis specimens were the most frequently used form of AML sample. 
This process concentrates all white cells. Therefore the relative numbers of 
different subsets should remain the same. As the absolute number of cells was 
calculated using the recorded relative cell number in relation to the total white cell 
count on the day it should be accurate. Furthermore, when the whole blood lysis 
method was used on relapsed AML patients (for example figure 3.19), the 
elevated number of total CD3+56+ cells was confirmed.   
 
CD56-expressing T cells were confirmed to be significantly increased in the 
peripheral blood of patients with AML compared with healthy volunteers. 
Although most AML samples were obtained by leucopheresis, CD56 expression 
was not thought to be directly altered as a result of this method of cell separation. 
It was shown that these cells are neither true NKT cells nor  T cells and are 
largely CD8 positive and CD16 negative. However, they do express the NK 
receptors NKG2D and CD94. Extended phenotyping demonstrated that these cells 
more frequently express markers representative of effector CTLs (CD45RA
High
 
CD27-CD57+CD28-) in patients with AML compared with healthy individuals. In 
addition, the activation markers CD25 and CD69 are more frequently expressed 
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on these cells in patients with AML than in healthy controls. As such, CD3+56+ 
cells appear to be poised to kill. Analysis of their scatter characteristics illustrates 
that a large proportion of these cells are large granular lymphocytes. As a 
consequence, a significantly larger percentage of CD3+56+ cells express the 
cytotoxic granules perforin and granzyme B compared with CD3+56- cells. In 
AML compared with healthy CD3+56+ cells, the only difference observed is 
when the LGL population (CD3+SSC
High
) is considered in isolation. A 
significantly lower percentage of these cells express cytotoxic granules in AML 
compared with healthy controls. Thus although CD3+56+ cells in AML are more 
likely to be effector CTLs with high expression of activation markers they have a 
reduced cytotoxic potential. Unfortunately, the analysis of cytokine secretion by 
CD3+56+ cells was inhibited by development of autofluorescence by this cell 
population on culturing and stimulation. Assessment of TCR clonality 
demonstrated oligoclonal populations of both CD3+56+ cells and CD8+56- cells 
in AML patients suggestive of outgrowth of T cell populations responsive to 
particular antigens which or may not be tumour-derived. CD3+56+ cells return to 
normal levels when a patient goes in to remission but a rise in the level of this 
population is not observed prior to clinical relapse. Absolute numbers of 
CD3+56+ cells at presentation do not correlate with patients‟ FAB type, 
prognostic group or response to first-line therapy. This is perhaps not surprising; 
at the time a patient presents with AML the immunosurveillance process has 
failed. From that time onwards the chance of that individual going into CR 
depends on the susceptibility of the tumour cells to chemotherapy, an intrinsic 
property of the tumour cells themselves. Although there is now some evidence to 
suggest that traditional chemotherapeutic agents can induce an enhanced host 
immune response (Vereecque, et al 2004b). However, of marked interest is the 
trend towards higher numbers of CD3+56+ cells at presentation being associated 
with lower relapse risk. This observation requires confirmation with larger patient 
numbers. However, as illustrated by allogeneic transplantation, once bulk tumour 
is cleared by the direct toxicity of chemotherapy, minimal residual disease can be 
controlled by an operational immune system. Therefore, this data raises the 
possibility that these cells truly represent an immunosurveillance function of the 
immune system. Nonetheless, absolute cell number is a crude way of assessing 
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immunity. Functional assessment of the cytotoxic capability of CD3+56+ cells 
would be more relevant. This analysis was not performed here because of the 
difficulties in isolating sufficient numbers of pure CD3+56+ cells from 
presentation AML samples. 
  
True NKT cells do not differ in terms of absolute numbers between AML and 
healthy individuals however the percentage of CD4 (DN) NKT cells is 
significantly higher in AML compared with normal. These cells represent the 
„anti-cancer‟ TH1 subset and as such may have a role of their own in tumour 
control. It was of interest to note that NKT cells in humans do not in fact express 
CD56 at high levels. This observation is in keeping with another report suggesting 
that CD56 is generally not expressed (Metelitsa, et al 2003) but contrary to that 
made by several publications that have described Vα24Vβ11 cells in humans as 
expressing CD56 (Lee, et al 2002, Prussin and Foster 1997). The absolute number 
of NKT cells does not correlate with any patient characteristic. 
 
Why are T cells, and more specifically CD3+56+ cells, increased in AML? This 
could represent failing immunosurveillance with the immune system desperately 
trying to control the uncontrollable. Most tumours escape immune recognition in 
ways such that T cells no longer see them and become unreactive. In AML, these 
immune cells appear to be proliferating, are activated, display effector phenotypes 
and have oligoclonal TCR gene rearrangements suggesting direction towards a 
particular antigen. Could immune recognition be occurring in this disease but 
effective cytotoxicity inhibited?  
 
In order to find out more about T cells in AML it was now necessary to separate 
those T cells from the large bulk of myeloblasts. The following chapter describes 
how this was eventually achieved. 
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Chapter 4 
Isolating T cells from AML presentation specimens 
4.1  Introduction 
Work published on T cells in AML to date involves flow cytometric studies on 
whole PBMC specimens or functional work looking at the impact of AML blasts 
on normal or remission T cells (see section 1.4). In order to perform gene 
expression microarrays and functional studies on T cells from AML samples it 
was necessary to find a suitable method of obtaining highly pure and ideally 
untouched CD4 and CD8 T cells. This minimizes the theoretical chance of 
triggering signal transduction pathways within the cell by the binding of surface 
molecules and so potentially altering the gene expression pattern. Methods 
considered were Fluorescence Activated Cell Sorting (FACS) and 
immunomagnetic cell separation.  
 
To separate the T cell populations, FACS was the obvious first choice. This 
method allows isolation at high purity of even very small cell populations. 
However, it requires sophisticated equipment and trained technical support. This 
was an available but highly stretched resource with a three week lead-time 
required for bookings. In general, the required cell population is labelled directly 
with an antibody. In order to obtain untouched cells, a cocktail of antibodies 
would need to have been used directed towards all other cells apart from the T 
cells. However, more importantly, even though the absolute number of T cells in 
the PB of patients with AML is increased, the number of T cells relative to the 
total white cell count is much reduced. Therefore, many more other cells have to 
be removed to get an equivalent number of T cells. 5 x 10
6 
cells CD4 or CD8 T 
cells were required to get sufficient quantity of RNA for gene expression profiling 
to avoid the necessity of template amplification. The amount of time that this 
would have entailed on a cell sorter was prohibitive. FACS was therefore 
excluded as a potential method at this stage. 
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Instead, immunomagnetic cell separation was explored. Two different systems 
were used; MACS® technology as developed by Miltenyi Biotec and StemSep™ 
cell separation method as marketed by StemCell Technologies. MACS® 
technology makes use of microbeads; superparamagnetic particles of 
approximately 50 nanometers in diameter to which antibodies are directly 
coupled. Cells are magnetically labelled by binding these microbeads. For 
untouched T cell isolation, a cocktail of biotin-conjugated monoclonal antibodies 
is incubated with the cells as a primary labelling reagent. Anti-biotin microbeads 
are then added as a secondary labelling reagent. Cell separation is achieved by 
passing the labelled cells through a MACS® column placed in a magnet (MACS 
Separator). The labelled cells are retained within the column and can then be 
eluted once the column is removed from the separator (Miltenyi, et al 1990). 
StemSep™ uses a slightly different labelling approach. Colloidal magnetic 
dextran iron particles are selectively bound to target cells by means of a bispecific 
tetrameric antibody complex that recognises both the dextran and the target cell 
surface antigen (Lansdorp, et al 1986). Cells are incubated first with an antibody 
cocktail and secondly with the magnetic colloid that magnetically labels the cells 
coated with antibody. Once again, labelled cells can be separated by passing the 
cell suspension over a column placed in a magnetic field. In a slight modification, 
StemCell Technologies supply a peristaltic pump that allows a controlled flow 
rate through the column rather than using gravity alone.  
 
4.2  Aims 
The aim of this study was to find a means of successfully separating highly pure 
ideally untouched CD4 and CD8 T cells from presentation AML specimens for 
the purposes of RNA extraction for gene expression microarrays and for 
functional studies. 
 
4.3  Materials and Methods 
Much of this initial optimisation work was made possible by the collection of a 
large leucopheresis sample from a newly diagnosed AML patient.  
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The methods used are described in detail in section 2.6. 
 
4.4  Results 
PBMCs from a patient with AML are made up of a large population of CD33 
positive myeloblasts and markedly smaller numbers of B cells (CD19+), 
monocytes, CD4 (CD3+/CD4+) and CD8 (CD3+/CD8+) T cells and NK cells 
(CD16+/CD56+) as demonstrated by the flow cytometric analysis in Figure 4.1. 
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Figure 4.1: Flow Cytometric Analysis of PBMCs from a Diagnostic AML PB 
Specimen 
 
The method previously used by our group for isolation of CD4 and CD8 T cells in 
CLL was immunomagnetic selection (Gorgun, et al 2005). A negative selection 
approach was employed: a cocktail of monoclonal antibodies was used to bind to 
all cells in the sample apart from the cell of interest which is therefore isolated 
untouched. CD4+ and CD8+ T Cell Isolation Kits II from Miltenyi Biotec were 
used in this part of the study. 
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The isolation kits used were designed for use with healthy peripheral blood. 
Separating T cells from leukaemia samples requires further consideration as the 
bulk of cells present do not express markers for which the antibodies within the 
cocktail are specific. In CLL the issue of removal of CLL B cells was addressed 
by adding x2 quantities of CD19 Microbeads to the CD4 or CD8 T cell negative 
isolation cocktail. Similarly, for AML samples, an extra step had to be included in 
order to remove circulating tumour cells. CD33 Microbeads were chosen as this 
antigen is highly expressed on myeloblasts. As myeloblasts often make up to 99% 
of total circulating cells it was felt a two-step procedure was necessary to ensure 
adequate myeloblast depletion (Figure 4.2). 
 
Total 
PBMC
Add anti-CD33 
labelled microbeads
Column containing
magnetic beads
CD33 -ve fraction
Add biotin-labelled antibody cocktail 
and anti-biotin microbeads (CD8 or 4, CD14, CD16, CD19, 
CD36, CD56, CD123, TCR / and glycophorin A)
CD4 or CD8 +ve cells only
POSITIVE SELECTION
NEGATIVE SELECTION
 
Figure 4.2: Experimental Design for Isolation of Unlabelled CD4 or CD8 T 
Cells 
 
Supervised analysis of gene expression profiles of isolated CD4 or CD8 T cells 
from CLL patients and healthy donors demonstrated no significant difference in 
gene expression on the basis of a cell purity of between 70% and 85% or more 
than 85% (Gorgun, et al 2005). A cut-off of 70% was therefore set as an 
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appropriate purity to obtain for isolated CD4 and CD8 T cells in these 
experiments. 
 
Using the recommended quantities of antibody for each step the quality of T cell 
purification was poor. As cell viability on thawing was between 50 and 75% and 
dead cells can bind non-specifically to the beads within the columns and inhibit 
adequate cell separation, a dead cell removal step was added. After dead cell 
separation by density gradient centrifugation, cell viability improved to between 
75-100%. However, the addition of this step did not improve T cell purity. 
 
Flow cytometric analysis illustrated that the depletion of CD33+ve myeloblasts 
using the protocol outlined in Figure 4.2 was ineffective (Figure 4.3). 
 
 
Pre-CD33 depletion Post-CD33 depletion
D
L
M
D
L
M
D = Dead cells
L = Lymphocyte zone
M = Myeloblast zone
 
Figure 4.3: Depletion of Myeloblasts by CD33 Positive Selection 
 
Therefore to improve the quality of CD33 depletion the quantity of CD33 
Microbeads was firstly doubled and then the CD33 labelled sample was passed 
through two columns prior to the negative selection step. Neither of these 
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modifications improved outcome. At this point it was felt to be important to 
ensure that the cell separation method worked well in my hands using the 
biological material it was designed for, that is, healthy blood. This worked well 
with good isolation achieved (Figure 4.4).  
CD4  Cells CD8 Cells
Gated to exclude dead cells on the basis of FSC/SSC
 
Figure 4.4: Negative Selection of CD4 and CD8 T Cells from Healthy 
Peripheral Blood 
 
Next it was tested whether the problem was the result of using frozen rather than 
fresh samples. When a fresh AML sample was used with the x1 quantity of CD33 
Microbeads, a relatively good isolation was achieved; 69% for CD4 and 51% for 
CD8. However, when repeated using a different patient sample, minimal CD4 or 
CD8 T cell isolation was achieved due to large numbers of residual myeloblasts. 
These experiments are summarized in Table 4.1. 
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Sample PBMC 
Count 
PBMC 
Viability 
CD4 CD8 Modification 
   Cell 
count 
Purity Cell 
count 
Purity  
Frozen 
AML 
PBMCs 
 
 
8.6 x 10
7
 
 
50% 
 
1.5 x 10
6
 
 
15% 
 
2.25 x 10
6
 
 
36% 
Protocol 
unchanged 
Frozen 
AML 
PBMCs 
 
 
1 x 10
8
 
 
81% 
 
4.5 x 10
6
 
 
5.5% 
 
2 x 10
6
 
 
3% 
Dead cell 
separation post 
thawing 
Frozen 
AML 
PBMCs 
 
 
7.8 x 10
7
 
 
64% 
 
1 x 10
6
 
 
10% 
 
3.5 x 10
5
 
 
6.7% 
2 x CD33 
Microbeads 
Frozen 
AML 
PBMCs 
 
 
 
5 x 10
7
 
 
76% 
 
1 x 10
5
 
 
9% 
 
2.5 x 10
5
 
 
11% 
2 x CD33 
Microbeads + 
2 x LD 
columns 
Fresh 
healthy 
PBMCs 
 
 
5.5 x 10
7
 
 
100% 
 
3.2 x 10
6
 
 
95% 
 
1.7 x 10
6
 
 
82% 
Protocol 
unchanged 
Fresh 
AML 
PBMCs 
 
4 x 10
8
 
 
92% 
 
2 x 10
6
 
 
69% 
 
1.6 x 10
6
 
 
50% 
1 x CD33 
Microbeads 
added to 
negative 
selection 
cocktail 
Table 4.1: T cell Isolation Experiments 
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An experiment was then performed to discover the identity of the contaminating 
cells. An AML mix of antibodies was used – CD117, CD13, CD33 and CD123 all 
labelled with PE along with CD3. This confirmed that the final sample contains 
„AML mix‟ positive blasts and T cells only.  
 
Cytospins were performed to visually assess the cells present in the sample after 
the isolation protocol. These confirmed that only blasts and lymphocytes were 
present (Figure 4.5). 
 
MYELOBLASTS
LYMPHOCYTES
 
Figure 4.5: Cytospin of T Cell Positive Fraction 
 
A titration experiment was then performed to see if larger quantities of CD33 
Microbeads would deplete more of the blasts – x1, x2 and x10 of CD33 
Microbeads were used (Figure 4.6).  
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20 l/107 Cells 40 l/107 Cells 200 l/107 Cells
CD33 MICROBEADS
 
Figure 4.6: Depletion of CD33+ve Myeloblasts using x1, x2 and x10 CD33 
Microbeads 
This illustrated that x10 quantities of CD33 Microbeads resulted in a marked improvement in blast 
depletion. 
 
x10 CD33 Microbeads were then used in the T cell separation protocol on two 
vials of frozen AML PBMCs, one for CD4 and one for CD8. On this occasion, the 
purity for CD8 was 49% and CD4 purity was only 6%. Therefore increasing the 
quantity of CD33 antibody used was only inconsistently successful. 
 
On the advice of a colleague, at this stage another step was introduced. AML 
PBMCs were incubated with 2% HAG prior to incubation with CD33 
Microbeads. This blocks Fc receptors on the cell surface that can non-specifically 
bind monoclonal antibodies. This is particularly the case for monocytes and 
macrophages but both healthy and malignant myeloblasts also express Fc 
receptors (Barrett, et al 1981, Ridway, et al 1976). The addition of this step did 
result in a small but significant improvement in isolated cell purity (Figure 4.7). 
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Figure 4.7: The Impact of the Use of 2%HAG on Isolated Cell Purity 
These scatter plots illustrate the percentage of live mononuclear cells that are total T cells (x axis) 
and myeloblasts (y axis, on this occasion defined by labelling with CD13) in the isolated cell 
fraction after no pre-incubation with 2% HAG (A) and with pre-incubation with 2% HAG (B).  
 
It was now apparent that CD33 alone was not sufficient for removing myeloblasts 
from PBMC samples in all AML patients. Further antibodies were required. 
However, AML samples are extremely heterogeneous and the expression of 
surface markers varies from patient to patient. This was noted by examining the 
surface expression of 7 potential blast markers in 36 AML patients by flow 
cytometry. These markers were chosen on the basis of which antibodies were 
potentially available for cell separation from StemCell Technologies. 
 
 CD11c CD13 CD33 CD34 CD36 CD38 CD123 
Mean 47.4% 43.4% 31.6% 29.9% 22.3% 85.9% 76.4% 
Range 3-99.7% 0.2-93.2% 0.04-81% 0.1-89% 0.4-79.0% 35.4-99.8% 9.4-98.8% 
Table 4.2: Expression of Cell Surface Markers on AML Blasts 
The expression of CD11c, CD13, CD33, CD34, CD36, CD38 and CD123 was examined on AML 
blasts in 36 patients. The mean percentage of blasts that expressed each marker along with the 
range of expression seen among the 36 samples is listed. 
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A cocktail of antibodies was required. An AML blast custom antibody cocktail 
was optimized, consisting of CD33, CD34, CD123, CD11c and CD36. CD33 was 
used at five times and CD123 three times their usual dose (Table 4.3). This was 
subsequently manufactured by StemCell Technologies as a custom StemSep 
antibody cocktail. The amount of magnetic colloid used was also increased from 
60 l per ml of cells to 100 l per ml of cells in case this was a limiting factor. 
 
 
Antibody CD3 % Conclusions 
CD33 CD123 CD34 CD11c CD36 PRE POST 
1x 0 0 0 0 7.4 10.2 Use 5x CD33.  
10x provides little 
advantage 
5x 0 0 0 0 7.4 29.9 
10x 0 0 0 0 7.4 30.5 
0 1x 0 0 0 9.75 17.6 Use 3x CD123 
5x provides little 
advantage 
0 3x 0 0 0 9.75 28.3 
0 5x 0 0 0 9.75 29.1 
3x 3x 0 0 0 3 24.8 CD33 + CD123 
insufficient alone 5x 3x 0 0 0 3 28.8 
5x 5x 0 0 0 0 30.8 
5x 3x 1x 0 0 8.4 92.1 5x CD33/3x CD123/1x 
CD34 very good for 
CD34+ve AMLs but not 
CD34-ve 
5x 3x 1x 0 0 9.2 91 
5x 3x 1x 0 0 4.5 34 
5x 3x 1x 1x 0 1.6 50.4 
Impact of addition of 
CD11c in a CD34-ve 
AML 
5x 3x 1x 1x 1x 23 75 Full cocktail used on 3 
different AML samples 5x 3x 1x 1x 1x 17.5 95.7 
5x 3x 1x 1x 1x 10.8 90 
 
Table 4.3: Blast Antibody Cocktail Optimization Experiments 
Each line represents a single experiment.  
 
 
In addition, due to the findings in the previous chapter regarding CD56 expressing 
T cells it was felt to be important to include these T cells in any analysis of 
function. Therefore CD56 needed to be excluded from the negative selection 
cocktail. Analysis of previous flow cytometric data on healthy peripheral blood 
demonstrated that the majority of CD56-expressing NK cells also express CD16 
(Figure 4.8) 
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Figure 4.8: CD16 Expression on Healthy CD56-expressing NK Cells 
NK cells are CD3 negative CD56 positive as seen in (A). The majority of these cells are also 
CD16 positive as demonstrated in (B). 
 
As the cocktail included CD16, it was concluded this would be sufficient to 
remove NK cells. StemCell Technologies therefore provided custom negative 
selection CD4 and CD8 T cell isolation kits composed of either CD4 or CD8, 
CD14, CD16, CD19, Glycophorin A and TCR /  antibodies. Finally, the 
combination of the blast depletion cocktail, T cell isolation custom cocktail, 2% 
HAG, increased magnetic colloid and the use of the peristaltic pump feed system 
resulted in isolation of highly pure untouched T cells from presentation AML PB 
samples (Figure 4.9). 
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Figure 4.9: Successful T cell Isolation from AML Presentation PB by 
Negative Immunomagnetic Selection. 
CD4 T cell isolation is shown in (A), these cells made up 3.17% of live mononuclear cells pre-
separation. The isolation protocol resulted in a purity of CD4 cells of 80.3%. CD8 T cell isolation 
is shown in (B). Initially, CD3+8+ cells made up 6.14% of total live mononuclear cells. Post 
separation, the purity of the isolated CD8 T cell fraction was 82%. 
 
It was noted that the purity of the isolated CD8 cells although adequate was not 
always as good as for CD4. However, rather than the contaminating cells being 
myeloblasts as had previously been the case, they were now CD3-56+ NK cells. 
The majority of these cells were also CD8 positive explaining why the 
contamination was less of an issue in CD4 isolation where the cocktail contained 
CD8. They also expressed CD16 and therefore theoretically should have been 
removed by the CD16 antibody used in the isolation cocktail (Figure 4.10). 
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Figure 4.10: Identity of Contaminating Cells in Isolated CD8 Specimens 
Isolated CD8 T cells had a purity of 70%. Contaminating cells fell into two subsets; CD3 negative 
CD8 positive (6.6%) and CD3 negative CD8 negative (19%) (A1). Both of these subsets were 
largely CD56 positive (A2 and A3). If CD3 negative CD56 positive cells were gated (B1), the 
majority were shown to be CD16 positive. 
 
Using healthy PBMCs, altering pump speeds and cocktail quantities had no 
impact on the removal of this cell population. CD16 is an Fc receptor found on 
NK cells, neutrophils, monocytes and macrophages. It has two alternative forms; 
CD16a is found on NK cells and monocytes whereas CD16b occurs on 
neutrophils. It was confirmed with StemCell Technologies that the antibody used 
in the T cell isolation cocktail was directed towards CD16a and therefore should 
remove NK cells. A sample of CD16 antibody used in the custom T cell isolation 
cocktail was provided by StemCell Technologies and Miltenyi Biotec generously 
donated CD16 Microbeads. The addition of either of these CD16 antibodies did 
not improve the purity of CD8 cells isolated using the CD56 negative custom T 
cell cocktail (Figure 4.11). This demonstrated that CD16 had not been omitted in 
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error from the StemCell Technologies T cell isolation custom cocktail and also 
that this antibody was not removing that CD16-expressing cells. 
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Figure 4.11: Impact of the Addition of CD16 to the CD56 Negative Custom 
Cocktail  
Prior to cell separation, CD16+56+ cells make up 4.1% of total live mononuclear cells (A). After 
CD8 T cell isolation using the custom T cell isolation cocktail alone these cells make up 12.8% of 
the isolated cell fraction (B). With the addition of CD16 antibody from StemCell Technologies (C) 
or CD16 Microbeads from Miltenyi Biotec (D) the percentage of these cells does not alter. 
 
The question then arose as to whether the human antiglobulin being used was 
blocking the CD16 antibody-binding site. However, omitting this incubation step 
did not significantly alter the removal of CD16-expressing cells. Addition of extra 
CD16 antibody in this situation made a small but not significant improvement 
(Figure 4.12).  
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Figure 4.12: Impact of Omission of 2% HAG Incubation step on Removal of 
CD16-expressing Cells 
In this individual, pre T cell separation, CD16+56+ cells made up almost 20% of live mononuclear 
cells (A). Post CD8 T cell isolation using the custom T cell isolation cocktail alone, these cells 
now make up 54% of the isolated cell fraction (B) although it is worth noting that the CD16+56- 
population has been removed. The addition of CD16 antibody from StemCell Technologies made 
little difference to the size of the CD16+56+ population (C). The additional use of CD16 
Microbeads from Miltenyi Biotec had a minor effect but this population still makes up 29% of the 
isolated cell fraction (D). 
 
It was concluded that the only way to adequately remove these CD3-56+16+ cells 
was to re-introduce CD56 back into the T cell isolation cocktail. However, having 
identified this population of potential biological relevance, it was deemed 
erroneous to exclude CD3+56+ cells from any analysis of T cells from AML 
patients (hereafter referred to as AML T cells) by removing them in the cell 
isolation method.  
 
Of interest, contaminating CD3-16+56+ cells did not impact so significantly on 
the purity of the majority of AML samples tested. This was because the use of two 
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antibodies in the blast depletion cocktail helped to improve cell purity by 
removing other cells. CD36, the thrombospondin receptor, is found on platelets, 
red blood cells and monocytes and CD11c, integrin alpha X, is found on dendritic 
cells, monocytes, neutrophils and also NK cells. When tested on healthy PBMCs, 
CD36 was found to be present on 12% of PBMCs and the CD36 antibody 
effectively removed this population. With regards to CD11c, this surface marker 
was present on 57% of CD3-56+ cells. Three populations were visible; a 
CD16+11c
Int
 subset, a CD16-11c
Int
 subset and a CD16-11c
High 
subset. Only the 
small CD16-CD11c
High
 population was removed by the CD11c antibody (Figure 
4.13). 
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Figure 4.13: Effect of CD36 and CD11c Antibodies on Depletion of Unwanted 
Cells  
A CD36 positive population is clearly apparent in (A). Post T cell separation this has been 
effectively removed. (B) shows the CD16-11c
High
 population pre T cell separation that is no longer 
visible post depletion. However, the CD11c
Int 
populations are still present. 
 
Therefore, the method of negative selection of T cells from presentation AML PB 
samples remained unchanged on the understanding that in certain individuals 
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contaminating CD3-16+56+ NK cells would compromise the purity of the 
CD3+8+ population. This variation in cellular populations would not be suitable 
for the molecular analyses of gene expression microarrays but may not 
compromise analysis of function provided flow cytometric data was taken into 
account.  
 
This technique was subsequently used on PB from 6 AML patients to isolate T 
cells for the functional analyses detailed in chapter 7 (Table 4.4).  
 
Sample CD4% 
PRE 
CD4% 
POST 
Total 
CD4 Cell 
Count 
CD8% 
PRE 
CD8% 
POST 
CD8% 
POST 
(inc 
CD56+) 
Total 
CD8 
Count 
AML1 3.0% 76.0% 16 x 10
6
 1.5% 36.0% 60.0% 10 x 10
6
 
AML2 14.0% 95.0% 18 x 10
6
 4.0% 79.0% 94.0% 6 x 10
6
 
AML3 8.6% 89.0% 8 x 10
6
 4.5% 73.0% 95.0% 2 x 10
6
 
AML4 3.2% 82.6% 2 x 10
6
 6.1% 82.0% 92.8% 4 x 10
6
 
AML5 2.7% 96.9% 2 x 10
6
 1.4% 91.9% N/A 3.8 x 10
6
 
AML6 10.9% 85.5% 1.1 x 10
6
 3.9% 72.0% 93.0% 3.2 x 10
6
 
 
Table 4.4: Successful CD4 and CD8 T Cell Isolation from Presentation PB 
from 6 AML Patients 
Percentages listed are the percentage of cells relative to total live mononuclear cells. Cell counts 
were performed post isolation procedure. N/A indicates CD56 expression was not checked post-
isolation. 
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4.5  Discussion 
Finding a successful method of obtaining untouched CD4 and CD8 T cells from 
AML presentation PB specimens proved highly problematic because myeloblasts 
make up the majority of the PBMC population in these patients and have 
heterogeneous cell surface markers. Nonetheless a method was eventually 
optimised through the use of a combination of five antibodies directed towards 
AML cell surface markers and StemSep™ technology. This technique was 
subsequently used for isolating CD4 and CD8 T cells from AML patients for the 
functional assays described in chapter 7. As this method had taken some time to 
work out, in the meantime, focus had turned to alternative means of obtaining 
AML T cells for gene expression microarrays, namely, positive immunomagnetic 
selection. However, before this method could be used, the issue as to whether 
isolating cells by binding them through surface receptors resulted in the activation 
of transcription pathways and altered gene expression required resolution. This 
will be addressed in the next chapter. 
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Chapter 5 
The Impact of the Method of Cell Selection on Gene 
Expression Profile 
5.1  Introduction 
Immunomagnetic selection is a popular and effective method of isolating cells. 
Companies such as Miltenyi Biotec and Stem Cell Technologies provide reagents 
that allow selection of particular cell populations within the lab without the 
requirement for FACS with its expensive and technologically complicated 
equipment. With positive selection, the required cells are isolated using an 
antibody bound directly to a magnetic bead. When the cell suspension is passed 
through a magnetic field, the labelled cells are retained and the unlabelled, 
unwanted cells pass through. With negative selection, an antibody cocktail is 
added that binds to all cells except the ones of interest. When this cell suspension 
is passed through a magnetic field, this time the unwanted cells are magnetically 
labelled and thus retained within the column and the desired cells are eluted 
effectively „untouched‟ (Figure 5.1).  
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Figure 5.1: Comparison of Positive versus Negative Selection for Cell 
Separation 
 
Negative selection has the disadvantage of reduced cell yield and purity however 
positive selection has the theoretical potential of activating the cell as a result of 
cross-linking surface antigens and therefore altering transcription. There are 
several reports of the impact of ligating antigens on the surface of T cells. Stanciu 
and colleagues demonstrated that positively selecting CD4 and CD8 T cells 
resulted in increased IL-4 production both at baseline and after 20 hours in culture 
compared with negatively selected cells (Stanciu, et al 1996). CD4 ligation has 
also been shown to induce cellular aggregates (Bernard, et al 2002), apoptosis 
(Berndt, et al 1998, Wang, et al 1994), TCR down-regulation (Chuck, et al 1993), 
and altered levels of downstream signalling molecules (Bernard, et al 2002, Milia, 
et al 1997). However, another report suggests no change in proliferative potential 
(as an indicator of activation) of positively selected T cells (Semple, et al 1993). 
For the purposes of gene expression profiling of lymphocytes, both 
immunological methods of separation have been used even within the same study 
(Palmer, et al 2006) yet at the time this work was initiated there were no 
published data directly comparing the impact of positive versus negative selection 
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on gene expression. Since that time, the results of a single study have been 
published that directly compared the gene expression profile of positively 
compared with negatively selected cells (Lyons, et al 2007). Three independent 
CD4 and CD8 separations were performed and the authors concluded that the few 
expression changes that were observed for CD4 cells could be attributed to 
contamination with monocytes. 
 
5.2  Aims 
Due to the potential problems associated with positively selecting T cells outlined 
and also to allow direct comparison with the CLL dataset in which T cells had 
been negatively selected, the initial aim had been to negatively select T cells from 
AML samples for gene expression microarray analysis. As described in Chapter 3, 
this method had proved difficult to optimise for AML samples, therefore attention 
turned to positive selection techniques. However, before performing the AML 
versus healthy T cell analysis, the question as to the impact of method of cell 
selection on the gene expression profile of healthy CD4 and CD8 T cells needed 
to be addressed. Therefore, in this study, the gene expression profile of CD4 and 
CD8 T cells isolated from healthy volunteers by positive and negative 
immunomagnetic selection was compared. 
 
5.3  Materials and Methods 
5.3.1  Samples 
Peripheral blood was taken from healthy volunteers. CD4 and CD8 cells were 
separated by positive and negative selection using the methods detailed in Chapter 
2, section 2.6. Cell purity was assessed by flow cytometry post separation. The 
characteristics of these samples are listed in Table 5.1.  
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Number of  
Samples 
 
Median Age 
 
 
Male:Female 
 
 
Mean Purity 
(range) 
 
CD4 
Negative Selection 5 44 2:3 
92.9% 
(89-95.5%) 
 
CD4  
Positive Selection  5  44  1:4  
94.9% 
(90-98.2%)  
 
CD8  
Negative Selection  5  35  4:1  
85.0% 
(76-91%)  
 
CD8  
Positive Selection  6  33  5:1  
89.9% 
(87-94%)  
Table 5.1: Characteristics of Healthy T Cell Samples 
 
5.3.2  RNA 
RNA was extracted using the technique detailed in Chapter 2, section 2.9. Quality 
was assessed on both a Nanodrop spectrophotometer and Bioanalyzer. Quantity 
measurements were taken from Bioanalyzer values (Table 5.2). 
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 Total RNA ( g) A
260
/A
280 
 
CO CD4_N  15 2.10 
KS CD4_N  2.5 2.1 
LG CD4_N  6.0 2.09 
AD CD4_N  4.7 2.13 
IK CD4_N  8.2 2.09 
KS CD4_P  4.2 2.27 
LG CD4_P  11.5 2.15 
AD CD4_P  4.3 1.74 
IK CD4_P  2.4 2.06 
EN CD4_P  6.5 2.10 
DM CD8_N  11.2 2.08 
PR CD8_N  3.3 2.14 
MR CD8_N  2.3 2.26 
AD CD8_N  5.4 2.14 
IK CD8_N  5.5 2.09 
PR CD8_P  2.3 2.07 
MR CD8_P  3.7 1.95 
IK CD8_P  3.3 2.13 
AD CD8_P  5.9 2.14 
DW CD8_P  5.8 2.1 
MG CD8_P  5.8 2.1 
Table 5.2: Quality and Quantity of T Cell RNA Obtained 
All 21 healthy samples included. _P: positive selection, _N: negative selection. 
 
Depending on the amount of starting material available, between 2.3 and 5 g of 
RNA were used for subsequent synthesis of fragmented biotinylated cRNA using 
the protocol described in Chapter 2, section 2.10. 
 
5.3.3  Quality Control (QC) Data for Affymetrix U133Plus2 GeneChips® 
Fragmented biotinylated cRNA was hybridised onto Affymetrix U133Plus2 
GeneChips®. Quality control data from the GeneChip runs is listed in Table 5.3. 
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Date  
Chip 
Run 
Sample  Scale 
Factor  
(~1) 
Background 
(<100)  
No. 
Present 
(~50%)  
No. 
Absent 
(~50%)  
GAPDH 
5’-3’ 
Ratio 
(<3)  
HSA  
5’-3’ 
Ratio 
(<3)  
26.6.07 CO CD4_N 1.627  44.63  44.50%  54%  1.25  2.5  
5.1.07  KS CD4_N 1.452  49.23  41.50%  56.80%  1.25  2.54  
5.1.07  LGCD4_N 1.116  57.74  42.90%  55.40%  1.04  1.63  
5.1.07  AD CD4_N 1.147  55.11  42.40%  55.90%  1.18  1.98  
14.2.07  IK CD4_N 2.37  37.33  41.60%  56.80%  1.24  3.91  
25.4.06  KS CD4_ 1.168  47.44  42.50%  55.90%  1.53  2.26  
25.4.06  LG CD4_P 1.025  61.56  43.10%  55.30%  3.5  7.13  
25.4.06  AD CD4_P 1.119  56.24  41.70%  56.70%  11.36  13.64  
25.4.06  IK CD4_P 0.989  92.61  38.20%  60.40%  10.02  5.1  
26.6.07  EN CD4_P 1.219  62.94  43.90%  54.60%  1.25  1.53  
26.6.07  DM CD8_N 1.724  45.31  43.50%  55.10%  1.35  2.26  
5.1.07  PR CD8_N 1.104  50.61  43.30%  55.10%  1.26  1.98  
5.1.07  MR CD8_N 1.182  53.39  43%  55.40%  1.29  2.22  
14.2.07  AD CD8_N 2.28  40.18  41.60%  56.70%  1.35  4  
14.2.07  IK CD8_N 2.678  37.16  40.90%  57.60%  1.22  3.42  
1.6.06  PR CD8_P 2.13  57.14  39.20%  59.20%  1.46  1.98  
17.5.06  MR CD8_P 1.104  54.5  42.3%%  56.1%%  9.99  3.54  
17.5.06  IK CD8_P 0.983  52.04  44.30%  54%  7.92  4.98  
17.5.06  AD CD8_P 1.114  52.19  42.30%  56%  10.42  4.95  
26.6.07  DW CD8_ 1.214  55.26  44.60%  53.80%  1.16  1.48  
26.6.07  MG CD8_P 0.888  72.9  43.60%  54.90%  1.16  1.43  
Table 5.3: Quality Control Data for Affymetrix U133Plus2 GeneChips® 
All 21 healthy samples are included. _P: positive selection, _N: negative selection. Figures 
highlighted in bold failed QC criteria.  
 
The six samples that failed the Affymetrix standard QC criteria for GAPDH and 
HAS 5‟-3‟ ratios were not excluded from further analysis. This was because this 
measure is supposed to represent the presence of degraded RNA in the specimen 
with a ratio >3 indicating degradation. However, Bioanalyzer analysis had 
indicated good quality RNA at the start of the procedure and only samples that 
passed all QC checkpoints were hybridised to chips. Analysing the signals from 
the GAPDH probes alone revealed that only the probes from the 5‟ end showed 
marked variability (Figure 5.2). 
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Figure 5.2: Expression of Affymetrix Human GAPDH Controls over 16 
Samples 
This demonstrates good consistency for the 3‟ and mid-probesets with only the probeset that binds 
to the 5‟ end of the RNA transcript showing variability. 
 
To examine if this was a consistent problem for all probesets binding to RNA 5‟ 
ends the following RNA digestion plot was drawn (Figure 5.3).  
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Figure 5.3: RNA Digestion Plot 
The mean fluorescence intensity of all 11 elements of every probeset on every chip across 16 
samples is illustrated.  
 
This plot identifies any trends in the data caused by RNA degradation (which 
typically targets the 5‟ end of the molecule) or 3‟-biased amplification. If RNA 
degradation was present, probe intensities would be systematically lowered at the 
5‟ end of a probeset. However, this plot shows that those elements that bind to the 
5‟ end of RNA transcripts are binding equally well as those that bind to the 3‟ end 
(the lines are almost flat). Therefore the problem noted with the 5‟-3‟ ratios in the 
QC check cannot indicate widespread truncated RNA. It is also of note that the 
majority of probes on the gene expression arrays target the 3‟ end of the RNA 
transcript. 
 
5.3.4  Analysis of Microarray Data 
Normalisation is the process whereby systematic or experimental error is removed 
from the dataset. In this analysis, microarray data was normalised using robust 
multi-array average (RMA) processing. Two samples, PR_CD8_P and 
IK_CD4_P, were removed from the analysis due to their discrepant normalised 
unscaled standard errors (NUSE). This quality control measure was calculated by 
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standardising RMA-estimated standard errors across the arrays. Unsupervised 
clustering was then performed (Figure 5.4).  
 
 
Figure 5.4: Unsupervised Clustering 
Dendrogram showing the results of clustering the 19 remaining arrays based on the signals of the 
2099 probesets with a coefficient of variation > 0.1. Colour denotes the date on which the samples 
were run. 
 
This clustering exercise demonstrated the presence within the samples of a batch 
effect; samples clustered according to the date on which they were processed 
rather than within their biological replicate groups. To accommodate for this, for 
each gene, a batch (date) and replicate group effect was modelled. It was then 
possible to look within the group effect, ignoring the batch effect, for genes 
differentially expressed using an unpaired t-test. This analysis was performed 
using Bioconductor software. The data was also examined on two alternative 
software packages, Genespring and Partek. In all cases the least stringent (default) 
multiple testing correction was applied to the analysis; a false discovery rate < 
0.05. False discovery rate (FDR) is a form of multiple testing correction. This 
statistical correction adjusts the p-value to correct for the occurrence of false 
positives. This had to be applied as effectively 54,000 t-tests were being 
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performed. There are a number of different multiple testing corrections that can be 
applied. These vary from the most stringent Bonferroni to the least stringent 
Benjamini and Hochberg False Discovery Rate. The latter is usually the default 
setting on analysis programmes as it offers a good balance between discovery of 
statistically significant genes and limitation of false positive occurrences. A FDR 
of 0.01 means 1% of the genes found to be differentially expressed will be picked 
up due to chance and are therefore false positives. 
 
5.3.5  Validation of Microarray Data by qRT-PCR 
The expression of four genes found to be differentially regulated by microarray 
was validated by qRT-PCR (Table 5.4). These were chosen on the basis of which 
genes were most significantly altered in positively compared with negatively 
selected T cells (NR4A2 and MS4A3) and genes which were of potential biological 
interest in T cells (CXCR4 and EEA1).  
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Symbol Name Function CD4 
(log(2) 
fold 
change 
PvN) 
CD8 
(log(2) 
fold 
change 
PvN) 
NR4A2 Nuclear receptor subfamily 
4, group A, member 2 
Probable nuclear receptor. 
May function as a general 
coactivator of gene 
transcription 
NS +2.7 
CXCR4 Chemokine (C-X-C motif) 
receptor 4 
Receptor for chemokine 
CXCL12/SDF-1 
NS +1.9 
MS4A3 Membrane-spanning 4-
domains, subfamily A, 
member 3 (hematopoietic 
cell-specific) 
Haematopoietic modulator 
for the G1-S cell cycle 
transition 
NS -5.3 
EEA1 Early endosome antigen 1 Binds phopholipid vesicles 
and participates in 
endosomal trafficking 
NS -1.6 
Table 5.4: Genes Validated by qRT-PCR 
NS: not differentially regulated between positively and negatively selected cells. 
 
qRT-PCR was performed using the same RNA samples that had been used for the 
microarrays. This meant that in many cases there was insufficient material 
available (Table 5.5).  
 
 Samples for microarray Samples for qRT-PCR 
 
CD4  
Negative Selection 
5 2 
CD4  
Positive Selection 
5 2 
CD8  
Negative Selection 
5 2 
CD8  
Positive Selection 
6 3 
Table 5.5: Availability of Microarray RNA Samples for qRT-PCR 
 
In all cases, 100ng of RNA were used for cDNA synthesis (Figure 5.5). 
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Figure 5.5: actin PCR for Confirmation of cDNA Synthesis 
CD4 negative selection: 1-2; CD4 positive selection: 3-4; CD8 negative selection: 5-6; CD8 
positive selection: 7-9; negative control cDNA synthesis: 10 and 22; negative control actin PCR: 
11and 23; Jurkat cell line: 12-16; K562 cell line: 17-21. The two rows look dissimilar due to the 
use of different size combs for forming wells. 
 
Three cell lines, Jurkat, K562 and KE37, were checked initially to see which 
could be used as a positive control (calibrator) for each TaqMan® Assay. On the 
basis of which gave the lowest CT values with each assay, K562 was chosen for 
NR4A2, MS4A3 and EEA1 and Jurkat was chosen for CXCR4. 
 
As the 2
- C
T method was used for the analysis of qRT-PCR data, a validation step 
was performed to demonstrate that the efficiencies of the target and reference 
gene (GAPDH) amplification were approximately equal. The positive control cell 
line chosen for each assay was used and input cDNA was 1000ng, 200ng, 40ng, 
8ng and 1.6ng. The absolute value of the slope of log input amount versus CT 
should be <0.1 (Figure 5.6).  
Rifca Le Dieu                                                                                                           Chapter 5 Results 
185 
 
y = -0.0286x + 4.8155
R2 = 0.0398
4.3
4.4
4.5
4.6
4.7
4.8
4.9
5
5.1
0 0.5 1 1.5 2 2.5 3 3.5
C
T
Log ng Total Input RNA
Relative Efficiency Plot CXCR4 and GAPDH
y = -0.022x + 8.213
R2 = 0.0415
7.7
7.8
7.9
8
8.1
8.2
8.3
8.4
8.5
0 0.5 1 1.5 2 2.5 3 3.5
C
T
Log ng Total Input RNA
Relative Efficiency Plot EEA1 and GAPDH
y = 0.1012x + 6.9898
R2 = 0.7683
6.7
6.8
6.9
7
7.1
7.2
7.3
7.4
0 0.5 1 1.5 2 2.5 3 3.5
C
T
Log ng Total Input RNA
Relative Efficiency Plot MS4A3 and GAPDH
y = 0.044x + 8.0077
R2 = 0.0733
0
1
2
3
4
5
6
7
8
9
10
0 0.5 1 1.5 2 2.5 3 3.5
C
T
Log ng Total Input RNA
Relative Efficiency Plot NR4A2 and GAPDH
 
Figure 5.6: TaqMan® Assay Relative Efficiency Plots  
Plots of log input RNA versus CT for NR4A2, CXCR4, MS4A3 and EEA1 with GAPDH. The 
absolute value of the slope is shown in red. 
 
5.4  Results 
5.4.1  Gene Expression Microarray 
Using both Genespring and Partek software and the least stringent multiple testing 
correction (FDR<0.05), no genes were identified as being differentially expressed 
between positively and negatively selected cells for both CD4 and CD8.  
 
However, using Bioconductor software and modelling for batch effect, 114 
probesets were found to be differentially expressed (again using an FDR<0.05) in 
positively selected CD8 cells compared with negatively selected cells of which 76 
were up-regulated and 38 down-regulated (Figure 5.7). Once again, no 
differentially expressed genes were found for CD4. 
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Figure 5.7: Supervised Clustering of CD8 Samples 
Heatmap demonstrating how the expression of the 114 differentially expressed probesets varies 
across all CD8 samples. 
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To evaluate if these genes were of any biological significance in T cells, firstly, 
the gene-list was compared to that published by Wang and colleagues of genes 
differentially expressed in human T cells activated ex vivo with anti-CD3/anti-
CD28 (Wang, et al 2008). 36 of the 114 genes (32%) were present in the list of 
3793 genes differentially regulated in CD3+ activated cells. These are marked in 
yellow in the Table 5.6 below. Only 9 genes were present in the list of 1258 genes 
differentially regulated in activated CD8 cells; CXCR4, NDUFV2, CREM, 
SLC19A2, ZNF331, TGIF, MYB, FBX05 and NET1. A search of each of the 114 
genes was then made on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/ ) to look 
for associations with T cells within published literature. These are marked in 
green in Table 5.6. 
 
Affymetrix 
Probe ID 
Log(2) 
Fold 
Change 
Symbol Present 
in Wang 
Gene-list 
Association 
with 
T cells 
Description 
204621_s_at 3.01 NR4A2     nuclear receptor subfamily 4, group A, 
member 2 
216248_s_at 3.00 NR4A2     nuclear receptor subfamily 4, group A, 
member 2 
204622_x_at 2.72 NR4A2     nuclear receptor subfamily 4, group A, 
member 2 
202988_s_at 2.46 RGS1     regulator of G-protein signaling 1 
1563473_at 2.32 PPP1R16B   protein phosphatase 1, regulatory 
(inhibitor) subunit 16B 
242836_at 2.14 ATP1B3    ATPase, Na+/K+ transporting, beta 3 
polypeptide 
241740_at 2.06 CREM     cAMP responsive element modulator 
209201_x_at 1.86 CXCR4     chemokine (C-X-C motif) receptor 4 
211919_s_at 1.85 CXCR4     chemokine (C-X-C motif) receptor 4 
1564248_at 1.85 LOC100130544   hypothetical protein LOC100130544 
1559203_s_at 1.83 KRAS     v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
1565716_at 1.80 FUS   fusion (involved in t(12;16) in 
malignant liposarcoma) 
233127_at 1.76 ZNF331   zinc finger protein 331 
238987_at 1.67 B4GALT1   UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
215850_s_at 1.48 NDUFA5   NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 5, 13kDa 
240231_at 1.40 AZIN1   antizyme inhibitor 1 
1566980_at 1.36    NA 
241438_at 1.36 RLF    rearranged L-myc fusion 
1566901_at 1.35 TGIF1     TGFB-induced factor homeobox 1 
214805_at 1.34 EIF4A1    eukaryotic translation initiation factor 
4A, isoform 1 
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242125_at 1.34 CAPZA1    capping protein (actin filament) muscle 
Z-line, alpha 1 
230328_at 1.33 RRN3   RRN3 RNA polymerase I transcription 
factor homolog (S. cerevisiae) 
215322_at 1.33 LONRF1   LON peptidase N-terminal domain and 
ring finger 1 
217591_at 1.25 SKIL     SKI-like oncogene 
242298_x_at 1.20    NA 
1559154_at 1.19 SNX1    sorting nexin 1 
201341_at 1.15 ENC1   ectodermal-neural cortex (with BTB-
like domain) 
230170_at 1.14 OSM     oncostatin M 
224454_at 1.14 ETNK1    ethanolamine kinase 1 
227394_at 1.14 NCAM1    neural cell adhesion molecule 1 
239476_at 1.07 PIK3R1    phosphoinositide-3-kinase, regulatory 
subunit 1 (alpha) 
243649_at 1.06 FBXO7   F-box protein 7 
242113_at 1.05 AKAP8     A kinase (PRKA) anchor protein 8 
231904_at 1.02 U2AF1    U2 small nuclear RNA auxiliary factor 
1 
239540_at 1.02 GTF3C1   general transcription factor IIIC, 
polypeptide 1, alpha 220kDa 
242858_at 1.00 C14orf2   chromosome 14 open reading frame 2 
1556952_at 1.00 NCALD   neurocalcin delta 
1554602_at 0.98 RBM8A    RNA binding motif protein 8A 
239404_at 0.98 TOP1    topoisomerase (DNA) I 
216278_at 0.97 KIAA0256   KIAA0256 gene product 
233834_at 0.97 NCOA2   nuclear receptor coactivator 2 
238704_at 0.95    NA 
232175_at 0.93 ARF1    ADP-ribosylation factor 1 
232824_at 0.93 ATP9B   ATPase, class II, type 9B 
244226_s_at 0.89 RNF43   ring finger protein 43 
220702_at 0.86    NA 
204614_at 0.86 SERPINB2   serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
1556602_at 0.85 SLC19A2    solute carrier family 19 (thiamine 
transporter), member 2 
210469_at 0.84 DLG5   discs, large homolog 5 (Drosophila) 
1565706_at 0.83    NA 
214918_at 0.81 HNRPM    heterogeneous nuclear 
ribonucleoprotein M 
233038_at 0.80 CENTG2   centaurin, gamma 2 
239450_at 0.76 NDUFV2    NADH dehydrogenase (ubiquinone) 
flavoprotein 2, 24kDa 
240358_at 0.76 DENND3   DENN/MADD domain containing 3 
228296_at 0.76 YPEL1    yippee-like 1 (Drosophila) 
239193_at 0.74 FUBP3   far upstream element (FUSE) binding 
protein 3 
243872_at 0.72 WAPAL   wings apart-like homolog (Drosophila) 
241150_at 0.72 SPTAN1   spectrin, alpha, non-erythrocytic 1 
(alpha-fodrin) 
208347_at 0.70    NA 
1569212_at 0.69 LOC619207   scavenger receptor protein family 
member 
237076_at 0.69 NCSTN   nicastrin 
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205238_at 0.69 CXorf34   chromosome X open reading frame 34 
240094_at 0.69 TXNDC13   thioredoxin domain containing 13 
223797_at 0.68 PRO2852   hypothetical protein PRO2852 
232200_at 0.68 HSPA9    heat shock 70kDa protein 9 (mortalin) 
225746_at 0.67 RAB11FIP4    RAB11 family interacting protein 4 
(class II) 
1565358_at 0.66 RARA   retinoic acid receptor, alpha 
1566456_at 0.61    NA 
240090_at 0.60 AUH    AU RNA binding protein/enoyl-
Coenzyme A hydratase 
225197_at 0.60 C16orf72   chromosome 16 open reading frame 72 
244659_at 0.59 TRIP12    thyroid hormone receptor interactor 12 
1564430_at 0.58    NA 
223586_at 0.57 ARNTL2   aryl hydrocarbon receptor nuclear 
translocator-like 2 
229136_s_at 0.57 ZNF302   zinc finger protein 302 
1557279_at 0.53    NA 
201174_s_at 0.44 TERF2IP   telomeric repeat binding factor 2, 
interacting protein 
202811_at -0.47 STAMBP    STAM binding protein 
209272_at -0.54 NAB1    NGFI-A binding protein 1 (EGR1 
binding protein 1) 
220397_at -0.55 MDM1   Mdm4, transformed 3T3 cell double 
minute 1, p53 binding protein (mouse) 
225132_at -0.62 FBXL3   F-box and leucine-rich repeat protein 3 
219074_at -0.63 TMEM34   transmembrane protein 34 
203403_s_at -0.65 RNF6   ring finger protein (C3H2C3 type) 6 
228855_at -0.66 NUDT7   nudix (nucleoside diphosphate linked 
moiety X)-type motif 7 
202930_s_at -0.66 SUCLA2   succinate-CoA ligase, ADP-forming, 
beta subunit 
239598_s_at -0.71 LPCAT2   lysophosphatidylcholine 
acyltransferase 2 
226693_at -0.71 SDHALP2   succinate dehydrogenase complex, 
subunit A, flavoprotein pseudogene 2 
206557_at -0.72 ZNF702   zinc finger protein 702 
219913_s_at -0.74 CRNKL1   crooked neck pre-mRNA splicing 
factor-like 1 (Drosophila) 
225030_at -0.74 FAM44B   family with sequence similarity 44, 
member B 
1557260_a_at -0.75 ZNF382   zinc finger protein 382 
1569543_at -0.78 RSU1   Ras suppressor protein 1 
230542_at -0.78 ZNF597   zinc finger protein 597 
208478_s_at -0.78 BAX   BCL2-associated X protein 
223576_at -0.79 C6orf203   chromosome 6 open reading frame 203 
205791_x_at -0.79 ZNF230    zinc finger protein 230 
243127_x_at -0.80 DNASE1   deoxyribonuclease I 
207338_s_at -0.91 ZNF200   zinc finger protein 200 
223433_at -0.93 C7orf36   chromosome 7 open reading frame 36 
219234_x_at -0.93 SCRN3   secernin 3 
218875_s_at -0.94 FBXO5   F-box protein 5 
241791_at -0.95 TTN   titin 
213007_at -0.96 FANCI   Fanconi anemia, complementation 
group I 
220987_s_at -1.00 NUAK2   NUAK family, SNF1-like kinase, 2 
Rifca Le Dieu                                                                                                           Chapter 5 Results 
190 
 
204264_at -1.00 CPT2    carnitine palmitoyltransferase II 
237459_at -1.02 PCTK2   PCTAIRE protein kinase 2 
234295_at -1.11 DBR1   debranching enzyme homolog 1 (S. 
cerevisiae) 
229732_at -1.18 ZNF823   zinc finger protein 823 
201829_at -1.51 NET1    neuroepithelial cell transforming gene 
1 
204840_s_at -1.57 EEA1    early endosome antigen 1 
201310_s_at -1.74 C5orf13    chromosome 5 open reading frame 13 
204798_at -1.82 MYB     v-myb myeloblastosis viral oncogene 
homolog (avian) 
212841_s_at -1.88 PPFIBP2   PTPRF interacting protein, binding 
protein 2 (liprin beta 2) 
1554892_a_at -4.53 MS4A3   membrane-spanning 4-domains, 
subfamily A, member 3 (hematopoietic 
cell-specific) 
210254_at -5.30 MS4A3   membrane-spanning 4-domains, 
subfamily A, member 3 (hematopoietic 
cell-specific) 
Table 5.6: List of 114 Differentially Expressed Genes in Positively Selected 
CD8 Cells 
Genes in red are up-regulated in positively selected cells compared with negatively selected. 
Genes in blue are down-regulated. 
 
The most up-regulated gene NR4A2, a coactivator of general gene transcription, 
was also found to be up-regulated in the Wang list and the authors postulated that 
this gene is important for activation and proliferation of both CD4 and CD8 T 
cells (Wang, et al 2008). CXCR4, as well as being the co-receptor for HIV with 
CD4, is important for lymphocyte recruitment to the bone marrow (Peled, et al 
1999). CREM binds to the IL-2 promoter and limits IL-2 production (Tenbrock, et 
al 2003). AKAP8 is a key component of the signalling complex regulating T cell 
activation (Asirvatham, et al 2004). RGS1 has a role in lymphocyte adhesion and 
chemotaxis (Rodriguez, et al 2004). Two genes, TGIF1 and SKIL (SNO) are 
implicated in TGF  signalling (Chen, et al 2003, Pearson-White and McDuffie 
2003). The actin-capping protein CAPZA1 recruits CD2 to the immune synapse 
(Hutchings, et al 2003). OSM is a cytokine that was noted to be up-regulated on T 
cell activation (Wang, et al 2008). EEA1 is an early marker of T cell activation 
and is important for fusion of synaptic vesicles (Gasser, et al 2005). MYB is 
involved with proliferative responses of mature T cells (Nakata, et al 2007). 
Finally, NCAM1 (CD56) has a role in cell adhesion allowing clustering of cell-cell 
contacts (Lanier, et al 1989).  
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Analysis of the gene-list using Ingenuity software revealed no relevant 
predominant individual pathway or biological function. 
 
As a means of validating this dataset, a comparison was made of CD4 samples 
compared with CD8 samples to see if the expected genes were present. All 
samples were loaded onto Genespring. Analysis of variance (ANOVA) testing 
was performed using an FDR <0.05 and genes were then filtered on the basis of 
two fold change. This gave a list of 364 genes. This validation list was then 
compared to a published list of signature genes for CD4 and CD8 cells (Palmer, et 
al 2006). Of the four signature genes for CD4, three were present in the list; CD4, 
ANK3 and CTSB. For CD8, plasma membrane receptors included in the list were 
CD8A and CD8B, killer cell lectin-type receptor and IL2RB. Common 
cytotoxicity associated genes were granzyme K, granzyme A, granzyme B, 
perforin 1 and granulysin. Of the three genes in the category „other‟, one, CCL5, 
was present in the validation gene-list.  
 
5.4.2  qRT-PCR Validation 
Only one out of the four genes validated failed to show a significant correlation 
between the microarray and the qRT-PCR data. This was EEA1 which was shown 
to have a -1.6 log(2) fold change in the microarray results (Figure 5.8). 
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Figure 5.8: qRT-PCR Validation 
qRT-PCR data and correlations with microarray data for NR4A2, MS4A3, CXCR4 and EEA1.  
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5.5  Discussion 
This study was initiated to answer the question - does the method of 
immunomagnetic cell selection have an impact on the gene expression profile of 
CD4 and CD8 T cells? The data presented here suggest that any effect it does 
have is minimal. The initial analysis performed on Genespring and Partek 
software packages demonstrated no differential gene expression using the least 
stringent multiple testing correction. This agrees with the conclusion published 
after this analysis by Lyons and colleagues and with unpublished data from 
Miltenyi Biotec. Using a third software package, Bioconductor, the same multiple 
testing correction but on this occasion modelling for the observed batch effect, 
114 genes were found to be differentially expressed in CD8 cells with none in 
CD4. This represents a mere 0.2% of the probesets on the Affymetrix U133Plus2 
GeneChip®. Nonetheless, that list of 114 genes does contain within it several 
genes previously reported to be involved in T cell activation or to have 
associations with T cells in the published literature. Although only a small number 
of genes were validated, three out of four genes had their differential expression in 
positively and negatively selected CD8 cells confirmed by qRT-PCR. However, it 
still remains only a handful of genes the significance of which should not be over-
interpreted. It can therefore be concluded that positive immunomagnetic selection 
has no effect on the gene expression profile of CD4 cells and minimal effect on 
CD8 cells. 
 
Several problems were encountered in the course of this study. The phenomenon 
of batch effect was noted within the gene expression data. This means that 
samples clustered according to the date of processing rather than according to any 
biological category. In retrospect, this should have been part of the experimental 
design since this is a recognised problem and could have been accommodated for 
by careful random processing of samples over a period of a few days. Statistical 
modelling was therefore performed to remove the batch effect from the analysis. 
Another potential explanation for the batch effect observed is that there is so little 
other difference between the samples that date of processing becomes the over-
riding difference. However, due to concern about the dataset, an additional step 
was performed that confirmed its validity: if the CD4 samples were compared 
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with the CD8 samples, the expected genes were found to be present. The second 
issue that arose was the elevated 5‟-3‟ ratios for GAPDH and HAS for 6 samples 
in the Affymetrix quality control checks. These samples were not removed from 
the analysis as the RNA digestion plot illustrated that there was not global 
evidence of RNA degradation within the samples. Finally, one out of the four 
genes chosen for assessment by qRT-PCR did not corroborate the microarray 
data. This was the gene that had the lowest fold change within the group (-1.6 
log(2) fold change) and therefore as such was less likely to be validated by the 
more sensitive technique of qRT-PCR (Dallas, et al 2005).  
 
Having established the minimal impact of positive selection on cellular 
transcription in CD4 and CD8 T cells, a positive selection technique was 
optimised for the separation of T cells from AML samples. The gene expression 
profile of these cells could then be compared to the data from healthy T cells 
generated in this part of the project. In view of the findings presented here, all 
positively and negatively selected healthy T cells were used in the comparison 
with positively selected AML T cells. These results will be described in the next 
chapter. 
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Chapter 6 
Gene Expression Profile of AML T Cells 
6.1  Introduction 
The previous work in this project had now made it possible to achieve the initial 
objective of this work; to examine the gene expression profile of T cells in 
patients with newly diagnosed AML compared to that of healthy T cells. Our 
group had previously examined the same question in CLL (Gorgun, et al 2005). In 
that study, CD4 cells were negatively selected from 22 patients with CLL and 12 
healthy donors and CD8 cells were negatively selected from 20 CLL patients and 
12 healthy donors. 3-15 g of total RNA were used for gene expression 
microarrays. Fragmented biotinylated cRNA was hybridised to the Affymetrix 
U133A chip and biostatistical analysis performed using Permax 2.1 and dChip. 
Using a P value <0.05, 90 genes were found to be differentially expressed in CD4 
cells from CLL patients with 22 found to be up-regulated and 68 down-regulated. 
Many of these genes were involved in the Ras-dependent JNK and p38 MAPK 
pathways both of which play a major role in T cell differentiation into TH1 or TH2 
cells. The patterns of expression seen in these pathways could result in impaired 
differentiation into TH1 cells. For CD8, 273 genes were differentially expressed in 
CLL patients with 105 down-regulated and 168 up-regulated. For these, the major 
pathways affected were cytoskeletal formation, vesicle trafficking and 
cytotoxicity. These changes would be expected to result in impaired cytotoxicity. 
From the gene expression data, a representative protein expression panel was 
developed to demonstrate by Western blotting that the changes seen in CLL T 
cells could be induced in T cells from healthy allogeneic donors in co-culture 
experiments with CLL cells. Direct contact was required for these changes to 
occur and they did not appear to be cytokine-mediated (Figure 6.1). More 
recently these results have been confirmed in a T cell leukaemia-1 (TCL-1) 
transgenic mouse model of CLL (Gorgun 2009). We now questioned whether 
similar T cell defects were apparent in another haematologic malignancy, AML. 
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Figure 6.1: Gene Expression Changes in CD4 and CD8 T Cells in CLL  
(From (Gorgun, et al 2005)) 
 
6.2  Aims 
As the previous study had documented potential defects in T cells in patients with 
CLL compared to those from healthy individuals, it was hypothesized that similar 
T cell defects may also occur in other malignancies. Therefore, the aim of this 
study was to test if gene expression changes were also present in the T cells of 
patients with AML compared with healthy individuals and if so, to compare those 
changes to those seen in the T cells from CLL patients. 
 
6.3  Materials and Methods 
6.3.1  AML Samples 
Frozen cryovials of PBMCs from patients at the time of diagnosis of AML were 
used. Patients were initially chosen on the basis of the number of cryovials 
available in the Tissue Bank with preference given to those for whom large 
numbers were available. The previous flow cytometric data were used to estimate 
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the number of T cells available in each patient vial. As 5 x 10
6
 T cells were 
required to obtain sufficient RNA for microarray analysis and a yield of 20% was 
predicted on cell separation, patients were selected for whom it was feasible to get 
the required number of T cells (Figure 6.2). It is appreciated that there is therefore 
an inherent selection bias but this was necessitated by the need for sufficient T 
cells to make the experiments feasible. 
 
Patient „A‟
1.5 x 108 live cells / vial
0.12% CD4 = 1.8 x 105
0.13% CD8 = 1.95 x 105
For 5 x 106 cells
CD4: 139 vials
CD8: 129 vials
Patient „B‟
7.5 x 108 live cells / vial
4.75% CD4 = 3.5 x 107
1.8% CD8 = 1.3 x 107
For 5 x 106 cells
CD4: 1 vial
CD8: 2 vials
NOT used for microarray
Used for microarray
 
Figure 6.2: Worked Example of the Method for Determining Samples for 
Microarray Analysis 
 
The characteristics of the 10 AML patients from whom CD4 and CD8 cells were 
separated are shown in Table 6.1.  
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FAB 
Type 
Prognostic 
Group 
 
Cytogenetics 
% Blasts in 
PB at 
presentation 
Response 
to first 
line therapy 
Relapse? 
AML 1  M2  Intermediate  Normal 92%  Fail   No  
AML 2  M4  Favourable  Inv(16) 61%  CR    Yes  
AML 3  M4  Favourable  -Y, inv(16) 58%  CR  No  
AML 4  M4  Intermediate  Normal 61%  CR  Yes  
AML 5  M1  Intermediate  Failed 100%  CR  No  
AML 6  M4  Favourable  Inv(16) 83%  CR  No  
AML 7  M1  Intermediate  +13 66%  CR  No  
AML 8  M2  Favourable  t(8;21) 80%  Fail  No  
AML 9  M4  Intermediate  Normal 40%  Fail  No  
AML 10  M1  Intermediate  Normal 96%  Fail  No  
Table 6.1: Characteristics of AML Patients 
 
6.3.2  Cell Selection 
In view of the previous data showing that positive selection has minimal effect on 
gene expression profile, T cells were positively immunomagnetically selected 
from diagnostic AML samples using the modifications detailed in Chapter 2, 
Section 2.6.2. The mean purity of CD4 samples was 85.9% (range 71.5 – 97.5%) 
with a mean yield of 33% (range 14 – 54%). The mean purity of CD8 samples 
was 92.3% (range 83.5 – 97.1%) with a mean yield of 40.5% (range 17.5 – 62%). 
 
6.3.3  RNA  
RNA was extracted as detailed in Chapter 2, section 2.9 (Tables 6.2 and 6.3).  
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 Total RNA A
260
/A
280
 A
260
/A
230
 RIN 
AML1 5.73 l in 9 l 1.73 2.52 9.7 
AML2 8.14 g in 9 l 1.79 2.46 9.4 
AML3 8.58 g in 9 l 1.8 2.43 9.5 
AML4 10.92 g in 9 l 1.82 2.43 9.2 
AML5 4.04 g in 9 l 1.66 2.6 8.9 
AML6 7.96 g in 9 l 1.8 2.48 9.4 
AML7 16.28 g in 9 l 1.88 2.37 9.1 
AML8 6.69 g in 9 l 1.75 2.58 9.3 
AML9 4.76 g in 9 l 1.59 2.70 9.4 
AML10 5.4 g in 9 l 1.68 2.63 9.5 
Table 6.2: Quality and Quantity of RNA for CD4 T Cells 
RIN: RNA Integrity Number. 
 
 
 Total RNA A
260
/A
280
 A
260
/A
230
 RIN 
AML1 5.6 l in 9 l 1.75 2.55 9.5 
AML2 4.37 g in 9 l 1.61 2.76 9.3 
AML3 7.62 g in 9 l 1.77 2.49 9.6 
AML4 6.78 g in 9 l 1.75 2.49 9.3 
AML5 2.69 g in 9 l 1.57 2.87 8.9 
AML6 14.4 g in 9 l 1.86 2.42 9.3 
AML7 17.28 g in 9 l 1.87 2.35 9.1 
AML8 6.52 g in 9 l 1.70 2.51 9.4 
AML9 3.77 g in 9 l 1.62 2.77 9.5 
AML10 5.4 g in 9 l 1.65 2.59 9.5 
Table 6.3: Quality and Quantity of RNA for CD8 T Cells 
RIN: RNA Integrity Number. 
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Fragmented biotinylated cRNA was synthesized using the protocol detailed in 
Chapter 2, Section 2.10 in all cases using 3 g of RNA as starting material (Figure 
6.3). 
 
 
Figure 6.3: Fragmented Biotinylated cRNA with 1Kb Ladder 
 
6.3.4  Quality Control Data for Affymetrix U133Plus2 GeneChips® 
Fragmented biotinylated cRNA was hybridised onto Affymetrix U133Plus2 
GeneChips®. Quality control data from the GeneChip runs is listed in Tables 6.4 
and 6.5. 
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Sample  Noise 
(<4)  
Scale 
Factor 
(~1)  
Background 
(<100)  
No. 
Present 
(~50%)  
No. 
Absent  
(~50%) 
GAPDH 
5’-3’ 
Ratio 
(<3)  
HSA 5’-
3’ Ratio 
(<3)  
AML 1  1.71  1.802  39.51  44.3%  54.0%  1.62  2.49  
AML 2  1.52  1.322  45.49  44.6%  53.6%  1.82  2.08  
AML 3  1.57  1.044  45.74  44.3%  54.0%  1.50  1.91  
AML 4  1.60  1.152  46.44  43.2%  55.0%  1.57  1.84  
AML 5  1.50  1.341  45.33  42.6%  55.6%  1.72  2.11  
AML 6  1.45  1.442  43.73  43.2%  55.1%  1.49  2.21  
AML 7  1.75  2.211  38.07  41.0%  57.3%  1.67  2.16  
AML 8  2.24  1.515  47.09  43.5%  54.7%  1.58  2.04  
AML 9  1.85  1.819  40.97  44.5%  54.0%  1.51  2.47  
AML 10  2.19  1.298  45.39  46.0%  52.2%  1.60  2.12  
Table 6.4: Quality Control Data for CD4 T Cells 
 
 
 
Sample  Noise 
(<4)  
Scale 
Factor 
(~1)  
Background 
(<100)  
No. 
Present 
(~50%)  
No. 
Absent 
(~50%)  
GAPDH 
5’-3’ 
Ratio 
(<3)  
HSA 5’-
3’ Ratio 
(<3)  
AML 1  1.45  1.500  44.30  44.8%  53.5%  1.60  2.31  
AML 2  1.28  1.302  39.09  45.1%  53.0%  1.43  1.98  
AML 3  1.36  1.515  40.79  43.3%  55.0%  1.32  1.89  
AML 4  1.32  1.750  40.70  43.6%  54.7%  1.67  2.18  
AML 5  1.4  1.671  43.90  42.2%  56.0%  1.44  2.09  
AML 6  1.21  2.068  38.18  42.2%  56.0%  1.42  2.47  
AML 7  1.24  1.681  38.01  43.1%  55.3%  1.47  1.73  
AML 8  1.28  1.972  39.87  41.1%  57.2%  1.37  2.13  
AML 9  1.21  1.606  36.93  43.2%  55.1%  1.28  2.05  
AML 10  1.27  2.350  38.85  41.6%  56.7%  1.64  2.38  
Table 6.5: Quality Control Data for CD8 T Cells 
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6.3.5  Healthy Samples 
Data from these chips was compared to the data from healthy CD4 and CD8 T 
cells previously generated (see chapter 5). Both positively and negatively selected 
healthy T cells were included in the analysis as it had previously been 
demonstrated that the method of cell selection had minimal impact on gene 
expression profile. The sample groups are compared in Table 6.6. 
 
   
Number 
of 
Samples 
Median 
Age 
Male:Female 
 
Purity of selected cells 
(range) 
AML CD4  10  62 8:2  
85.9%  
(71.5 - 97.5%)  
Healthy CD4  10  44 3:8  
94.3%  
(89 - 98.2%)  
AML CD8  10  62 8:2  
92.3%  
(83.5 - 97.1%)  
Healthy CD8  11  33 9:2  
87%  
(76 - 94.1%)  
Table 6.6: Characteristics of AML and Healthy Donor T Cell Datasets 
 
6.3.6  Analysis of Microarray Data 
Initial analysis was performed using Bioconductor software. 
 
Samples were at first normalised using RMA and five samples were then excluded 
on the basis of QC checks. Three samples were excluded due to discrepant NUSE. 
Using this quality control measure the differences in variability between probesets 
could be adjusted and the boxplot of these standardised values used to compare 
chip qualities. Ideally, distributions should be tight and centred around one 
(Figure 6.4).  
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* *
*
 
Figure 6.4: NUSE Analysis of All Samples  
*: sample excluded on the basis of analysis. 
 
Two samples were excluded on the basis of poor chip pseudo-images. These were 
built on the residuals from the RMA model fitting procedures and high-lighted 
artefacts that could cause problems. 
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Good quality 
pseudo-image
Poor quality pseudo-images
Samples excluded from further analysis
 
Figure 6.5: Pseudo-images of GeneChip® Data  
 
Normalisation is the process whereby systematic or experimental error is removed 
from the dataset. Initial analysis made it clear that there were marked differences 
in the gene expression profile of T cells in AML patients compared with healthy 
individuals. So different were these groups that it was felt that using RMA to 
normalise the samples was inappropriate as this form of normalisation makes the 
assumption that the vast majority of genes will be expressed across all the samples 
in an equivalent fashion. This was not true for the current dataset. An alternative 
form of normalisation, Microarray Suite Version 5.0 (MAS5), was therefore 
applied. This considers data on a per-array basis.  
 
After normalisation, probesets were removed that were not reliably detected above 
background i.e. not called “present” by MAS5 in at least one of the replicate 
groups at a frequency of >=GroupSize/2. The remaining data was then scale 
normalised such that the arrays were aligned along their median signal intensities. 
 
A gene-list was generated using a FDR of <0.01 and a fold change >2.  
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Pathway analysis was subsequently performed using Ingenuity software and 
PubMed. 
 
6.3.7  Validation of Microarray Data by qRT-PCR 
The genes listed in Table 6.7 were chosen for validation of expression levels by 
qRT-PCR either because they were the most significantly differentially regulated 
genes in AML compared with healthy T cells (FOSB and JUN) or because they 
were of potential biological significance in T cells (ATM, CD48 and ACTN1). 
 
CD4  
UP-regulated  
AMLvHealthy  
(log(2) fold change) 
CD4  
DOWN-regulated  
AMLvHealthy  
(log(2) fold change) 
CD8  
UP-regulated 
AMLvHealthy 
(log(2) fold change) 
CD8  
DOWN-regulated 
AMLvHealthy 
(log(2) fold change) 
FOSB (x 6) ATM (x 1.5) FOSB (x 5.3) ACTN1 (x 2.2) 
JUN (x 5)  CD48 (x 1.5) JUN (x 4.7) ATM (x 1.5) 
Table 6.7: Genes Chosen for Validation of Microarray Data 
 
qRT-PCR was performed using the same RNA samples that had been used for the 
microarrays. This meant that in some cases there was insufficient material 
available (Table 6.8).  
 
 Samples for microarray Samples for qRT-PCR 
AML CD4 10 8 
Healthy CD4 10 4 
AML CD8 10 7 
Healthy CD8 11 5 
Table 6.8: Samples Available for qRT-PCR 
 
In all cases, 100ng of RNA were used for cDNA synthesis (Figure 6.6). 
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1Kb DNA 
ladder
1Kb DNA 
ladder
1   2     3     4     5     6    7    8    9    10  11  12   13 14   15
16  17   18  19   20  21  22  23   24   25  26  27   28  29   30  
Figure 6.6: actin PCR for Confirmation of cDNA Synthesis  
AML CD4: 1-8; Healthy CD4: 9-12; Jurkat cell line: 13; K562 cell line: 14; -ve control cDNA 
PCR: 15; AML CD8: 16- 22; Healthy CD8: 23-27; Jurkat cell line: 28; K562 cell line: 29; -ve 
control actin PCR: 30. 
 
All five TaqMan® Gene Expression Assays were initially tested on Jurkat and 
K562 T cell lines to determine which cell line could be used as a positive control 
(calibrator) for each gene (Table 6.9).  
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Table 6.9: Choice of Positive Control for each TaqMan® Assay  
The highlighted cell line was the one chosen to be the positive control for that TaqMan® assay on 
the basis of the lowest CT values. 
 
The 2
- C
T method was used for analysis of qRT-PCR data. This approach was 
validated by demonstrating that the efficiencies of the target and reference gene 
(GAPDH) amplification were approximately equal. The positive control cell line 
chosen for each assay was used and input cDNA was 1000ng, 200ng, 40ng, 8ng 
and 1.6ng. The absolute value of the slope of log input amount versus CT should 
be <0.1. A representative plot is shown in Figure 6.7.  
 
y = -0.0141x + 4.8446
R2 = 0.0335
4.3
4.4
4.5
4.6
4.7
4.8
4.9
5
5.1
5.2
5.3
0 0.5 1 1.5 2 2.5 3 3.5
C
T
Log ng Total Input RNA
Relative Efficiency Plot ACTN1 and GAPDH
 
Figure 6.7: Plot of Log Input RNA versus CT for ACTN1 and GAPDH 
The absolute value of the slope is shown in red. 
 
6.3.8  Protein Validation of Gene Expression Changes 
As numerous cell surface markers featured in the gene-lists generated, protein 
validation was undertaken by flow cytometry rather than western blotting. The 
markers examined are listed in Table 6.10.  
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Cell Surface 
Molecule 
Function CD4 
(log(2) fold change 
AMLvHealthy) 
CD8 
(log(2) fold change 
AMLvHealthy) 
CD48 Adhesion molecule 
crucial for T cell 
activation 
-1.58 -1.2 
CD69 Earliest inducible T 
cell activation marker 
+1.75 +2.44 
CD94 Killer cell lectin-like 
receptor subfamily 
D1. Pairs with 
NKG2A 
-1.97 NS 
CD86 T cell costimulatory 
receptor 
+1.24 NS 
CD21 (CR2) Complement 
component that binds 
to C3d 
NS -2 
CCR7 Activates T cells 
Ligand = CCL19 
NS -1.25 
CD119 IFN  receptor I +1.7 +1.4 
Dectin1 Pattern recognition 
receptor for beta-
glucans 
+2.7 NS 
Table 6.10: Cell Surface Molecules used for Protein Validation of Gene 
Expression Changes 
NS: not significantly differentially expressed between AML and healthy T cells. 
 
This experiment was performed on five AML samples and five samples from 
healthy donors. As live cells were required, cryovials from AML patients stored 
on the same day as the original vial used for microarray analysis were used. For 
healthy controls, no cells had been frozen at the time of initial cell separation for 
microarray work so fresh blood was taken from five of the original individuals 
used for the microarray studies. Once PBMCs had been separated, they were 
frozen for future use to ensure that the flow cytometric assessment was done on 
samples treated equivalently. The cell staining protocol is listed in Table 6.11.  
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Tube number  APC  PE  FITC  
1  CD3 (IgG
1
)  CD4 (IgG
1
)  CD48 (IgM)  
2  CD3 (IgG
1
)  CD8 (IgG
1
)  CD48 (IgM)  
3  CD3 (IgG
1
) CD4 (IgG
1
)  CD69 (IgG
1
)  
4  CD3 (IgG
1
)  CD8 (IgG
1
)  CD69 (IgG
1
)  
5  CD3 (IgG
1
)  CD4 (IgG
1
)  CD94 (IgG
1
)  
6  CD3 (IgG
1
)  CD4 (IgG
1
)  CD86 (IgG
1
)  
7  CD3 (IgG
1
)  Dectin 1 (IgG
2b
)  CD4 (IgG
1
)  
8  CD3 (IgG
1
)  CD21 (IgG
1
)  CD8 (IgG
1
)  
9  CD3 (IgG
1
)  CCR7  
(Rat IgG
2a
)  
CD8 (IgG
1
)  
10  CD3 (IgG
1
)  CD119 (IgG
1
)  CD8 (IgG
1
)  
11  IgG
1 
 IgG
1 
 IgG
1 
 
12   IgG
2b 
 IgM  
13   Rat IgG
2a 
  
Table 6.11: Staining Protocol for Flow Cytometric Validation of Microarray 
Data 
The fluorochromes APC, PE and FITC are listed at the top. The isotype of each antibody is listed 
in brackets. Tubes 11-13 represent isotype control tubes. 
 
6.4  Results 
6.4.1  Gene Expression Microarray 
6.4.1.1  Unsupervised Clustering 
Unsupervised clustering of all samples using all probesets resulted in a clear 
separation of healthy and AML T cells illustrating the global differences in gene 
expression profile between T cells from patients with AML and healthy 
individuals (Figure 6.8). AML T cells did not cluster according to FAB type or 
prognostic group. Therefore, using gene expression profiling, it is possible to 
differentiate AML from healthy individuals by analysis of T cells that are not part 
of the malignant clone.  
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Healthy AML
 
Figure 6.8: Unsupervised Clustering of All samples and All Probesets 
 
6.4.1.2  Generation of Gene-lists 
The broad gene expression differences between AML and healthy T cells are also 
demonstrated by the fact that out of 54675 probesets analysed, using standard 
filtering criteria of FDR<0.05, 16% are differentially expressed in AML compared 
with healthy CD4 cells and 10% in CD8 cells. As this was far too great a number 
of genes to work with, more stringent filtering criteria were applied; FDR<0.01 
and fold change>2. This resulted in 1407 differentially expressed genes for CD4 
and 779 for CD8 (Table 6.12). It was felt to be inappropriate to apply yet more 
stringent filters as clearly there are broad differences between the two groups. 
Manipulating the gene-lists to result in much smaller numbers of genes may have 
been more workable but would not have made biological sense. 
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 Differentially Expressed Probesets 
AML v Healthy 
 
Analysis CD4 CD8 
FDR < 0.05 
 
8745 5648 
FDR < 0.01 
FC > 2 
1407 779 
Table 6.12: Differentially Expressed Probesets Identified Using Different 
Filtering Parameters 
Further analysis was continued using the probesets marked in red. FC: fold change. 
 
More genes were up-regulated than down-regulated in AML T cells. In addition, 
there was found to be a large overlap in the probesets that were differentially 
expressed in CD4 and CD8 cells. For CD4, this represented 35% of the probesets 
and for CD8, 63% (Figure 6.9). This is not an unfamiliar phenomenon. When the 
data from CLL compared with healthy T cells previously published was 
reanalysed using Bioconductor with a FDR<0.05, 43% of the probesets 
differentially expressed in CD4 cells were also differentially expressed in CD8 
cells and 8% of the CD8 probesets were also present in the CD4 list. 
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CD4 CD8
633
287
339
148
143
149
UP
DOWN
AML v Healthy
 
Figure 6.9: Venn Diagram Illustrating the Distribution of Differentially 
Regulated Probesets  
Filtering criteria used were FDR < 0.01, Fold Change > 2. Up-regulated genes are shown in red 
and down-regulated in blue. 
 
6.4.1.3  Supervised Clustering 
Supervised analysis was performed using the top 50 most significantly up and 
down-regulated genes. The heatmap generated is shown in Figure 6.10 below. 
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    CD4           CD8 
CD4
         Healthy         AML    Healthy AML 
Figure 6.10: Supervised Analysis: AML versus Healthy T cells 
Heatmap created using the top 50 most significantly up and down-regulated genes for CD4 and for 
CD8 in the comparison AML v Healthy. Up-regulated genes are in red and down-regulated in blue. 
The yellow bars on the otherwise grey vertical bar highlight genes that were also found to be 
differentially expressed in the CLL v Healthy experiment 
 
6.4.1.4  Comparison of Differentially Expressed Genes Between AML 
and CLL T Cells 
The AML dataset was compared to that generated in the CLL versus healthy T 
cell comparison performed using Bioconductor. For CD4 T cells in CLL, of 1039 
probesets found to be differentially expressed, only 34 (2.4% of AML CD4 
probesets) were common to the AML and CLL gene-lists. For CD8 CLL T cells, 
5851 probesets were identified as differentially expressed of which 52 were also 
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present in the AML gene-list (6.7% of AML probesets) (Figure 6.11). The full 
gene-lists can be found in Appendix C. 
AML v Healthy CLL v Healthy
1373 56234
CD4
AML v Healthy CLL v Healthy
727 535652
CD8
 
Figure 6.11: Common Genes in AML and CLL T Cell Datasets 
 
Pathway analysis of these lists using Ingenuity software did not indicate 
involvement of any one particular pathway. Although it was interesting to note 
that four genes from the CD8 list, KRAS, PLEC1, TTN and HGF, are all involved 
in actin organisation although only PLEC1 moved in the same direction in both 
the CLL and AML T cell datasets. Therefore, this analysis suggests that the gene 
expression changes observed in AML T cells are different to those seen in CLL. 
 
6.4.1.5  Impact of Clinical and Biological Parameters on AML T Cell 
Gene Expression Patterns 
It was questioned whether the gene expression profile of the T cells in a patient 
with AML varied depending on clinical or biological parameters. Therefore, the 
AML T cell gene expression profiles were also examined on their own to 
investigate if certain characteristics resulted in differential gene expression 
patterns. Prognostic category (favourable or intermediate), response to first line 
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therapy (CR or fail), relapse (yes or no), absolute T cell count (above or below 
median value) and absolute CD3+56+ cell count (above or below median value) 
were investigated. This supervised analysis using an FDR <0.05 and fold change 
>2 resulted in the identification of a total of only four genes shown in Table 6.13. 
 
Probeset logFC FDR Analysis Symbol 
Acc 
Number Description 
242782_x_at 1.559505 0.03374 
Favourable v 
Intermediate TMEM198 BF307733 
transmembrane 
protein 198 
218359_at 2.562301 0.0005 
Relapse v  
No Relapse NRSN2 NM_024958 neurensin 2 
243784_s_at -3.84362 0.008415 
Relapse v  
No Relapse  AW085489 NA 
1559109_a_at -3.16812 0.043727 
Relapse v  
No Relapse  BE147896 NA 
Table 6.13: Differentially Expressed Genes Found on Supervised Analysis of 
the AML T Cell Samples Only 
FC: fold change, FDR: false discovery rate. 
 
Firstly, this is a very small list of genes therefore this data would suggest that it is 
unlikely that any T cell factor is impacting on patient clinical outcome. Nor would 
it seem that either the absolute T cell count or the quantity of our population of 
interest, CD3+56+ cells, makes any difference to the gene expression profile seen. 
The significance of the four genes found is difficult to interpret. Only one gene 
was found in the favourable versus intermediate prognostic group analysis. 
TMEM198 has only a single reference in PubMed that is of no significance. More 
interesting are the three genes found to be differentially expressed in the relapse 
versus no relapse comparison. NRSN2 may play a role in maintenance and 
transport of vesicles and has previously been studied in neural tissue (Nakanishi, 
et al 2006) which may have relevance for T cell cytotoxic capability. Furthermore 
investigation of AW085489 using the UCSC browser (http://genome.ucsc.edu/ ) 
suggests the probe binds to the 5'UTR of FUBP3, a potent transcriptional 
activator. A family member FUPB1 is known to bind to the Far Upstream 
Element (FUSE) region of the MYC proto-oncogene. 
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6.4.1.6  Impact of T Cell Purity on Differential Gene Expression 
Pattern 
As the purity of T cells varied across samples, a linear model was used to assess 
the impact of T cell purity on the gene expression changes. If there were a large 
number of genes whose expression covaried with purity then it might be expected 
that the differences between AML and healthy T cells might be driven by this 
factor instead. A linear model was fitted to the expression data (log-expression 
values) for each probe. A line of best fit was overlaid onto a scatter plot 
displaying the purity of sample „I‟ on the x-axis and the expression on the y-axis, 
defined as: 
    yI = a + bxI + eI 
where a = the intercept of the line with the y-axis (average expression value if 
there is no purity effect) , b = the slope of the line, e = random error. Genes that 
had a purity dependence were defined as having a slope (b) which was non-zero. 
If many such genes were identified in this fashion, the implication would be that a 
proportion of the differentially expressed genes found in the AML versus healthy 
comparison were there due to purity effect. Using an FDR < 0.05, no significant 
genes were found for either CD4 or CD8 suggesting that purity does not have an 
impact on the gene-lists generated.  
 
6.4.1.7  Pathway Analysis 
The ten most up and down-regulated genes in AML compared with healthy T 
cells are listed in Tables 6.14 and 6.15. 
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FOSB FBJ  murine osteosarcoma viral oncogene 
homolog B 
JUN JUN oncogene 
HIST1H2AE histone cluster , H2ae 
THRAP3 thyroid hormon receptor associated protein 3 
C13ORF15 chromosome 13 open reading frame15 
HIST1H2BC histone cluster 1, H2bc 
SOX4 SRY (sex determining region) box 4 
FOS V-fos FBJ murine osteosarcoma viral oncogene 
BAT2D1 BAT2 domain containing 1 
YPEL5 yippee-like 5 (Drosophila) 
LTF lactotransferrin 
HBB haemoglobin beta 
HBA2 haemoglobin A2 
KLRC2 killer cell lectin-type receptor subfamily C, 
member 2 
ID3 inhibitor of DNA binding 3 
PCDH9 protocadherin 9 
LRRN3 leucine rich repeat neuronal 9 
PECR peroxisomal trans-2-enoyl-CoA reductase  
ANKS1A ankyrin repeat and sterile alpha motif domain 
contain 1A 
FYB FYN binding protein 
Table 6.14: CD4 AML v Healthy - Top 10 Up-regulated (red) and Down-
regulated (blue) Genes  
Genes indicated in bold have biological relevance in T cells.  
 
JUN is an oncogene that forms part of the AP1 transcription factor family. It 
dimerizes with FOS to form AP1, a critical component of the T cell activation 
pathway. FOSB is also part of the Fos gene family and also forms dimers with 
members of the Jun family to form AP1. KLRC2 (or NKG2C) is an inhibitory 
receptor most frequently expressed by NK cells. ID3 is preferentially expressed in 
TH1 cells (Lund, et al 2005) and FYB is involved in the TCR signalling pathway 
as part of the FYN and SLP-76 signalling cascade (da Silva, et al 1997). 
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FOSB FBJ  murine osteosarcoma viral oncogene 
homolog B 
JUN JUN oncogene 
HIST1H2AE histone cluster 1, H2ae 
HIST1H2AM histone cluster 1, H2am  
FOS V-fos FBJ murine osteosarcoma viral oncogene 
HIST1H2BG histone cluster 1, H2bg 
C10ORF46 chromosome 10 open reading frame 46 
HNRPA3 heterogeneous nuclear ribonucleoprotein A3 
NXT1 NTF2-like export factor 1 
HIST1H2BH histone cluster 1, H2bh 
LTF lactotransferrin  
HBA1 haemoglobin alpha 1 
HBB haemoglobin beta 
HBA2 heamoglobin alpha 2 
LRRN3 leucine rich repeat neuronal 3 
DSC1 desmocollin 1 
ORM1 Orosomucoid 1 
RUNX2 runt-related transcription factor 2 
DECR2 2,4-dienoyl CoA reductase 2, peroxisomal  
RTN1 reticulon 1 
Table 6.15: CD8 AML v Healthy - Top 10 Up-regulated (red) and Down-
regulated (blue) Genes  
Genes indicated in bold have biological relevance in T cells.  
 
FOSB, JUN and FOS have been discussed above. RUNX2 is involved in T cell 
development accelerating development to a CD8 immature single positive stage 
(Vaillant, et al 2002) and RTN1 modulates the anti-apoptotic activity of Bcl-xl 
and Bcl-2 (Tagami, et al 2000). 
 
Rifca Le Dieu                                                                                                           Chapter 6 Results 
221 
 
Examining the gene-lists revealed a large number of transmembrane receptors and 
other genes of potential interest in T cells. These are listed in Tables 6.16 and 
6.17. 
 
TRANSMEMBRANE RECEPTORS / 
 KLRC2 (NKG2-C)  killer cell lectin-like receptor subfamily C, member 2 
 KLRD1 (CD94)  killer cell lectin-like receptor subfamily D, member 1 
 MR1  major histocompatibility complex, class I-related 
 CLEC2D   C-type lectin domain family 2, member D 
 IGHM  immunoglobulin heavy constant mu 
 CD74   CD74 molecule, major histocompatibility complex, class II invariant chain 
 FCGR1A   Fc fragment of IgG, high affinity Ia, receptor (CD64) 
 FCGR1B  Fc fragment of IgG, high affinity Ib, receptor (CD64) 
 LILRB3  leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 3 
 B2M   beta-2-microglobulin 
 CCR1  chemokine (C-C motif) receptor 1 
 IFNGR1  interferon gamma receptor 1 
 TGFBR2  transforming growth factor, beta receptor II (70/80kDa) 
 LTBR  lymphotoxin beta receptor (TNFR superfamily, member 3) 
 CLEC7A (dectin 1)   C-type lectin domain family 7, member A 
 MSR1  macrophage scavenger receptor 1 
CELL SURFACE MOLECULES 
 CD47  CD47 molecule 
 CD48  CD48 molecule 
 CD9  CD9 molecule 
 CD36   CD36 molecule (thrombospondin receptor) 
 CD55  CD55 molecule, decay accelerating factor for complement (Cromer blood group) 
 CD68   CD68 molecule 
 CD69  CD69 molecule 
INTEGRINS 
 ITGA6  integrin, alpha 6 
 ITFG2  integrin alpha FG-GAP repeat containing 2 
 ITGA4  integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 
SECRETED MOLECULES 
 TNFSF13  tumor necrosis factor (ligand) superfamily, member 13 
 IL18  interleukin 18 (interferon-gamma-inducing factor) 
CELL CYCLE COMPONENTS 
 ATM ataxia telangiectasia mutated 
 CCNC  cyclin C 
 CCND2  cyclin D2 
 CCNI  cyclin I 
 CCNL1  cyclin L1 
 CDC14A  CDC14 cell division cycle 14 homolog A (S. cerevisiae) 
 CDKN1A  cyclin dependent kinase inhibitor 1A (p21) 
CALCIUM SIGNALLING 
 RCAN2  regulator of calcineurin 2 
 NFAT5  nuclear factor of activated T-cells 5, tonicity-responsive 
 NFATC2IP  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting protein 
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 CALM1  calmodulin 1 
 CALM2  calmodulin 2 
T CELL ACTIVATION 
 TAGAP  T-cell activation RhoGTPase activating protein 
 PIK3CB  phosphoinositide-3-kinase, catalytic, beta polypeptide 
 PIK3CG  phosphoinositide-3-kinase, catalytic, gamma polypeptide 
VESICLE TRANSPORT 
 VAPA  VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa 
 LAMP2  lysosomal-associated membrane protein 2 
TRANSCRIPTION FACTORS 
 FOS  v-fos FBJ murine osteosarcoma viral oncogene homolog 
 JUN  jun oncogene 
 FOSB  FBJ murine osteosarcoma viral oncogene homolog B 
MICRO RNAs 
 MIRN21   microRNA 21 
Table 6.16: CD4 AML v Healthy – Genes of Potential Relevance  
Down-regulated genes in AML T cells compared with healthy T cells are indicated in blue. Up-
regulated genes are indicated in red. 
 
TRANSMEMBRANE RECEPTORS 
 CR2  complement component (3d/Epstein Barr virus) receptor 2 
 IL6ST  interleukin 6 signal transducer (gp130, oncostatin M receptor) 
 IL6R   interleukin 6 receptor 
 CCR7   chemokine (C-C motif) receptor 7 
 IGF1R  insulin-like growth factor 1 receptor 
 MR1  major histocompatibility complex, class I-related 
 IFNGR1  interferon gamma receptor 1 
 B2M  beta-2-microglobulin 
CELL SURFACE MOLECULES 
 CD48  CD48 molecule 
 CD69  CD69 molecule 
INTEGRINS 
 ITGA6  integrin, alpha 6 
 ITGAV  integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51) 
CELL CYCLE COMPONENTS 
 ATM  ataxia telengiectasia mutated 
 CCNL1  cyclin L1 
 CDK6  cyclin-dependent kinase 6 
 CDC14A  CDC14 cell division cycle 14, homolog A 
 CDC2  cell division cycle 2, G1 to S and G2 to M 
 CDCA7  cell division cycle assciated7 
CALCIUM SIGNALLING 
 NFATC2IP  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting protein 
 CALM1  calmodulin 1 
 CALM2  calmodulin 2 
T CELL ACTIVATION 
 PRKCA  protein kinase C, alpha 
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 PIK3CG  phosphoinositide-3-kinase, catalytic gamma polypeptide 
 PIK3R1  phosphoinositide-3-kinase regulatory subunit 1 
VESICLE TRANSPORT 
 VAPA  VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa 
 LYST  lysosomal trafficking regulator 
 VTI1A  vesicle transport through interaction with t-SNAREs homolog 1A (yeast) 
TRANSCRIPTION FACTORS 
 JUNB  jun B proto-oncogene 
 FOS  v-fos FBJ murine osteosarcoma viral oncogene homolog 
 JUN  jun oncogene 
 FOSB  FBJ murine osteosarcoma viral oncogene homolog B 
ACTIN CYTOSKELETON 
 ACTN1  actinin, alpha 1 
 ABLIM1  actin binding LIM protein 1 
 FILIP1  filamin A interacting protein 1 
 TRAK2  trafficking protein, kinesin binding 2 
Table 6.17: CD8 AML v Healthy - Genes of Potential Relevance  
Down-regulated genes in AML T cells compared with healthy T cells are indicated in blue. Up-
regulated genes are indicated in red. 
 
Of particular interest were the genes noted to be involved in the actin cytoskeleton 
that were picked up in the CD8 gene-list. Subsequent analysis of the CLL dataset 
had identified abnormalities in the actin cytoskeletal pathways in both CD4 and 
CD8 cells that had led to further functional investigation of these defects by 
visualising actin polarisation in immunological synapses (Ramsay, et al 2008a). 
 
To obtain biological meaning from these gene-lists, data was first analysed using 
Ingenuity software. Globally, for both CD4 and CD8, many genes fell into the 
function „other‟ and location „unknown‟. Transcription regulators, enzymes, 
kinases and transporters were most well represented within both lists with the 
most frequent locations being the nucleus and cytoplasm (Figures 6.12 and 6.13). 
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Figure 6.12: CD4 AML v Healthy - Location and Function of Differentially 
Expressed Genes  
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Figure 6.13: CD8 AML v Healthy - Location and Function of Differentially 
Expressed Genes  
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Biological processes and potential pathway involvement of the differentially 
expressed genes was subsequently examined. Again, much similarity was noted 
between CD4 and CD8. Gene expression, cell proliferation and haematological 
system development and function featured in both lists as notably, did cancer. IL-
2 and TCR signalling were also common relevant pathways (Tables 6.18 and 
6.19). 
 
Top Functions Top Pathways 
Gene Expression IL-2 Signalling 
Cancer EGF Signalling 
Cell Morphology B cell receptor Signalling 
Cell Death GM-CSF Signalling 
Cellular Development PDGF Signalling 
Haematological System  Development and 
Function 
JAK/STAT Signalling 
Table 6.18: CD4 AML v Healthy - Top Functions and Pathways Identified by 
Ingenuity  
 
Top Functions Top Pathways 
Cancer PDGF Signalling 
Cell Morphology IGF-1 Signalling 
Connective Tissue Disorders EGF Signalling 
Gene Expression 14-3-3-mediated Signalling 
Cellular Development TCR Signalling 
Haematological System  Development and 
Function 
IL-2 Signalling 
Table 6.19: CD8 AML v Healthy - Top Functions and Pathways Identified by 
Ingenuity  
 
Genes involved in the TCR signalling pathways are illustrated (Figures 6.14 and 
6.15). Of note, contrary to initial expectation, only in CD4 T cells were significant 
Rifca Le Dieu                                                                                                           Chapter 6 Results 
226 
 
numbers of genes involved in the actin cytoskeleton pathway (as defined by 
Ingenuity software) (Figure 6.16). 
 
 
Figure 6.14: TCR Signalling Pathway for CD4 AML v Healthy analysis. 
Genes from within the gene-list are distinguished in colour with red indicating up-regulation and 
green, down-regulation. 
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Figure 6.15: TCR Signalling Pathway for CD8 AML v Healthy Analysis 
Genes from within the gene-list are distinguished in colour with red indicating up-regulation and 
green, down-regulation. 
 
Figure 6.16: Actin Cytoskeleton Signalling Pathway for CD4 AML v Healthy 
Analysis 
Genes from within the gene-list are distinguished in colour with red indicating up-regulation. 
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To try to identify which genes within the lists were relevant to T cells, a search 
was performed on PubMed of each gene name in association with „T cell‟. From 
the list of 1407 genes for CD4, 179 were found to have associations with T cells. 
From the list of 779 genes for CD8, 120 were found to have associations with T 
cells. These genes were then categorised into signalling pathways (Table 6.20). 
For both CD4 and CD8, the pathways that genes were most frequently associated 
with were TCR signalling and activation. 
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CD4  CD8 
Signalling Pathway Genes  Signalling Pathway Genes 
TCR signalling 25  T cell activation 27 
WNT signalling 16  TCR signalling 14 
Actin cytoskeleton 12  Proliferation 9 
T cell activation 10  AP1 signalling 8 
Adhesion/migration 9  Cytokine signalling 8 
Receptors 8  Apoptosis 6 
TH1 v TH2 7  WNT signalling 6 
AP1 pathway 6  Motility 5 
Co-stimulation 6  Ras signalling 4 
IL-2 signalling 6  Ca2+ signalling 3 
Apoptosis 6  Vesicle transport 3 
Cytokine signalling 6  Lymphocyte development 3 
Vesicle transport 5  Actin cytoskeleton 3 
TNF signalling 5  SDF1  induced chemotaxis 3 
TGF  signalling 4  Cell survival/homeostasis 3 
MHC 4  TGF  signalling 2 
Lectins 3  Adhesion 2 
CD4 down-regulation 3  MHC 2 
Extracellular matrix 3  Complement 2 
Ca2+ signalling 3  DNA repair 2 
Memory v Effector 3  Immune synapse 2 
Cytotoxicity 2  Cytotoxicity 2 
Cell fate 2  TCR 2 
NOTCH signalling 2  Co-stimulation 1 
Homeostasis T cell numbers 2  Reduced transcription 1 
MicroRNA 2  NOTCH signalling 1 
DNA repair 2  Transport 1 
IL-4 signalling 1  T cell homing 1 
Cell survival 1  TNF signalling 1 
Recombination of TCR 1  Tumour-specific T cells 1 
Proliferation 1  NK-like killing 1 
Transcription 1  PDGF signalling 1 
   IFN  signalling 1 
   IFN  signalling 1 
   BMP signalling 1 
Table 6.20: PubMed Analysis of Gene Function 
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This data suggests that T cells from patients with AML are more likely to be 
activated in comparison with healthy T cells. However, a comparison was made 
with the gene-lists from Wang et al. (Wang, et al 2008) that had looked at the 
pattern of gene expression on normal T cell activation. Only 6.8% of the CD4 
AML v Healthy gene-list and 10.7% of the CD8 AML v Healthy list were present 
in the list of genes differentially expressed on T cell activation. This indicates that 
the gene expression changes seen in T cells from patients with AML are not 
simply due to the normal signalling that occurs on T cell activation.  
 
6.4.2  qRT-PCR Validation 
Only one out of the 10 correlations tested failed to show a statistically significant 
correlation between the microarray result and the qRT-PCR result. This was 
CD48 in CD8 cells which was shown to have a -1.2 log(2) fold change in the 
microarray experiment (Figure 6.17). 
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Figure 6.17: qRT-PCR Validation of Microarray Data 
Correlations between microarray and qRT-PCR data are shown for CD4 and CD8 T cells for the 
genes ACTN1, ATM, CD48, FOSB and JUN.  
 
6.4.3  Protein Validation 
Five cell surface markers found to have significant differential expression 
between AML and healthy T cells by gene expression were examined by flow 
cytometry in CD4 cells and five in CD8. Both mean fluorescence intensity (MFI) 
(reflecting the level of expression on each cell) and the percentage of cells 
expressing the marker (reflecting the level of expression within the population of 
T cells) were assessed. All markers were found to move in the expected direction 
(up or down in AML cells compared with healthy) except for CD69 MFI on CD4 
cells. However, the only statistically significant difference in expression was seen 
for the percentage of CD4 cells expressing CD86 and the percentage of CD8 cells 
expressing CD119 (Figure 6.18 and 6.19). 
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Figure 6.18: CD4 T Cells - Protein Validation of Microarray Data  
Flow cytometric assessment of the expression of the surface markers CD48, CD69, CD94, CD86 
and Dectin-1 found to be differentially expressed in CD4 cells in AML patients compared with 
healthy donors. Both MFI and the mean percentage of cells expressing the marker were assessed. * 
indicates p value < 0.05. 
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Figure 6.19: CD8 T Cells - Protein Validation of Microarray Data 
Flow cytometric assessment of the expression of the surface markers CD48, CD69, CD21, CCR7 
and CD119 found to be differentially expressed in CD8 cells in AML patients compared with 
healthy donors. Both MFI and the mean percentage of cells expressing the marker were assessed. * 
indicates p value < 0.05. 
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6.4  Discussion 
These experiments have demonstrated that there are global differences in gene 
expression between AML and healthy T cells for both CD4 and CD8. The focus 
of these gene expression changes appears to be the nucleus with an up-regulation 
of molecules involved in gene transcription. A primary pathway that appears to be 
affected is TCR signalling and T cell activation. The costimulatory molecule 
CD86 is unregulated in CD4 T cells in AML as is the accessory molecule GRAP. 
Molecules involved in calcium signalling include CALM1, CALM2, RYR3, 
STXBP3 and ITPR1. Two molecules related to NFAT were found to be up-
regulated; NFATC2IP and NFAT5. Three crucial downstream signalling pathways 
had genes represented; MAPkinase pathway – MAP3K8, MAP4K4, MAP3K3; 
PI3K and protein kinase C pathway; PI3CG and PRKCA and the AP1 pathway; 
JUN, JUNB, KLF6, TNPO1, FOSB and FOS. Up-regulation of the early cell 
surface activation marker, CD69 is seen. One terminal event of T cell activation is 
proliferation and the cell cycle genes CCND2, CDC2 and CDK6 are up-regulated 
in AML T cells. However the other product of T cell activation, the production of 
IL-2 is not apparent. Nonetheless, these changes do not correlate with those 
described by Wang and colleagues in an in vitro T cell activation gene expression 
assessment. Some changes are fundamentally different; FOSB and JUN were the 
most up-regulated genes found in both cell types yet they appeared down-
regulated in the Wang paper. Thus the gene expression changes seen in AML T 
cells cannot be ascribed to T cell activation alone. Anergy is closely related to 
activation: NFAT activation in the absence of concurrent activation of 
transcription factors such as AP1 or NF B results in anergy. However, a search 
for 14 anergy-related genes (Dominguez-Villar, et al 2007) within the AML v 
Healthy gene-lists revealed the differential expression of only two, JMJD2B and 
RAB10.  
 
An important observation from the genes relevant in T cells is the frequency of 
genes associated with the actin cytoskeleton and cellular polarisation on 
activation. For CD4, WASL, WAVE, ABI1, ARP2, IQGAP1, EVL, SNX9 and 
CAPZA1 are all either associated with actin or involved in actin remodelling 
whereas CTBP2 is a cytoskeletal regulator, CTNNA1 is a component of the 
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cytoskeleton and MYH9 is associated with LFA-1 at the uropod of migrating T 
cells and links directly to the cytoskeleton. All of these are up-regulated apart 
from EVL. For CD8 cells, the list is shorter but ACTN1 and CAPZA1 are actin 
binding proteins, FILIP1 interacts with filamin1 and is therefore involved in 
intracellular motility processes and PLEC1 is a cytoskeletal organiser. All of these 
are down-regulated apart from CAPZA1. There are also genes involved in the 
related function of T cell motility; for CD4, OPA1, RAP1B are up-regulated and 
the adaptor protein RASSF5 is down-regulated; for CD8, DOCK2 and OPA1 are 
up-regulated. Of interest, the lymphocyte homing receptor, CCR7, is down-
regulated in CD8 cells. Several genes involved in cell adhesion are up-regulated 
in CD4 cells; RHOA, RHOB, ADAM28, LGALS8 and LPXN. MicroRNA21 was 
noted to be up-regulated in CD4 AML T cells. However, it has not so far been 
implicated in regulation of immune cell function (Baltimore, et al 2008) although 
levels have been shown to be up-regulated in healthy CD8 cells (Wu, et al 2007). 
These observations would suggest that there may be defects in actin cytoskeletal 
remodelling and T cell motility in AML T cells.  
 
The issue regarding contaminating tumour cells impacting on the gene expression 
profile was addressed. Firstly, every attempt was made to obtain as pure a T cell 
population as possible. This required several modifications of the standard cell 
separation protocol. The cell populations eventually used for microarrays had a 
mean purity of 85.9% for CD4 and 92.3% for CD8. Secondly, a biostatistical 
linear model was used in analysis. This suggested that the variation in T cell 
purity had no impact on the gene expression changes seen. In addition, the CLL 
study had also noted in supervised analyses no significant difference in the gene 
expression profiles based on cell purity less than or greater than 85%. The 
biological function cancer did feature prominently in pathway analysis of both 
CD4 and CD8 gene-lists. Nonetheless, these genes are normal genes involved in 
cell cycle control, proliferation and apoptosis so although they are associated with 
cancer they are not specific to it. 
 
The wide overlap in the gene-lists for CD4 and CD8 cells was notable but not 
unexpected. A similar phenomenon was noted in the CLL data and published data 
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has shown CD8 T cells to have an expression signature of 23 genes whereas for 
CD4 cells it is only four genes indicating that that the vast majority of gene 
expression is similar (Palmer, et al 2006).  
 
It was also of note that the gene expression changes documented were not the 
same as those seen in CLL T cells both in terms of the numbers of common genes 
and also pathways. Neither the RAS-dependent JNK MAPK pathway nor 
cytotoxicity pathways featured prominently in the AML versus healthy 
comparison. This is perhaps not surprising. CLL is an indolent condition in 
contrast to the aggressive nature of AML. By the time patients with CLL come 
into contact with medical professionals often long periods of time will have 
elapsed since their condition began allowing many months of interaction with the 
immune system. In contrast, patients with AML will present within days or weeks 
of their malignancy developing resulting in much less time for tumour–T cell 
interactions to take place. 
 
The microarray data correlated well with qRT-PCR data in the five genes 
examined across both cell populations with the exception of CD48 in CD8. This is 
unlikely to be due to the phenomenon of cross-hybridizing transcripts as a 
correlation was seen in CD4 cells. More likely is that the lack of correlation seen 
is due to the low fold change of CD48 in CD8 cells (-1.2 logFC). Small variations 
in mRNA levels are much more accurately detected by qRT-PCR than microarray 
expression scores resulting in discrepant correlation coefficients (Dallas, et al 
2005). 
 
An attempt was made to validate the gene expression changes seen by protein 
expression using flow cytometric assessment of differentially expressed surface 
markers. Unfortunately, only two out of the 10 markers examined, CD86 on CD4 
cells and CD119 on CD8 cells, demonstrated the expected statistically significant 
difference in expression. All other markers, except for CD69 MFI on CD4 cells, 
showed a trend in the right direction. Flow cytometry would generally be 
considered to be more sensitive than western blotting for assessing protein. 
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However, using antibodies directed towards cell surface markers may not 
accurately reflect the total protein content of the cell due to cellular trafficking. 
 
There are several issues that may impact on the validity of the data generated. 
Firstly, the AML GeneChips were processed at a time point much later than the 
normal chips. This could result in a potential batch effect; that is, the differences 
observed could be due to differences in processing rather than biology. However, 
although for practical purposes only a small number of genes could be validated 
by qRT-PCR, nonetheless, for this small selection, the changes observed by 
microarray were found to be true. Secondly, the AML and healthy samples were 
not age and sex matched. This was largely due to the fact that most AML patients 
are elderly (the median age for these samples was 62) and finding age-matched 
healthy donors was difficult from the donor pool available. With regards to sex, 
the choice of AML samples was limited to the patients from whom sufficient T 
cells could be obtained for the analysis, allowing no room for manoeuvre and the 
healthy GeneChips had already been processed by the time AML patients were 
selected. 
 
In summary, these experiments have demonstrated a global difference in the gene 
expression profile between AML and healthy T cells with changes particularly 
noted in TCR signalling and activation suggesting both CD4 and CD8 T cells in 
AML are undergoing some form of activation via the TCR. However, this does 
not result in the expected changes in gene expression seen in published in vitro 
experiments suggesting some form of aberrant signalling. Numerous genes were 
found to be involved in actin cytoskeletal signalling and cellular motility 
indicating these functions may be impaired in AML T cells. Finally, the gene 
expression changes noted, both in terms of the number of common genes and 
pathways involved were different to those observed in CLL leading to the 
conclusion that there is a different molecular basis to the T cells defects observed 
in these very different diseases. 
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The changes noted in the expression of genes involved in the actin cytoskeletal 
pathway in both CD4 and CD8 T cells in AML led to a functional examination of 
this pathway in AML T cells as will be described in the next chapter. 
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Chapter 7 
Immunological Synapse Formation in AML Patients 
7.1  Introduction 
The functional implications of the gene expression changes previously noted in T 
cells in AML now required investigation. As genes within the actin cytoskeletal 
pathway had been found to be differentially regulated in AML compared with 
healthy T cells this was the pathway chosen for further study. 
 
The actin cytoskeleton is critical for T cell activation. Firstly, actin filaments are 
fundamental for the large-scale molecular rearrangements necessary for the 
formation of the immunological synapse and secondly, the actin scaffold is 
required for the recruitment and stabilisation of signalling complexes involved in 
downstream signalling pathways (Dustin and Cooper 2000). On TCR engagement 
with appropriate MHC-peptide complexes, polarisation of the T cell actin cortical 
cytoskeleton occurs with a reorientation towards the T cell – APC interface where 
F-actin subsequently accumulates. 
 
Previous work from our group demonstrated that the actin cytoskeletal pathway 
was differentially regulated in T cells from CLL patients compared with healthy T 
cells. We subsequently showed that immunological synapse formation was 
defective in CD4 and CD8 T cells in CLL due to impaired actin polymerisation 
(Ramsay, et al 2008a). We also established that recruitment of key actin 
regulatory proteins such as Cdc42, WASp, Filamin-A and Dynamin-2 to the 
immune synapse was inhibited. This impairment in immunological synapse 
formation was seen when CLL T cells were conjugated with autologous CLL B 
cells and also healthy allogeneic B cells. These defects could also be induced in 
healthy allogeneic T cells by culturing them with CLL cells. We went on to 
demonstrate the same defect in T cells from the E -TCL1 transgenic mouse 
model of CLL as the mice developed leukaemia (Gorgun 2009).  
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This led to the hypothesis that a similar defect in immune synapse formation may 
be present in T cells in both AML and CLL even though the differentially 
regulated genes noted in the actin cytoskeletal signalling pathway were not the 
same in AML T cells compared with CLL T cells. 
 
7.2  Aims 
The aim of this part of the study was to examine the functional consequences of 
the gene expression changes noted in AML T cells. Two questions were posed. 
Firstly, could AML blasts act as APCs to form immunological synapses when 
conjugated with healthy T cells? Secondly, could AML T cells form effective 
immune synapses with autologous blasts? 
 
7.3  Materials and Methods 
The cell conjugation assay used is described in detail in section 2.13. In brief, 
APCs were stained with Cell Tracker Blue CMAC (blue) then either pulsed or not 
pulsed with a cocktail of superantigen. T cells were then conjugated with B cells 
or AML blasts at a ratio of 1:2 for 15 minutes. This is optimal time for the 
formation of mature immune synapses established within the literature and from 
experience within our laboratory. After plating onto coverslips, cell conjugates 
were fixed and permeabilised prior to staining with rhodamine phalloidin (red) 
which stains F-actin. This results in T cells stained with a red outline and clear 
delineation of actin polarisation at the T cell-APC interface indicative of an 
immunological synapse. Conjugates were also stained with an antibody directed 
towards phosphotyrosine signalling molecules (green) to examine the downstream 
effect of immune synapse formation. Confocal imaging of the fixed and stained 
cell conjugates could then performed at a convenient time. 
 
Healthy B cells were obtained by positive selection from buffy coat preparations 
supplied by the National Blood Service. Healthy CD4 and CD8 T cells were 
obtained by negative selection from the same buffy coats. Since these samples are 
anonymised no demographic data was available on these individuals. For both T 
and B cell separation, Miltenyi MACS® beads were used. AML T cells were 
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isolated by negative selection using StemCell Technologies antibody cocktails 
and equipment with the method optimised in chapter 4 (described in section 
2.6.3). T cells were isolated from fresh leucopheresis specimens. Cells were then 
frozen post-separation and subsequently thawed and revived on the day of the 
experiment. Details of the patients are listed in Table 7.1. 
 
 Age (years) Sex FAB Type Prognostic 
Group 
AML1 40.9 M M5 Intermediate 
AML2 54.3 M secondary  
AML3 45.7 F M2 Intermediate 
AML4 27.8 F M5 Intermediate 
AML5 63 M M1 Intermediate 
AML6 66 M M4 Favourable 
Table 7.1: Characteristics of AML Patients 
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The experiments were set up to answer the two questions in the manner listed in 
Tables 7.2-7.3. 
 
Coverslip APC sAg T cell  
1 Healthy B allo + Healthy CD4 Control 
2 Healthy B allo - Healthy CD4 Control 
3 Healthy B allo + Healthy CD8 Control 
4 Healthy B allo - Healthy CD8 Control 
5 Blasts allo + Healthy CD4 Test 
6 Blasts allo - Healthy CD4 Test 
7 Blasts allo + Healthy CD8 Test 
8 Blasts allo - Healthy CD8 Test 
Table 7.2: Experimental Set-up: Do Blasts Form Immune Synapses with 
Healthy T Cells? 
APC: antigen-presenting cell, allo: allogeneic, sAg: superantigen. 
 
Coverslip APC sAg T cell  
1 Healthy B auto + Healthy CD4 Control 
2 Healthy B auto - Healthy CD4 Control 
3 Healthy B auto + Healthy CD8 Control 
4 Healthy B auto - Healthy CD8 Control 
5 Auto Blasts + AML CD4 Test 
6 Auto Blasts - AML CD4 Test 
7 Auto Blasts + AML CD8 Test 
8 Auto Blasts - AML CD8 Test 
Table 7.3: Experimental Set-up: Do AML T cells Form Immune Synapses 
with Autologous Blasts? 
APC: antigen-presenting cell, allo: allogeneic, sAg: superantigen. 
 
In all cases, at least three AML cases were tested. A healthy control was included 
in each experiment. Healthy control data had been generated on many occasions 
previously by the group during the work on CLL. As this data was consistent with 
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the control data generated here, all control data was combined to allow statistical 
analyses to be performed.  
 
Images of a minimum of 50 cell conjugates were acquired and subsequently 
scored independently by three investigators. Each coverslip was assessed for the 
percentage of total T cells forming conjugates with APCs (Figure 7.1), the 
percentage of conjugates that resulted in immunological synapse formation 
(Figure 7.2) and the percentage of conjugates in which phosphotyrosine 
signalling was apparent at the immune synapse (Figure 7.3).  
No conjugates Numerous conjugates
BA
 
  
Figure 7.1: Immunofluorescence Images of Cell Conjugates. 
Blue (CMAC): APCs; red (rhodamine phalloidin): F-actin. (A) shows T cells and APCs failing to 
form conjugates. (B) shows numerous conjugates, one of which is indicated by the white arror. 
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Conjugate, no synapse Conjugate with immune synapse
BA
 
Figure 7.2: Immunofluorescence Images of Immune Synapses 
Blue (CMAC): APCs; red (rhodamine phalloidin): F-actin. (A) shows a conjugate between an 
APC and a T cell but no actin polarisation to form an immune synapse. (B) shows a strong F-actin 
band at the T cell-APC interface (white arror) indicative of an immunological synapse. 
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Weak p-Tyr signal at T cell-APC interface Strong p-Tyr signal at T cell-APC interface
A B
 
Figure 7.3: Immunofluorescence Images of Phosphotyrosine (p-Tyr) 
Signalling 
Green (Alexa 488): phosphotyrosine molecules. (A) shows only weak phosphotyrosine signalling 
at the T cell-APC interface. (B) shows recruitment of large quantities of phosphotyrosine 
molecules to the immune synapse indicated by the white arror. 
 
All statistical analysis was performed using Excel. T-tests were 2-tailed with 
samples assumed to have unequal variance. 
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7.4  Results 
7.4.1  Do Blasts Form Immune Synapses with Healthy T cells? 
Firstly, the ability of AML blasts to act as APCs in a cell conjugation assay with 
healthy allogeneic CD4 and CD8 T cells was examined. Contrary to expectation, 
this showed that AML blasts were as good at forming immunological synapses 
with healthy T cells as healthy allogeneic B cells (Figure 7.4). There was no 
apparent correlation between the FAB type of the blasts and the ability to form 
immune synapses with T cells. 
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Figure 7.4: Healthy T Cells can Form Immune Synapses with AML Blasts 
Bar chart (A) shows the percentage of cell conjugates that resulted in actin polarisation within the 
T cell to form an immune synapse when healthy T cells were conjugated with the APCs listed. 
Data presented represents the mean with error bars corresponding to standard deviation in five 
AML patients and at least two healthy controls. In the immunofluorescence images (B) and (C), T 
cells are red only (rhodamine phalloidin) and APCs/blasts are blue (CMAC). Strong F-actin 
immune synapses are visible with both healthy allogeneic B cells (B) and AML blasts (C). sAg: 
superantigen. 
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7.4.2  Do AML T Cells Interact with Autologous Blasts? 
Secondly, the interaction between the T cells in AML patients with their 
autologous tumour cells was examined. Contrary to the situation seen in CLL, 
AML T cells were capable of forming cellular conjugates with autologous blasts. 
In fact, in the case where blasts were not pulsed with superantigen, AML CD4 
cells were significantly better than healthy CD4 cells at forming cell conjugates 
(p=0.03) (Figure 7.5). 
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Figure 7.5: AML T Cells can Form Cell Conjugates with Autologous AML 
Blasts 
Data presented represents the mean with error bars corresponding to standard deviation in at least 
three AML patients (except CD8 minus superantigen where n=1 due to lack of available T cells) 
and four healthy controls.  
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Despite this capacity to interact with the blasts, there was a significant reduction 
in the ability of AML T cells to then form immunological synapses at the sites of 
cell contact (Figure 7.6).  
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Figure 7.6: Immune Synapse Formation between AML T Cells and 
Autologous AML Blasts 
Bar chart (A) shows the percentage of cell conjugates that resulted in actin polarisation within the 
T cell to form an immune synapse when healthy or AML T cells were conjugated with the APCs 
listed. All healthy autologous B cell APCs were conjugated with healthy T cells. Data presented 
represents the mean with error bars corresponding to standard deviation in at least three AML 
patients (except CD8 minus superantigen where n=1 due to lack of available T cells) and four 
healthy controls. In the immunofluorescence images (B) and (C), T cells are red only (rhodamine 
phalloidin), APCs/blasts are blue (CMAC) and phosphotyrosine signalling molecules green (Alexa 
488). These images illustrate reduced immune synapse formation between AML T cells and 
autologous AML blasts (C) compared with healthy T cells and autologous B cells (B). sAg: 
superantigen. 
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Furthermore, this reduced ability to polarise actin to form immunological 
synapses was associated with reduced recruitment of phosphotyrosine signalling 
molecules to the synapse when T cells from AML patients were conjugated with 
autologous blasts. This reached statistical significance for CD4 cells without 
superantigen (p=0.05) and CD8 cells with superantigen (p=0.006) (Figure 7.7).  
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Figure 7.7: Phosphotyrosine Signalling at the Immune Synapse between 
AML T Cells and Autologous AML Blasts 
Bar chart (A) shows the percentage of cell conjugates that resulted in accumulation of 
phosphotyrosine signalling molecules at the T cell-APC interface when healthy or AML T cells 
were conjugated with the APCs listed. All healthy autologous B cell APCs were conjugated with 
healthy T cells. Data presented represents the mean with error bars corresponding to standard 
deviation in at least three AML patients (except CD8 minus superantigen where n=1 due to lack of 
available T cells) and four healthy controls. In the immunofluorescence images (B) and (C), T 
cells are red only (rhodamine phalloidin), APCs/blasts are blue (CMAC) and phosphotyrosine 
signalling molecules green (Alexa 488). Images on the left show phosphotyrosine signalling alone. 
Those on the right are the merged image of all three colours for the same area of the slide. These 
images illustrate reduced recruitment of phosphotyrosine signalling molecules to the T cell-APC 
interface when AML T cells were conjugated with autologous AML blasts (C) compared with 
when healthy T cells were conjugated with healthy autologous B cells (B). sAg: superantigen. 
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7.5  Discussion 
Even though these experiments were initiated to look at T cell function in AML, 
the first question had to be to examine whether the tumour cells in AML could act 
as APCs with healthy T cells in an equivalent fashion to CLL B cells. Were the 
tumour cells completely invisible to T cells or were they capable of inducing 
immunological synapse formation? Despite the fact that myeloblasts have low 
expression of MHC Class I and co-stimulatory molecules (Brouwer, et al 2000, 
Vollmer, et al 2003, Whiteway, et al 2003) the data presented here suggests that 
they are as good as healthy allogeneic B cells at forming immunological synapses 
with healthy allogeneic CD4 and CD8 T cells. This came as a surprise but was 
supported by data generated within our group that looked at the ability of AML 
blasts to form immune synapses with healthy peripheral blood NK cells (Figure 
7.8). 
 
 
Figure 7.8: AML Blasts can Form Immune Synapses with Healthy NK Cells 
PB: peripheral blood, NK: natural killer cell. Blue (CMAC): APC (in this case a myeloblast); red 
(rhodamine phalloidin): F-actin. 
 
Previous data has shown that myeloblasts inhibit healthy T cell proliferative and 
cytokine responses (Buggins, et al 1999). Therefore whatever inhibitory signal is 
being sent by myeloblasts does not impact on the ability of a normal T cell to 
polarise actin to form the necessary unit for subsequent T cell activation, the 
immune synapse.  
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Having established that no defect in immune synapse formation is seen with the 
blasts and healthy T cells, attention then turned to the T cells in AML. In contrast 
to the situation seen in CLL, when AML T cells are conjugated with autologous 
AML tumour cells they are as capable as healthy T cells at forming a cell 
conjugate. However, like T cells in CLL, their ability to polarise actin to form an 
immunological synapse is significantly reduced. Furthermore, this results in 
reduced recruitment of upstream phosphotyrosine signalling molecules to the 
TCR at the centre of the immunological synapse. 
 
These observations indicate a functional defect of T cells in patients presenting 
with AML and lead to speculation that this is induced by myeloblasts. This would 
suggest that within a patient, T cells can recognise and form a conjugate with 
tumour cells but their ability to form immune synapses is impaired. This results in 
a lack of recruitment of upstream phosphotyrosine signalling molecules which 
would be expected to have a profound impact on downstream TCR signalling and 
subsequent T cell activation. Although this T cell defect is not as marked as that 
observed in CLL, where T cells have a significantly reduced ability to form 
conjugates with autologous B CLL cells, this data would suggest that there is a 
common means by which T cell function is impaired in these very different 
diseases.  
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Chapter 8 
Discussion 
 
For much of the 20
th
 century, cancer research has focused on the tumour cell. 
Much effort has been expended to identify the genomic events that accumulate 
within a normal cell resulting in the uncontrolled growth, invasion and metastasis 
that characterise cancer. What is now apparent is that these genetic changes are 
complex and heterogeneous with no single underlying mechanism responsible for 
every cancer. This diversity would suggest that the original hope for an all-
encompassing „cure for cancer‟ that targets the tumour cell is unrealistic. Current 
treatment strategies for cancer remain based on drugs that target all dividing cells 
with the result that off-target side-effects occur and make it unlikely that the 
tumour stem cell is destroyed. As a result, modern rational drug design has aimed 
to develop chemicals that target the tumour cell specifically. However, the early 
enthusiasm for „magic bullets‟ sparked by the remarkable success of Imatinib in 
CML that acts as a specific inhibitor of the bcr-abl tyrosine kinase has yet to be 
followed by other similarly successful agents (O'Brien, et al 2003). This is largely 
due to the fact that tumour-specific targets are difficult to identify and when they 
are, the agents developed may not have the expected clinical efficacy as was seen 
with the FLT3 inhibitors in AML (Illmer and Ehninger 2007). Using antibodies to 
target tumour cells has proved useful. These may simply label the cancer cell for 
destruction by the immune system or alternatively toxins or radioisotopes can be 
tagged to antibodies allowing more directed cytotoxicity. The targeting of the B 
cell surface molecule CD20 with the monoclonal antibody Rituximab has 
arguably been the most significant event in the modern history of B cell 
lymphoma treatment. However, as a single agent its effects are modest. It is only 
when combined with chemotherapy that significant improvements in event-free 
and overall survival are observed (Coiffier, et al 2002). New approaches to 
treating cancer are required if the goal of cure is to be achieved. 
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There is now unambiguous data that the immune system has a crucial role to play 
in the development of cancer. According to Schreiber‟s „Three E‟ hypothesis of 
cancer immunoediting, in the initial elimination phase, immune cells recognise 
and destroy transformed cells. In some cases, this process may fail and an 
equilibrium phase follows in which the transformed cell remains but its 
proliferative capacity is held in check by the immune system. As a result of the 
genomic instability of the tumour cell, mutant daughter cells may arise. The 
immune system subsequently selects for mutant tumour cells less visible to the 
immune system by destroying those daughter cells it can see. Therefore, at some 
point, the tumour „escapes‟ the restraining immune response and begins to 
proliferate uncontrollably (Dunn, et al 2002). If the tumour cells could once again 
be perceived by the immune system, a powerful anti-tumour response may occur. 
The potential of the immune system to eliminate minimal residual disease and 
maintain long-term remissions is already apparent in the graft-versus-leukaemia 
effect seen in allogeneic stem cell transplantation. However, this treatment has 
limited applicability and is associated with high toxicity.  
 
In 1894 the American surgeon William Coley, often regarded as the father of 
immunotherapy, noted that tumour regression could be induced by stimulating the 
immune system with bacterial toxins (Coley 1894). Since that time interest in 
immunotherapy has waxed and waned. Initial promise has frequently been 
followed by disappointing and sometimes catastrophic results such as were seen 
in the clinical trial of the CD28 superagonist antibody TGN1412 at Northwick 
Park Hospital in 2006 (Suntharalingam, et al 2006). However, as the field of 
immunology has progressed so hopes for finding a means of controlling and re-
directing the immune system have grown. Most recently, much interest has been 
directed towards vaccine therapy in cancer. However, results reported thus far are 
disappointing. The use of adoptive T cell therapy using genetically engineered 
autologous T cells has shown some exciting anecdotal results in metastatic 
melanoma but data thus far are limited (Morgan, et al 2006). These brilliantly 
engineered vaccines and T cells that have been years in the designing theoretically 
should work – vaccines, by re-educating the patient‟s own immune system to 
recognise the tumour cell as foreign and autologous T cells by direct cytotoxicity. 
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Nonetheless, the potent anti-cancer GVL effect seen in the allogeneic 
haematopoietic transplant setting has not so far been reproduced when autologous 
T cells are being re-educated towards self – recognition that lacks the benefit of 
minor histocompatibility antigen mismatch. Therefore, a better understanding of 
the impact of the tumour cell on the immune system is critical if these techniques 
are to eventually prove successful. 
 
These issues have begun to be explored by our group in CLL. Data has been 
published demonstrating that the T cells in CLL have a differential gene 
expression pattern when compared with normal healthy T cells. Genes impacting 
on TH1 differentiation are differentially expressed in CD4 cells and on 
cytoskeletal formation, vesicle trafficking and cytotoxicity in CD8 cells. These 
gene expression changes could be induced in healthy allogeneic T cells by direct 
contact with CLL B cells (Gorgun 2005). Similar gene expression changes were 
found in the T cells in the E -TCL1 transgenic mouse model of CLL (Gorgun 
2009). It was also observed that genes involved in the actin cytoskeletal pathway 
were differentially expressed in both CD4 and CD8 T cells in CLL. This led to an 
investigation of the functional implications of these gene expression changes. As 
the actin cytoskeleton is critical for the formation of the immunological synapse 
between a T cell and an APC, actin polymerisation was examined in cell 
conjugation experiments. It was found that immunological synapse formation is 
impaired in both CD4 and CD8 cells in CLL and that this actin polymerisation 
defect could be induced in healthy allogeneic T cells by culturing them with CLL 
cells (Ramsay, et al 2008a).  
 
The question then arose as to whether these T cell defects were unique to CLL or 
were common to other malignancies. Although AML represents a very different 
disease to CLL it does offer the same opportunity for widespread interaction 
between tumour cells and T cells within the peripheral blood and bone marrow 
that is seen in CLL. Also, due to the widespread interest within the Medical 
Oncology laboratory in AML, numerous patient samples were available within the 
Tissue Bank with associated clinical data. In addition, in view of the poor 
prognosis associated with relapse in conjunction with evidence for a GVL effect, 
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AML represents a disease in which outcome may be improved by immune 
manipulation to eradicate minimal residual disease and prevent relapse. To date, 
the only studies to examine T cells in AML have either been on patients in 
remission or post stem cell transplantation or functional studies investigating the 
impact of AML blasts on healthy or remission T cells. 
 
In view of the limited data available on T cells in patients presenting with AML 
(Ersvaer, et al 2007, Panoskaltsis, et al 2003, Vidriales, et al 1993) a flow 
cytometric analysis of T cell subsets in newly diagnosed AML patients was the 
starting point for this thesis. This revealed that absolute T cell numbers, rather 
than being decreased as is generally perceived or normal as reported in the studies 
listed, were increased with the CD8 subset showing the greater amplification. This 
phenomenon did not represent a general proliferative response of the bone 
marrow. Why should this be? T cells are not part of the malignant clone and 
therefore their increased number in the peripheral blood of AML patients may 
either represent a specific proliferation of T cells in response to local 
environmental growth signals secondary to the myeloblast proliferation. 
Alternatively, it may represent a redistribution of T cells as they are „crowded out‟ 
of the bone marrow compartment by the mass of proliferating blasts. However, 
this is less likely to be the case as CD3 staining of bone marrow trephines 
illustrates the presence of numerous T cells (Figure 8.1). If this does denote a 
proliferative T cell response, it would suggest that rather than the picture of a 
burnt-out anergic immune system associated with cancer, that this is an active 
reaction to the malignancy that is attempting, though failing, to contain its spread. 
This is also supported by the oligoclonality of the T cell populations in AML 
suggesting a polarisation towards particular antigens. 
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Figure 8.1: T Cells in a Bone Marrow Trephine from a Patient Presenting 
with AML 
CD3 positive T cells are stained brown. 
 
It was observed that a population of CD56-expressing T cells was significantly 
increased in the peripheral blood of patients with AML. These cells were not true 
NKT cells but did express certain NK receptors. Instead, their phenotype was that 
of effector cytotoxic T lymphocytes with high expression of activation markers 
but lower expression of cytotoxic granules compared to the same cell population 
in healthy individuals which may indicate an impaired cytotoxic potential in 
AML. As this cell population has already been identified as having anti-tumour 
cytotoxicity (Ohkawa, et al 2001, Pittet, et al 2000) it was hypothesized that these 
cells could represent an immunosurveillance mechanism. They were found to 
return to normal levels when patients entered CR however a change in their 
absolute number was not a prelude to relapse in the single individual examined. 
This does not negate the hypothesis. A functional assessment of the ability of 
isolated CD3+56+ cells to kill autologous blasts is an obvious next step. 
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True NKT cells present a new and exciting avenue in cancer immunotherapy. 
Reduced absolute numbers or numbers secreting IFN have been reported to be 
reduced in the peripheral blood of patients with a variety of malignancies (Fujii, et 
al 2003a, Molling, et al 2005, Tahir, et al 2001, Yoneda, et al 2005). In this 
thesis, absolute numbers of NKT cells were not found to be significantly different 
in the peripheral blood of patients with AML compared with healthy individuals. 
However, the relative number of NKT cells in the double-negative „anti-cancer‟ 
TH1 subset was found to be significantly higher in AML patients compared with 
healthy controls again suggesting an immunosurveillance role for this population. 
This observation also points to an idea of an immune system that is attempting 
unsuccessfully to contain the aggressive spread of malignant cells. 
 
Further analysis of T cells in presentation AML specimens required the ability to 
isolate T cell fractions in relatively high purity. This proved extraordinarily 
difficult to achieve but led to an understanding why much previous work on AML 
T cells had either used remission T cells or observed the effect of AML blasts on 
healthy T cells. One reason why this proved so problematic is the heterogeneous 
nature of AML blasts. No single surface marker is sufficiently widely expressed 
to give good immunomagnetic blast depletion. With much work, we developed a 
method of negatively selecting CD4 and CD8 T cells from presentation AML 
specimens using a cocktail of antibodies. This technique was subsequently used to 
isolate T cells for the functional studies performed. However, this method is 
extremely costly and whether it is economical to obtain large numbers of T cells 
using this technique in future studies remains doubtful. 
 
The initial goal of this study had been to perform gene expression profiling on 
negatively selected CD4 and CD8 T cells from presentation AML specimens. As 
the method of negative selection took so much time to optimise, attention turned 
to the possibility of using positive selection to isolate the T cells. This method was 
associated with concerns about the potential for activating the cell of interest by 
cross-linking surface antigens and resulting in altered gene transcription. At the 
time this study was initiated there was no published data directly comparing the 
impact of positive versus negative immunomagnetic cell selection on cellular gene 
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expression profile. Therefore this experiment was undertaken in the course of this 
project. Data presented here on a total of 19 healthy volunteers demonstrated the 
minimal impact of the method of cell selection on the gene expression profile of 
the cell in agreement with a subsequent study published in 2007 that looked at the 
same question using cells from three individuals and custom arrays containing 
10,515 genes (Lyons, et al 2007). This led to the use of positive selection for 
isolating T cells from presentation AML specimens for microarray analysis. A 
very small percentage of probesets were found to be differentially expressed in 
positively selected CD8 T cells and some of these genes were associated with T 
cells or T cell activation. However, this finding was made using only one of the 
three software packages used for analysis. In view of this small impact of positive 
selection on CD8 T cell gene expression in conjunction with the published 
functional data available (Bernard, et al 2002, Berndt, et al 1998, Chuck, et al 
1993, Milia, et al 1997, Stanciu, et al 1996, Wang, et al 1994) it was felt 
appropriate to use the negative selection technique for isolating T cells for the 
analyses of T cell function performed.  
 
Gene expression profiling was performed on positively selected AML CD4 and 
CD8 T cells and compared to those from normal healthy controls. Importantly, the 
gene expression changes observed were validated by qRT-PCR with further 
validation at a protein level performed by flow cytometry. Major differences were 
found between the AML and healthy T cells which impacted on the way in which 
the data could be analysed. T cell signalling and activation pathways appeared to 
be primarily affected in both CD4 and CD8 cells. Although when the 
differentially regulated gene-lists were compared to those generated from T cells 
activated ex vivo (Wang, et al 2008) little overlap was seen suggesting that the 
gene expression changes seen in AML T cells are not purely due to the normal 
signalling seen on T cell activation. Anergy was explored and discarded as an 
alternative explanation for the gene expression changes by comparison of gene-
lists from a source in the literature (Dominguez-Villar, et al 2007). Thus both 
CD4 and CD8 T cells in AML appear to be undergoing some form of aberrant 
activation process. On comparison of the gene-lists with those generated from the 
CLL dataset, little commonality was observed. This leads to the conclusion that 
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although T cells in both of these malignancies show different gene expression 
patterns to healthy T cells, they differ in what those changes are. In view of the 
very different natures of CLL and AML this is not an unpredictable conclusion 
but did support the viewpoint that different cancers do not adopt a similar final 
pathway to down-regulate host T cell mediated immune responses.  
 
Although the genes themselves were different, it was noteworthy that in both CLL 
and AML numerous genes were differentially regulated that were involved with 
the actin cytoskeleton and cellular polarisation. Since this observation led to the 
finding of impaired immunological synapse formation in CLL T cells, it was 
therefore felt to be relevant to use the same cell conjugation assay to examine the 
functional ability of AML CD4 and CD8 T cells to polarise actin appropriately to 
form immune synapses with APCs. These experiments demonstrated that, 
contrary to expectation, AML blasts could act as APCs to induce T cell 
immunological synapse formation in cell conjugation assays with healthy 
allogeneic T cells. However, when AML T cells were conjugated with autologous 
blasts, although they were able to form conjugates, their ability to form immune 
synapses was impaired. This was associated with reduced recruitment of 
phosphotyrosine signalling molecules to the immune synapse. This is in keeping 
with the observed gene expression changes noted. The differentially regulated 
gene profiles of T cells in AML were suggestive that the cells were undergoing 
signalling via the TCR but the pattern of gene expression changes observed was 
aberrant. Thus T cells may be interacting with myeloblasts and forming cell 
conjugates but subsequent downstream signalling events including actin 
reorganisation to form the immunological synapse is impaired. The implications 
of this could be that although T cells are recognising malignant cells their means 
of destroying them are being thwarted. This would explain the clinical situation 
when patients relapse with AML post allogeneic SCT despite GVHD where 
alloreactive T cells are clearly failing to control the disease. The question remains 
as to the identity of the signal from the myeloblasts that induces these changes. 
Previous work from King‟s College London has identified an unknown inhibitory 
protein secreted by blasts that does not require cell contact to induce its functional 
effects on T cells (Buggins, et al 2001). In contrast, in CLL, direct contact is 
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required between the tumour cell and the T cell to induce both the gene expression 
and immune synapse formation defects observed (Gorgun, et al 2005, Ramsay, et 
al 2008a). Therefore, although actin cytoskeletal reorganisation may be a 
fundamental pathway affected in both AML and CLL T cells, the means by which 
this defect is induced may differ in these diseases. This first requires further 
exploration in AML. Can an immune synapse formation defect be induced in 
healthy T cells by first culturing them with AML blasts? If so, is the same thing 
seen when a transwell culture system is used to prevent contact between the blasts 
and T cells? The experiments performed by the group from King‟s College should 
be repeated and if confirmed, subsequent proteomic studies performed to identify 
the nature of the inhibitory molecule secreted by blasts. These studies were 
beyond the scope of this thesis.  
 
This work was initiated to examine if defects observed in T cells in one 
malignancy, CLL, were unique to that disease or common to others. AML, 
although also a haematological malignancy and therefore by its nature allowing 
many opportunities for contact between tumour cells and T cells, is nonetheless a 
very different disease. CLL is in general a chronic disorder that many individuals 
will die with rather than from. The clonal lymphoproliferation may be present for 
months or even years before it becomes clinically apparent. This allows much 
time for interaction between tumour and T cells. In contrast, AML is an 
aggressive, progressive disorder in which patients will present within weeks if not 
days of disease development. Therefore, it does not come as much of a surprise 
that the gene expression changes observed in the T cells from these two clinically 
heterogeneous diseases are not the same. From a functional standpoint however, 
immunological synapse formation does appear to be similarly affected in AML T 
cells as in CLL although not to the same extent. These observations require 
further consolidation. It is of note that work from our group has demonstrated that 
similar immune synapse defects seen in CLL T cells are also apparent in T cells 
from affected lymph nodes of patients with follicular lymphoma, an equivalently 
chronic disorder to CLL (Ramsay 2008b). The consequence of these findings is to 
elucidate some mechanism of reversing the observed defects. In CLL and 
follicular lymphoma, work is already underway to attempt to reverse the immune 
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synapse defects observed with the immunomodulatory drug lenalidomide showing 
some effect (Ramsay 2008b, Ramsay, et al 2008a). It is of interest that this drug 
has already demonstrated efficacy in AML (Fehniger, et al 2009). Following on 
from this, the question will need to be asked as to whether reversing the defect in 
T cell actin repolarisation results in immune recognition of tumour cells and 
subsequent improved cytotoxicity before clinical efficacy can be addressed. 
Nonetheless, these encouraging results that may lead to a time when cancers are 
treated not only by targeting the tumour but also the T cell. 
 
In summary, this thesis has provided technical information on methods of 
separating T cells from presentation AML specimens and the impact of the 
method of immunomagnetic cell selection on the gene expression profile of T 
cells. In addition, a picture has been obtained of AML at presentation as not only 
an aggressive proliferating mass of myeloblasts but also an associated florid 
immune response. The resulting T cells can form conjugates with tumour cells but 
subsequent immune synapse formation and recruitment of downstream signalling 
molecules is inhibited. This is associated with a gene expression profile that 
indicates aberrant TCR signalling and T cell activation patterns. Therefore, T cells 
in patients with AML are different from healthy T cells and also from T cells in 
patients with CLL. However, the common strand of impaired actin cytoskeletal 
formation in immunological synapse formation may represent a means of 
improving T cell function in these malignancies. These ongoing developments 
mean that in the future we may well at last develop effective treatments for cancer 
thus finally contradicting that ancient writer of the Egyptian papyri from 3600 
years ago (Breasted 1922).  
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Future Work 
 
Firstly, the data on immune synapse formation between T cells presenting with 
AML and autologous blasts requires extension. Preliminary data suggest that the 
defect in synapse formation resides primarily in the T cells and not in the 
leukaemic blasts. Evaluation of more patients, to cover the variety of AML FAB 
types as well as molecular subtypes, require evaluation. The next question would 
be to address if AML blasts can induce the observed synapse defect in healthy 
allogeneic T cells by culturing them either in direct contact or in a transwell 
culture system to establish if a diffusible factor is responsible for the changes 
observed. In view of the data from CLL, ongoing experiments are addressing  if 
the immunomodulatory drug lenolidomide can repair the demonstrated T cell 
immune defect. A subsequent demonstration of improved T cell cytotoxicity 
against AML blasts would then be required. 
 
With regards to the population of CD3+CD56+ cells identified to be increased in 
the peripheral blood of patients presenting with AML, an assessment of their 
function is an obvious first line of enquiry as their absolute number may not be as 
critical as their functional efficacy. Cytotoxicity assays using AML blasts as the 
target cells and ELISPOT assessment of IFN  production in response to culture 
with AML blasts would be valuable.  
 
Finally, no further progress seems to have been made in the identification of the 
protein secreted by AML blasts that reduces T cell activation since the work 
published by Buggins and colleagues in 2001. In the light of the data presented 
here, it would be worthwhile repeating their experiments and confirming their 
data with a subsequent proteomic investigation to identify the nature of the 
secreted protein. This work is beyond the scope of the present thesis. 
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Appendix A: Company Addresses 
 
Abgene UK ABgene House, Blenheim Road, Epsom. KT19 9AP 
 
Affymetrix 
UK Ltd. 
Voyager, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe. 
HP10 0HH 
 
Agilent 
Technologies 
UK Ltd. 
 
710 Wharfedale Road, Winnersh Triangle, Wokingham, Berkshire. RG41 5TP 
Amersham 
(GE 
Healthcare) 
 
Pollards Wood, Nightingales Lane, Chalfont St. Giles, Bucks.HP8 4SP 
Ancell 
Corporation 
 
P.O. Box 87, 243 3
rd
 Street N, Bayport MN 55003 USA 
Applied 
Biosytems 
 
Lingley House, 120 Birchwood Boulevard, Warrington. WA3 7QH  
 
Axis-Shield 
PoC 
 
P.O. Box 6863 Rodelokka, N-0504, Oslo, Norway 
BD 
Biosciences 
The Danby Building, Edmund Halley Road, Oxford Science Park, Oxford. 
OX4 4DQ  
 
Beckman 
Coulter 
Oakley Court, Kingsmead Business Park, London Road, High Wycombe, 
Buckinghamshire. HP11 1JU 
 
Carl Zeiss 
Ltd 
 
15-20 Woodfield Rd., Welwyn Garden City, Hertfordshire. AL7 1JQ 
 
CRUK Media 
Production 
Lab 
 
Clare Hall Laboratories, Blanche Lane, South Mimms, Potters Bar, Herts. EN6 
3LD  
Dako UK Ltd Cambridge House, St. Thomas Place, Ely, Cambridgeshire CB7 4EX 
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eBioscience 
Inc. 
 
10255 Science Center Drive, San Diego, CA 92121 USA 
Fisher 
Scientific 
 
2000 Park Lane Drive, Pittsburgh, PA 15275 USA 
Hund 
Wetzlar 
 
Wilhelm-Will-Str. 7, Wetzlar, 35580 Germany 
Immunotech 130, Avenue de Lattre de Tassigny, BP177, 13276 Marseille Cedex 9, France 
 
Ingenuity 
Systems, Inc. 
 
1700 Seaport Blvd., Third Foor, Redwood City, CA 94063 USA 
Invitrogen 
Ltd 
 
3 Fountain Drive, Inchinnan Business Park, Paisley. PA4 9RF 
InVivoScribe 
Technologies 
 
Le Forum - Bât B, 515 Avenue de la Tramontane, ZI Athelia IV, 13600 La 
Ciotat, France  
Millipore 
(UK) Ltd 
 
2-4 Fleming Road, Kirkton Campus, Livingston. EH54 7BN 
Miltenyi 
Biotec Ltd 
 
Almac House, Church Lane, Bisley, Surrey. GU24 9DR 
MJ Research 590 Lincoln Street, Waltham, 02451 USA 
 
Nalgene Nalge (Europe) Limited, Unit 1a, Thorn Business Park, Hereford. HR2 6JT 
 
NanoDrop 
Products 
3411 Silverside Rd, Bancroft Building, Wilmington, DE 19810 
USA 
 
National 
Blood Service 
 
 
Colindale Avenue, Colindale, London. NW9 5BG 
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NIH 
Tetramer 
Facility 
 
Emory University Vaccine Center, 954 Gatewood Road, Atlanta, GA 30329 
USA 
PAA 
Laboratories 
Ltd. 
 
Termare Close, Houndstone Business Park, Yeovil, Somerset. BA22 8YG 
Partek 
Incorporated 
 
12747 Olive Blvd., Suite 205, St. Louis, Missouri 63141 USA 
Promega UK 
Ltd 
 
Delta House, Southampton Science Park, Southampton, Hampshire. SO16 7NS 
Qiagen Ltd QIAGEN HOUSE, Fleming Way, Crawley, West Sussex. RH10 9NQ 
 
R&D Systems  
Europe Ltd 
 
19 Barton Lane, Abingdon Science Park, Abingdon. OX14 3NB 
Sanquin Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands 
 
Sigma 
Aldrich 
 
The Old Brickyard, New Road, Gillingham, Dorset. SP8 4XT 
StemCell 
Technologies 
Miniparc POLYTEC, Batiment Tramontane, RDC, 60 rue des Berges, 38000 
Grenoble, France 
 
Syngene 
Europe 
 
Beacon House, Nuffield Road, Cambridge. CB4 1TF 
TAAB 
Laboratories 
Equipment 
Ltd 
 
3 Minerva House, Calleva Park, Aldermaston, Berkshire. RG7 8NA 
Thermo 
Fisher 
Scientific Inc.  
 
81 Wyman Street, Waltham, MA 02454 USA 
Tree Star Inc 340 A Street Bd. 1#203 Ashland, Oregon 97520 USA 
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Appendix B: Antibodies 
 
Antibody Clone Isotype Company Catalog 
Number 
CD2-PE RPA-2.10 Mouse IgG1,k BD 555327 
CD3-PECy7 SK7 Mouse IgG1k BD Pharmingen 557851 
CD3-PE UCHT1 Mouse IgG1k BD Pharmingen 555333 
CD3-FITC UCHT1 Mouse IgG1,k BD Pharmingen 555332 
CD3-APC UCHT1 Mouse IgG1,k BD Pharmingen 555335 
CD4-PE RPA-T4 Mouse IgG1k BD Pharmingen 555347 
CD4-PERCP SK3 Mouse IgG1 BD 345770 
CD4-FITC 13B8.2 Mouse IgG1 Immunotech IM0448 
CD8-FITC SK1 Mouse IgG1 BD 345772 
CD8-PE SK1 Mouse IgG1,k BD 345773 
CD8-PERCP SK1 Mouse IgG1 BD 345774 
CD11c-PE HI10a-
EMPTY 
Mouse IgG1 BD Pharmingen 555375 
CD13-APC WM15 Mouse IgG1,k BD Pharmingen 557454 
CD14-FITC RMO52 Mouse IgG2a Immunotech IM0645U 
CD16-PE B73.1 Mouse IgG1,k BD 332779 
CD16-FITC 3G8 Mouse IgG1,k BD Pharmingen 555406 
CD16-FITC NKP15 Mouse IgG1 BD 335035 
CD19-APC HIB19 Mouse IgG1,k BD Pharmingen 555415 
CD20-FITC LT20 Mouse IgG1 Miltenyi 130-091-108 
CD21-PE B-ly4 Mouse IgG1,k BD Pharmingen 555422 
CD25-PE 4E3 Mouse IgG2b Miltenyi 130-091-024 
CD25-APC M-A251 Mouse IgG1,k BD Pharmingen 555434 
CD27-PE M-T271 Mouse IgG1,k BD Pharmingen 555441 
CD28-PE CD28.2 Mouse IgG1 Immunotech IM2071U 
CD33-PE AC104.3E3 Mouse IgG1 Miltenyi 130-091-732 
CD33-FITC HIM3-4 Mouse IgG1,k BD Pharmingen 555626 
CD34-PERCP 8G12 Mouse IgG1 BD 345803 
CD36-APC CB38 Mouse IgM,k BD Pharmingen 550956 
CD38-PECy7 HB7 Mouse IgG1 BD 335825 
CD45RA-FITC HI100 Mouse IgG2b,k BD Pharmingen 555488 
CD45RO-PE UCHL1 Mouse IgG2a,k BD Pharmingen 555493 
CD48-FITC TÜ145 Mouse IgM,k BD Pharmingen 555759 
CD56-PE B159 Mouse IgG1,k BD Pharmingen 555516 
CD56-APC B159 Mouse IgG1,k BD Pharmingen 555518 
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CD57-FITC NK-1 Mouse IgM,k BD Pharmingen 555619 
CD69-FITC FN50 Mouse IgG1,k BD Pharmingen 555530 
CD69-PE FN50 Mouse IgG1,k BD Pharmingen 555531 
CD86-FITC GL1 Rat IgG2a,k BD Pharmingen 553691 
CD94-FITC HP-3D9 Mouse IgG1,k BD Pharmingen 555888 
CD117-PE YB5.B8 Mouse IgG1 BD Pharmingen 555714 
CD119-PE GIR-208 Mouse IgG1 eBioscience 12-1199 
CD122-PE Mik- 3 Mouse IgG1,k BD Pharmingen 554525 
CD123-PE 9F5 Mouse IgG1 BD Pharmingen 555644 
CD244-FITC 2B4 Mouse IgG2a,k BD Pharmingen 550815 
CCR7-PE 3D12 Rat IgG2a,k eBioscience 12-1979 
Dectin 1/CLEC7A -PE 259931 Mouse IgG2B R&D Systems FAB1859P 
Granzyme B-PE CLB-GB11 Mouse IgG1 Pelicluster 
(Sanquin) 
M2289 
HLA-DR-PE Immu-357 Mouse IgG1 Immunotech IM1639 
IL-4-PE 8D4-8 Mouse IgG1 BD Pharmingen 554516 
IL-2-PE MQ1-17H12 Rat IgG2a BD Pharmingen 554566 
TNF -FITC MAb11 Mouse IgG1 BD Pharmingen 554512 
IFN -FITC B27 Mouse IgG1 BD Pharmingen 554700 
NKG2D-APC 1D11 Mouse IgG1,k BD Pharmingen 558071 
Perforin-FITC Delta G9 Mouse IgG2b Ancell 358-040 
TCR -FITC T10B9.1A-31 Mouse IgM,k BD Pharmingen 555547 
TCR FITC B1 Mouse IgG1,k BD Pharmingen 559878 
V 24-PE C15 Mouse IgG1 Immunotech 2290 
V 11-FITC C21 Mouse IgG2a Immunotech 1586 
Mouse IgG1,k isotype 
control-FITC 
MOPC-21  BD Pharmingen 555909 
Mouse IgG1,k isotype 
control-APC 
MOPC-21  BD Pharmingen 555751 
Mouse IgG1,k isotype 
control-PERCP 
MOPC-21  BD Pharmingen 559425 
Mouse IgG1,k isotype 
control-PECy7 
MOPC-21  BD Pharmingen 557646 
Mouse IgG2a,k isotype 
control-PE 
G155-178  BD Pharmingen 559319 
Mouse IgG2b,k isotype 
control-APC 
27-35  BD Pharmingen 555745 
Mouse IgG2b,k isotype 
control-FITC 
27-35  BD Pharmingen 555742 
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Mouse IgG2b,k isotype 
control-PE 
27-35  BD Pharmingen 555058 
Mouse IgM,k isotype 
control-FITC 
G155-228  BD Pharmingen 555583 
Rat IgG2a,k Isotype 
control-PE 
R35-95  BD Pharmingen 554689 
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Appendix C: Common Differentially Expressed Genes in 
AML and CLL Datasets 
 
CD4 
Probeset Symbol Description CLL AML 
211947_s_at BAT2D1 BAT2 domain containing 1   
204285_s_at 
 
PMAIP1 
 
phorbol-12-myristate-13-acetate-induced protein 
1 
  
207540_s_at SYK spleen tyrosine kinase   
201161_s_at CSDA cold shock domain protein A   
204286_s_a 
t 
PMAIP1 
 
phorbol-12-myristate-13-acetate-induced protein 
1 
  
208268_at ADAM28 ADAM metallopeptidase domain 28   
217282_at MAN1A2 mannosidase, alpha, class 1A, member 2   
204713_s_at F5 coagulation factor V (proaccelerin, labile factor)   
201560_at CLIC4 chloride intracellular channel 4   
210479_s_at RORA RAR-related orphan receptor A   
201160_s_at CSDA cold shock domain protein A   
210384_at PRMT2 protein arginine methyltransferase 2   
213650_at GOLGA8A golgi autoantigen, golgin subfamily a, 8A   
208690_s_at PDLIM1 PDZ and LIM domain 1 (elfin)   
210426_x_at RORA RAR-related orphan receptor A   
212007_at UBXD2 UBX domain containing 2   
214723_x_at ANKRD36B ankyrin repeat domain 36B   
210407_at 
 
PPM1A 
 
protein phosphatase 1A (formerly 2C), 
magnesium-dependent, alpha isoform 
  
217620_s_at 
 
PIK3CB 
 
phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
  
220940_at ANKRD36B ankyrin repeat domain 36B   
211944_at BAT2D1 BAT2 domain containing 1   
217607_x_at 
 
EIF4G2 
 
eukaryotic translation initiation factor 4 gamma, 
2 
  
216682_s_at FAM48A family with sequence similarity 48, member A   
211824_x_at NLRP1 NLR family, pyrin domain containing 1   
216850_at SNRPN small nuclear ribonucleoprotein polypeptide N   
214298_x_at SEPT6 septin 6   
222279_at RP3- hypothetical protein FLJ35429   
Rifca Le Dieu                                                                                                                      Appendices 
272 
 
377H14.5 
213666_at SEPT6 septin 6   
215921_at LOC388237 hypothetical LOC388237   
212921_at SMYD2 SET and MYND domain containing 2   
214823_at ZNF204 zinc finger protein 204 (pseudogene)   
215859_at NCLN nicalin homolog (zebrafish)   
218793_s_at SCML1 sex comb on midleg-like 1 (Drosophila)   
220936_s_at H2AFJ H2A histone family, member J   
 
CD8 
Probesets Symbol Description CLL AML 
217649_at ZFAND5 zinc finger, AN1-type domain 5   
214516_at HIST1H4B histone cluster 1, H4b   
219654_at 
 
 
PTPLA 
 
 
protein tyrosine phosphatase-like 
(proline instead of catalytic 
arginine), member A 
  
215224_at RPL23 ribosomal protein L23   
216474_x_at TPSAB1 tryptase alpha/beta 1   
202708_s_at HIST2H2BE histone cluster 2, H2be   
210407_at 
 
 
PPM1A 
 
 
protein phosphatase 1A (formerly 
2C), magnesium-dependent, alpha 
isoform 
  
206847_s_at HOXA7 homeobox A7   
218847_at 
 
IGF2BP2 
 
insulin-like growth factor 2 mRNA 
binding protein 2 
  
201348_at GPX3 glutathione peroxidase 3 (plasma)   
203557_s_at 
 
 
PCBD1 
 
 
pterin-4 alpha-carbinolamine 
dehydratase/dimerization cofactor 
of hepatocyte nuclear factor 1 alpha 
  
213649_at 
 
SFRS7 
 
splicing factor, arginine/serine-rich 
7, 35kDa 
  
219588_s_at 
 
NCAPG2 
 
non-SMC condensin II complex, 
subunit G2 
  
AFFX-
HUMRGE/M10098_M_at  NA 
  
211944_at BAT2D1 BAT2 domain containing 1   
210742_at 
 
CDC14A 
 
CDC14 cell division cycle 14 
homolog A (S. cerevisiae) 
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213517_at PCBP2 poly(rC) binding protein 2   
216022_at  NA   
201354_s_at 
 
 
FUT1 
 
 
fucosyltransferase 1 (galactoside 2-
alpha-L-fucosyltransferase, H 
blood group) 
  
208610_s_at SRRM2 serine/arginine repetitive matrix 2   
210755_at 
 
HGF 
 
hepatocyte growth factor 
(hepapoietin A; scatter factor) 
  
214352_s_at 
 
KRAS 
 
v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
  
208129_x_at 
 
 
RUNX1 
 
 
runt-related transcription factor 1 
(acute myeloid leukemia 1; aml1 
oncogene) 
  
202124_s_at 
 
TRAK2 
 
trafficking protein, kinesin binding 
2 
  
211572_s_at 
 
SLC23A2 
 
solute carrier family 23 (nucleobase 
transporters), member 2 
  
216203_at 
 
SPTLC2 
 
serine palmitoyltransferase, long 
chain base subunit 2 
  
210479_s_at RORA RAR-related orphan receptor A   
210528_at 
 
MR1 
 
major histocompatibility complex, 
class I-related 
  
208195_at TTN titin   
211824_x_at 
 
NLRP1 
 
NLR family, pyrin domain 
containing 1 
  
218638_s_at 
 
SPON2 
 
spondin 2, extracellular matrix 
protein 
  
206828_at TXK TXK tyrosine kinase   
216971_s_at 
 
PLEC1 
 
plectin 1, intermediate filament 
binding protein 500kDa 
  
215921_at LOC388237 hypothetical LOC388237   
217950_at 
 
NOSIP 
 
nitric oxide synthase interacting 
protein 
  
221790_s_at 
 
LDLRAP1 
 
low density lipoprotein receptor 
adaptor protein 1 
  
219139_s_at 
 
CROCCL2 
 
ciliary rootlet coiled-coil, rootletin-
like 2 
  
221878_at LOC388969 hypothetical LOC388969   
204319_s_at RGS10 regulator of G-protein signaling 10   
202723_s_at FOXO1 forkhead box O1   
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57082_at 
 
LDLRAP1 
 
low density lipoprotein receptor 
adaptor protein 1 
  
221397_at TAS2R10 taste receptor, type 2, member 10   
218793_s_at 
 
SCML1 
 
sex comb on midleg-like 1 
(Drosophila) 
  
216330_s_at POU6F1 POU class 6 homeobox 1   
215555_at 
 
C1orf63 
 
chromosome 1 open reading frame 
63 
  
204105_s_at NRCAM neuronal cell adhesion molecule   
215692_s_at 
 
MPPED2 
 
metallophosphoesterase domain 
containing 2 
  
219664_s_at 
 
DECR2 
 
2,4-dienoyl CoA reductase 2, 
peroxisomal 
  
211696_x_at HBB hemoglobin, beta   
214414_x_at HBA1 hemoglobin, alpha 1   
211745_x_at HBA2 hemoglobin, alpha 2   
209116_x_at HBB hemoglobin, beta   
 
Red: up-regulated in patient T cells compared with healthy T cells, blue: down-regulated in patient 
T cells compared with healthy controls. 
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